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Abstract 
S. pneumoniae is one of the most significant human pathogens, causing high morbidity 
and mortality rates globally. Although there are vaccine available such as PPV 23, 
PCV7, PCV10, and PCV13, they are ineffective in some situations due to the differing 
epidemiology of various serotypes depending on the site of infection and the 
geographical location. Furthermore, they are expensive to produce and distribute. 
Universal research is presently concentrated on establishing other pneumococcal-
vaccine approaches such as using pneumococcal surface protein A (PspA) which relate 
to pathogenesis and are common to all serotypes. In this study polymeric nanoparticles 
(NPs) encapsulating PspA4Pro were incorporated into microcarriers using L-leucine 
and spray dried to produce nanocomposite microparticles (NCMPs) dry powder for 
inhalation. 
Parameters for the preparation of protein-loaded polyester poly (Glycerol Adipate-co-ω-
Pentadecalactone), (PGA-co-PDL) NCMPs were optimised using Taguchi design and 
BSA as a model protein, by the double emulsion solvent evaporation method followed 
by spray drying. Particle size was mainly affected by the polymer mass and small 
particle size ≤‎ 500nm‎was achieved. The most important factor for obtaining a high 
BSA loading was BSA concentration. The spray drying process was optimised to 
produce NCMPs with a porous corrugated surface, 50% yield, MMAD of 1.71±0.10 µm 
and FPF% of 78.57±0.1%. 
Adsorption of chitosan hydrochloride (CHL) onto PGA-co-PDL NPs can be used as 
successful strategies to produce cationic NPs. Cationic NPs were prepared with similar 
particle size to anionic NPs ≤‎ 500nm. The In vitro aerosolisation performance of 
cationic NPs/NCMPs showed FPF% of 46.79±11.21% and MMAD of 1.49±0.29 µm. 
Further cell viability studies on A549 cell line showed a good profile with a cell 
viability of 79±4.7% for anionic NPs/NCMPs and 78.85±9.96% for cationic 
xviii 
 
NPs/NCMPs at 2.5 mg/ml concentration after 24 h exposure. The previous results 
introduced a successful method for preparing anionic and cationic NPs/NCMPs for 
delivering PspA4Pro as dry powder via inhalation. The particle size of PspAPro4 loaded 
anionic NPs and cationic NPs were 310±25.3 nm and 409.7±49.5 nm, respectively, to 
be effectively taken up by dendritic cells (DCs). The PspA4Pro loading in anionic NPs 
was 65.73±5.6 µg/mg and in cationic NPs was 9.84±1.4 µg/mg. The PspA4Pro released 
from anionic and cationic NPs/NCMPs preserved its primary and secondary structure as 
evaluated by SDS-PAGE and circular dichroism. In vitro release studies showed that the 
anionic NPs/NCMPs formulations achieved a cumulative release of 21.01±1.5% while 
the cationic NPs/NCMPs formulation released 83.13 ±0.84% after 48 h. DCs uptake 
studies provide evidence of particles uptake by DCs upon incubation for 1 h as 
visualized by confocal microscopy. These results indicate the use of optimised methods 
for developing polymeric based NCMPs for vaccine delivery via inhalation against 
pneumococcal diseases. 
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1. Introduction 
1.1 Streptococcus pneumoniae  
In the late 1880s George M. Sternberg (1838–1915), a US Army physician, and Louis J. 
Pasteur (1822–1895) independently isolated Streptococcus pneumoniae from rabbits. 
The rabbits injected with human saliva extracted from patients with pneumococcal 
disease developed fatal septicaemia (1). Both researchers described the same organism; 
named Microbe septicemique du salive by Pasteur and Micrococcus pasteuri by 
Sternberg. In 1886 this organism was referred to as Pneumococcus by Fraenkel because 
of its liability to cause pulmonary disease (2). It was renamed Diplococcus pneumoniae 
in 1920 a nomination clearly describing pairs of cocci inducing pneumonia. In 1974, the 
pneumococcus was given its current name, Streptococcus pneumoniae, mainly due to its 
distinguishing growth as chains of cocci in liquid media (2). 
S. pneumoniae is one of the most significant human pathogens, causing high morbidity 
and mortality rates globally (3). Asymptomatic human nasopharyngeal carriage is the 
main reservoir of S. pneumoniae and it colonizes the nasopharynx up to 60% in healthy 
children and 30% in healthy adults (3). This harmless organism becomes a major human 
pathogen when the immunity of the host is weakened as in young children, adult, 
elderly or immunocompromised patients. However, the relationship between the 
carriage and the development of natural immunity is not clear (3).  
1.2 S. pneumoniae virulence components 
S. pneumoniae is a gram-positive encapsulated bacterium (4). It has a wide range of 
virulence components that are presented as cell surface proteins, toxins or secreted 
proteins (Figure ‎1-1). The most important of these virulence components is the 
polysaccharide capsule. According to the structure of the capsules (serotypes), S. 
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pneumoniae are divided into 94 serotypes. Just 20-30 of the common serotypes account 
for 62% of invasive infections globally (5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
The epidemiology of various serotypes differs depends on site of infection, vaccine use 
and the geographical location (6). The function of each virulence factor in the 
pathophysiology of the disease is ongoing. These virulence components have been 
discussed in detail (6) and Figure ‎1-2 shows the important virulence components of S. 
pneumoniae and their function in disease development (6). 
 
 
Figure ‎1-1: Virulence components of S. pneumoniae. PspA: pneumococcal surface 
protein A; PspC: pneumococcal surface protein C; CbpA: choline-binding 
protein A (with permission from (6)). 
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Pneumococcal 
virulence 
components 
Capsule 
Avoids opsonophagocytosis. 
Avoids eradiction by mucus. 
Pneumolysin 
(Ply) 
Cytolytic toxin effect. 
Complement-activating effect. 
Neuraminidase 
(NanA, B, and C)  
Binds to N-acetyl neuraminic acid found on tissue cell 
surfaces and displays binding sites of the bacteria. 
Nan A have a significant function in biofilm formation.   
Hyaluronidase  Enhances transmission of infection. 
Pneumococcal 
surface protein 
A (PspA) 
Avoids stimulation of complements and 
 cleaves to lactoferrin. 
Pneumococcal 
surface protein 
C (PspC or CbpA 
or SpsA) 
 Cleaves to sIgA and factor H. 
 Inhibits formation of C3b. 
Pilus Promotes bacterial cleaves to host cells. 
Autolysin A 
(LytA) 
 Induces autolysis of bacteria. 
Releases Ply.  
Inhibits phagocytosis. 
Figure ‎1-2: Most significant virulence factors of S. pneumoniae and their function 
in disease development. 
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1.3 Pneumococcal disease 
S. pneumoniae are generally transmitted by air droplets or direct contact with 
contaminated respiratory secretions and they are implicated in both non-invasive and 
invasive diseases (7).  
Non-invasive pneumococcal diseases (e.g. otitis media, sinusitis, and bronchitis) are 
generally not life threating conditions, but lead to discomfort and loss of school or work 
days (4). The Health Protection Agency estimates that non-invasive pneumococcal 
diseases lead to approximately 60,000 general practitioner visits per year (4). 
Additionally, there is a possibility to develop invasive pneumococcal diseases (4).  
The most important manifestations of invasive pneumococcal diseases are pneumonia, 
bacterial meningitis, and septicaemia which are life threatening conditions (8; 9).  
Pneumonia can develop when bacteria invade the lower respiratory tract (Figure ‎1-3). 
The alveoli and intracellular spaces fill with macrophages, due to the inflammatory 
response of the immune system. This leads to the production of a fibrin-rich exudate 
which fills the infected and adjacent alveolar spaces, making them stick together and so 
airless. Furthermore, neutrophils proliferate causing pulmonary oedema which 
deteriorates lung expansion (8). The patient presents with a persistent dry or productive 
cough, fever, dyspnoea, rigors, and pleuritic pain (10). The first-line choice of the 
antibiotic amoxicillin or doxycycline is suggested for all cases (4). Due to an extensive 
increase in antimicrobial resistance it is difficult to implement effective antimicrobial 
therapy (3). When S. pneumoniae reach the blood stream they will cause bacteraemia 
(Figure ‎1-3) and induce an immune response that can be devastating. Macrophages 
stimulate the release of tumour necrosis factor-alpha (TNF-α),‎ leading‎ to‎vasodilation‎
which causes an increase in vascular permeability and drop in blood pressure. The aim 
of this reaction is to permit an influx of neutrophils and other lymphocytes to the site of 
infection to defend host cells (9). 
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The consequences can be a massive loss of plasma volume due to leakage into the 
tissues (oedema). Moreover, the TNF-α‎ stimulates‎ disseminated‎ intravascular‎
coagulation (DIC), leading to clots in the capillaries, which withhold blood flow to vital 
organs and consume the clotting proteins in the general circulation, causing multiple 
organ failure (9). 
When S. pneumoniae cross the blood-brain barrier in large numbers (Figure ‎1-3), it is 
thought that the immune system tries to remove the pathogens and this can lead to tissue 
damage. Neutrophils are engaged at the site of infection to engulf the bacteria and 
release products e.g. nitric oxide, superoxide anion, and hydrogen peroxide that are 
toxic to the bacteria and host tissue. This is considered to have importance in the 
damage to neurons that can cause the sequalae commonly observed after pneumococcal 
Figure ‎1-3: General path of S. pneumoniae spread from the nasopharynx (1) is 
invading the lower respiratory tract and leading to pneumonia (2). The lung 
inflammation can then allow leak out of S. pneumonia into the blood stream 
leading to bacteraemia (3), but can also cause spread to the cerebrospinal fluid 
(CSF) via the capillary networks leading to meningitis (4a), also S. pneumonia 
can spread into the central nervous system (CNS) leading to encephalitis (4b); 
but this occurs rarely (with permission from 
http://www.immunopaedia.org.za/index.php?id=750 (11)). 
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meningitis. Up to 30 % of surviving patients suffer from sensomotor deficit, hearing 
loss, and cognitive impairment (8; 11). 
The common clinical symptoms of meningitis are headache, fever, neck stiffness and 
altered mental status. In children less than 5 years old presenting symptoms may be 
nonspecific such as fever, vomiting, irritability, and drowsiness (12). The first line 
treatment is antibiotics such as cephalosporin e.g. cefoxamine which can cross the blood 
brain barrier and corticosteroids such as dexamethasone to prevent complications from 
excessive inflammation (12).  
In the UK, community-acquired pneumonia is an important cause of morbidity and 
mortality with rate of 5–11 per 1000 adults (4) with hospital admission indicated for 22-
42 % of the overall community-acquired pneumonia (13). Furthermore, the case fatality 
rate of 47.2 % for more than 85 years and 5.6 % for less than 65 years of age has been 
reported displaying the burden of community acquired pneumonia in aging population 
(14). In‎Europe,‎estimates‎show‎that‎the‎cost‎due‎to‎pneumonia‎is‎approximately‎€ 10.1 
billion‎ annually‎with‎ indirect‎ costs‎ due‎ to‎ lost‎work‎ days‎ amounting‎ to‎ €‎ 3.6‎ billion‎
(14). It is a worldwide problem; but, in low middle income countries, morbidity and 
mortality are highest in children under age of 5 years (15). In 2010, the Health 
Protection Agency assessed that there were 40,000 admissions to hospital per year due 
to pneumococcal pneumonia, where 10 % needed intensive care and 10–12 % of cases 
will lead to death (16). Many studies show an incidence for community acquired 
pneumonia 1.6-9 cases per 1000 adult population with the financial burden globally 
estimated to be US $ 4.8 billion for adult aged more than 65 years and US $ 3.6 billion 
for adults aged less than 65 years (17; 18; 19; 20). 
A review of disease burden in children under the age of five reported that in 2007, of an 
estimated 9 million child deaths, around 1.8 million were due to pneumococcal diseases 
(15). The situation is worse in low middle income countries, where 90% of these deaths 
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occur. In addition, pneumonia is implicated in the death of the elderly and 
immunocompromised individuals (21). 
The death rate from pneumococcal meningitis is around 16 – 37 %, and up to 50 % 
adults who recover will have neurological abnormalities (12). It has been accepted that 
many of these invasive pneumococcal disease and accompanied deaths can be avoided 
by vaccination (21). 
1.4 Pneumococcal vaccine 
Vaccines are antigenic formulations utilized to initiate immunity to establish protection 
against infectious diseases (22). There are two different types of pneumococcal vaccine 
currently available: pneumococcal polysaccharide vaccine (PPV) and pneumococcal 
conjugate vaccine (PCV). 
1.4.1 Pneumococcal polysaccharide vaccine (PPV) 
Pneumococcal polysaccharide vaccine (PPV) consists of a plain polysaccharide capsule 
covering the outer surface of the pneumococcus. In 1977, a 14-serotype pneumococcal 
capsular polysaccharide vaccine was approved for use but was replaced in 1983 after 
the current 23-serotypes vaccine (Pneumovax, Merck & Co) was licensed (3). 
Pneumovax (PPV23) contains 23 capsular polysaccharides from the most common S. 
pneumoniae serotypes associated with pneumococcal infections and it is administered 
by intramuscular or subcutaneous injection (3).  
Polysaccharides mainly provoke a B-cell dependent immune response (23). This 
vaccine was highly effective in children above 2 years of age and young adults with re-
vaccination after 5–6 years (4; 24). Its main limitation was the inability to stimulate a 
significant immune response in children under 2 years of age probably due to their 
immature immune systems (4; 24). In the elderly (above 65 years old) research suggests 
that immunization was short-term as antibody titres decreased rapidly from the highest 
concentrations measured one month after immunization. The administration of 
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additional doses of PPV to maintain immunity in the elderly is restrained, as antibody 
titres after following doses of PPV are similar or lower than after primary 
immunization. This phenomenon, known as ‘‘hyporesponsiveness’’ has also been 
noticed after meningococcal polysaccharide immunization. Researchers have suggested 
that hyporesponsiveness is a result of the consumption of the peripheral B-cell pool by 
plain polysaccharide antigens that urge B cells into terminal differentiation, without 
replacing the B-cell pool (23). Additionally, PPV is not suitable for 
immunocompromised patients (4). Moreover, PPV does not induce mucosal immunity 
so has no influence on the nasopharyngeal carriage of the S. pneumoniae (4). In the UK, 
this vaccine was only indicated for children and young adults who were in high-risk 
groups, i.e. with underlying medical conditions such as non-functioning spleen, chronic 
heart diseases, and renal or liver dysfunction (4; 25). 
To enhance the immune response to the capsular polysaccharide in children less than 2 
years of age, elderly and immunocompromised patients, a new form vaccine where 
capsular polysaccharides are conjugated to one of various proteins were developed (4). 
1.4.2 Pneumococcal conjugate vaccine (PCV) 
Pneumococcal conjugate vaccines (PCV) have been prepared by coupling capsular 
polysaccharides to several carrier proteins including; tetanus toxoid, diphtheria toxoid, 
CRM197 (a nontoxic mutant of diphtheria toxin), pneumolysin, and meningococcal 
outer membrane proteins (7). The protein stimulates a T-cell dependent immune 
response leading to immune memory and, as a result, induces a booster response (4). 
This type of vaccine overcomes the issue with immune response seen with PPV in 
children under the age of 2 years. The first PCV 7 (Prevenar 7, Wyeth) included 
purified capsular polysaccharides of seven serotypes conjugated to CRM197 and 
administered by intramuscular injection (26).  
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In 2002, PCV was initially recommended for children in the higher risk clinical groups 
(such as heart, renal, and liver disease) in the UK (4) and in 2006, PCV was added in 
the national programme for all children under the age of 2 years (4; 25). In 2010, a PCV 
including 13 serotypes replaced the 7-valent vaccine in the national programme (4). 
Prevenar 13 (Pfizer Inc) was available in 2011 for active immunisation for the 
prevention of invasive pneumococcal disease in adults aged above 50 years. 
Researchers suggest that there is a decrease in cases of community-acquired pneumonia 
and invasive pneumococcal disease from the serotypes included in the PCV (4).  
Regardless of Prevnars protection against vaccine serotypes, it has been demonstrated to 
evoke serotype redistribution; the substitution of vaccine serotypes by strains not 
included by the vaccine (3). Thus, the appearance of less common serotypes is 
anticipated to be more frequent. Serotype substitution is a serious concern, especially in 
regions with an increased disease burden, due to its ability to change the landscape of 
disease rapidly (3). However, the vaccine is mainly produced for U.S. and European 
epidemiological settings, so for low middle income countries it has only a limited 
coverage of the serotypes provoking invasive pneumococcal diseases (3). In Asia and 
Africa there are considerable variations in serotype distribution (3). This vaccine is also 
more expensive than all the other vaccines in the national immunization programmes in 
many low middle income countries. The unit price of a vial of PPV23 (Pneumovax II, 
Sanofi Pasteur MSD) is £8.32 and for a vial of PCV13 (Prevenar 13, Pfizer) is £49.10 
(retrieved from the British National Formulary 63, 2012). The cost of administration is 
expected to‎ be‎ 10‎ min’‎ time‎ of‎ a‎ band‎ 7‎ advanced‎ nurse,‎ as‎ seen‎ in‎ the Health 
Protection Agency (now Public Health England) research on seasonal influenza 
vaccination program. The average cost of administration was evaluated at £6.92 per 
vaccine (27). However, according to the Royal College of General Practitioners data 
54.5% of pneumococcal vaccinations will be co-administered with influenza 
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vaccination so there is no additional administration cost. In addition, the PCV requires a 
three-dose vaccination regimen (27). To broaden the protection, the development of a 
protein-based pneumococcal vaccine could be a feasible and preferable alternative (3).  
1.4.3 Pneumococcal protein-based vaccine 
Pneumococcal proteins relate to pathogenesis and are common to all serotypes. Over the 
last twenty years, many pneumococcal protein antigens have been examined for their 
virulence and vaccine ability. These involve pneumolysin (Ply) toxoid (PdB); choline 
binding proteins PspA and PspC (also called CbpA or SpsA); metal binding lipoprotein 
(PsaA); iron uptake ABC transporters PiuA and PiaA; heat shock protein (ClpP); 
neuraminidases A and B; LytA and hyaluronidase; and pneumococcal histidine triad 
(Pht) proteins PhtB and PhtE. All the proteins listed above have demonstrated a 
significant level of protection against systemic challenge with different S. pneumoniae 
serotypes in animal models but not all have been fully evaluated or directly compared, 
and the outcomes are highly reliant on the mouse strain and challenge strain examined 
(28).  
PspA has gained a special focus, and is a surface protein located on the cell wall in all 
strains of pneumococci (Figure ‎1-1). It has N-terminal‎α-helical domain displayed on 
the bacterial surface and a repeated region of C-terminal choline-binding that attaches 
the molecule to the bacterial cell wall (29). There are different PspA sequences, mainly 
in the N-terminal domain, and according to the similarity of the sequence, PspA is 
categorised into three families where there is a high serological cross-reactivity between 
the various families. Around 95% of S. pneumoniae strains have PspA categorized in 
family 1 or family 2 (29). PspA is a critical pneumococcal virulence factor, mainly 
interfering with host complement function (29). PspA avoids the accumulation of 
complement on the surface of the bacterium which leads to inhibition of clearance and 
phagocytosis of S. pneumoniae (30). PspA also prevents bactericidal activity by 
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lactoferrin (30). Lactoferrin is a human protein located on mucosal surfaces and its main 
function is to bind to elemental iron preventing its use by bacteria on mucosal surfaces. 
It‎has‎been‎demonstrated‎that‎the‎α-helical domain of PspA binds lactoferrin and may be 
a means by which pneumococci can either utilize environmental iron or inhibit one 
mechanism of host defence (31). Some studies showed that PspA vaccine protects mice 
against a lethal challenge with S. pneumoniae through the generation of anti-PspA 
serum antibodies that are highly cross reactive to other strains (30). 
Consequently, it is essential to formulate novel adjuvants - substances that augment an 
immune response in order to evoke sufficient responses (30) and/or delivery system for 
the preparation of efficient vaccines that can defend against different strains of S. 
pneumoniae and improve patient compliance by using a tolerable dose regimen. PspA 
has been the object of many studies examining different vaccine delivery systems such 
as the delivery of PspA with live attenuated bacteria such as salmonella (32) and via co-
administration with a whole-cell pertussis vaccine (33). Furthermore, nano-preparations 
such as gold nanoparticles (34), nanogel-based vaccine formulations (35), and 
biodegradable polyanhydride nanoparticles containing PspA have been previously 
examined (30). 
1.5 Pulmonary drug delivery  
1.5.1 Lung anatomy and physiology 
The respiratory tract comprises the conducting and respiratory airways (Figure ‎1-4). The 
lung, weighing about one kilogram, is divided by pleural membranes into lobes; three 
on the right and two on the left (36). Inhaled air travels through the nose and mouth, 
passes from the larynx and trachea to 16 generations of conductive bronchi and 
bronchioles. Alveoli begin to appear from the 17th generation of bronchioles 
(respiratory airways) and by the 20th generation of airways, the alveoli result in alveolar 
ducts (36). Blind sacs lined with alveoli known as alveolar sacs become evident at the 
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23rd generation. Nearly 300 million alveoli are present in the lung and provide a surface 
area of exchange of 80–90 sq. m (36). On the bronchial surface the submucosal glands 
and‎ the‎ ‘goblet‎ cells’‎ secrete‎ mucus.‎ The‎ mucus‎ lining the conducting airways is 
transported towards the mouth in accordance with the movement of cilia found on the 
ciliated columnar cells followed by swallowing of the mucus transported to the mouth. 
 
This movement is primarily responsible for removing any foreign materials that enter 
the bronchial area (36). The alveoli and the pulmonary capillaries are separated by a 
barrier consisting of endothelial cells, interstitial space and pneumocytes (pulmonary 
epithelial cells). The pneumocytes are divided into two types; type I and type II cells. 
Type I cells are very flat and cover the alveolar surface enhancing the gaseous exchange 
between the alveoli and blood whereas type II cells are irregularly shaped which 
produce and secrete surfactants (36; 37). 
Figure ‎1-4: Diagram of the human respiratory tract (with permission from 
(37)). 
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1.5.2 The lung as a delivery site for drugs 
The pulmonary region as a site of drug administration provides many advantages that 
can be divided into two different categories; one related to the lung and the other related 
to the drug delivery system. The advantages of the lung include the large surface area of 
approximately 80 m² available for drug absorption, thin epithelium in the alveolar lung 
tissue (around 0.1 - 0.5‎ μm‎ thick), lower enzymatic activity than the gastrointestinal 
system, and large vascularisation that can enable the efficient systemic delivery of 
drugs. The advantages of the pulmonary delivery system include: the non-invasive 
method of delivery and the reduced risk of cross contamination due to the reuse of 
needles and syringes (38). The reuse of needles is a major obstacle in low middle 
income countries and global rates of 10.4 – 20.9 million infections per year caused by 
vulnerable injections were reported, with vaccines representing 5 to 15% of all 
injections administered (39). Nearly 80 % of infections transmitted by injections are 
hepatitis B, followed by hepatitis C, while less than 1 % of infections are HIV (39). In 
addition, such an approach diminishes a serious waste disposal problem and eliminates 
needle stick injuries, in both patients and healthcare workers. Following a needle stick 
injury the transmission risk from an infected patient to medical person is estimated as 
0.3% for HIV, and 3-10% for hepatitis B. Around 2 million of 35 million medical 
personal are infected by needle stick injuries (39). Additional benefit applies for patients 
who need a substitute for needle-based therapy due to fear of injections enhancing 
patient compliance and leading to improved treatment outcomes (38).  
Pulmonary delivery would be useful for mass immunization campaigns when there is an 
outbreak of a disease that is usually contained by vaccination. In these circumstances, 
important factors are; speed (the number of vaccinations per unit of time), easy and pain 
free delivery, no requirement for trained medical personnel and the elimination of cold-
chain requirements. Most available vaccine preparations are dependent on the effective 
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availability of continuous refrigerator storage conditions to maintain vaccine stability. 
This cold chain requirement presents significant difficulties in the effective performance 
of immunization campaigns in low middle income countries where a regular and stable 
supply of electricity and cold-chain storage is often unavailable (39).  
In a clinical research study where volunteers could choose between an intranasal 
virosomal influenza vaccine and an injection formulation, around 97 % choose the nasal 
vaccine. When they were asked for the reason, 14% answered that they were afraid of 
injections. This is in agreement with other investigations, where around 10% of the 
people reported injection phobia (39). 
 
Despite the many advantages, both the lung anatomy and properties of the delivery 
system present limitations for pulmonary drug administration. An important obstacle for 
the absorption of inhaled drugs is the thick lung epithelium (around 50 – 60 µm) in the 
trachea although this decreases in the alveoli to around 0.1 - 0.5‎μm‎(36). Additionally, 
mucociliary clearance, lung mucus and enzymes such as proteases which degrade 
macromolecules, act as barriers for the absorption of drugs through the pulmonary 
region (36). 
Moreover, there are some important factors that influence the delivery of drugs through 
the lung: the patient, the inhalation pattern, and the properties of the aerosol system e.g. 
the morphology, particle size etc. Deep lung delivery requires the production of 
particles with an aerodynamic diameter between 1 – 5‎μm. The aerodynamic diameter 
(dae) is defined as the diameter of a sphere with a density of 1 g/cm
3
 in air characterized 
by the same velocity in air as that of the particle being examined and represented by the 
following equation: 
𝒅𝒂𝒆 = 𝒅𝒈 √
𝝆
𝝆𝒂
             Equation ‎1-1 
where‎ρ‎is‎the‎mass‎density‎of‎the‎particle,‎ρa is the unit density (1 g/cm
3
) and dg is the 
geometric diameter (36). 
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1.5.3 Pulmonary delivery of vaccines 
The mucosal surface of the respiratory system is the main entrance for airborne 
pathogens. Many researchers have shown that the induction of systemic immunity by 
parenteral immunization can clear systemic infections efficiently but is unable to protect 
the mucosal surface (40). The antibodies produced due to systemic immunity; do not 
provide mucosal immunity to the mucosal surface, which is the main entry site for 
airborne pathogens. Thus mucosal immunisation affords the first line defence, through 
stimulation of the production of the secretory IgA (sIgA) which does not allow the 
bacterial or viral binding to the mucosal surface so avoids colonisation (41; 42; 43). 
Several studies examined the development of mucosal vaccine without use of the 
adjuvant; however the results showed poor immunogenic response. Thus different 
methods have been used to enhance the mucosal vaccine immunogenic properties, by 
using adjuvants e.g. polymeric nano/microparticles such as PLGA (44; 45), and 
chitosan nano/microparticles (46; 47), liposomes (48; 49), and cholera toxin (50; 51). 
Also, due to the extensive mucosal surface area available to inhaled particles upon 
deposition, an efficient system for delivering vaccines in aerosol particle form might 
enable the delivery of vaccines at lower doses than via the parenteral route (43).  
The mucosal immune system in the respiratory tract produces a wide range of 
protection, as the respiratory tract involves a large network of bronchus-associated 
lymphoid tissue (BALT); the respiratory part of mucosal-associated lymphoid tissue 
(MALT), extensive dendritic cells (DCs) network that line the respiratory epithelium in 
the submucosa and on the alveoli and the macrophages network in the interstitium and 
on the alveolar surface (52). BALT readily shares antigenic information and are known 
to induce systemic immunity (42).  
MALT epithelial surfaces are occupied with nonciliated macro-fold cells (M cells) 
which function as antigen-sampling. M cells are responsible for transporting antigens 
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from mucosal surfaces to the underlying lymphoid tissues (Figure ‎1-5). Following the 
antigen getting into the lymphoid tissues, the antigens are up taken and processed by 
antigen presenting cells (APCs): DCs and macrophages, and presented to B cells and T 
cells found in the lymphoid tissues. This leads to activation of T-cells which provoke 
IgG and IgA-committed B-cell maturation in the germinal centre of the MALT. At the 
end, antigen-specific CD4+ T-cells and activated B-cells will travel through the 
draining lymph nodes and the thoracic duct to the systemic circulation and other 
mucosal effector sites, where IgA+ B cell in the presence of interleukin-5 (IL-5) and 
interleukin-6 (IL-6), secreted by CD-4+ T helper 2 (TH2) cells, differentiate in to IgA 
producing plasma cells, which develop IgA antibodies. Whereas IgG-committed B-
cells, after stimulation by TH2 cells differentiate in to IgG producing plasma cells, 
which develop IgG antibodies (40). 
1.5.4 Dendritic cells  
Antigen uptake by DCs induces antigen-specific adaptive immunity (53). The innate 
immunity (Table ‎1-1) is an immediate protective response with broad action upon entry 
of a pathogen. The innate immunity depends on natural defence mechanisms that are 
applied to rapidly attack the invading pathogen. The innate system consist of epithelial 
barriers; mucosal membranes; phagocytes (monocytes, macrophages, and neutrophils); 
complements, natural killer cells; cytokines produced by the phagocytes; and DCs. 
These constituents promote phagocytosis and lysis of pathogen. The bone-marrow 
derived DCs with multiple long membranous projections share common characteristic 
with macrophages, and thus shares an overlapping function of phagocytosis. DCs 
function as APCs to activate naïve T cells (53; 54).  
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Figure ‎1-5: Simple scheme illustrates the stimulation of humoral immunity in the 
bronchus-associated lymphoid tissue (BALT). On the mucosal surface, M-cells 
transport antigen through sub-mucosa. Followed by antigen processing by DCs 
and macrophages and presenting to naïve T-cells in the mucosal lymph nodes and 
induce naïve T-cells. Then, the activated cells stimulate B-cell maturation in the 
original centre of the BALT. At the end, CD4+ T-cells (specific to the antigen) and 
stimulated B-cells will travel through the draining lymph nodes and the thoracic 
duct to the systemic circulation. Then CD-4+ T helper 2 (TH2) cells secrete 
interleukin-5 (IL-5) and interleukin-6 (IL-6) leading to IgA+ B and IgG+ B cells 
differentiation in to IgA generating plasma cells which develop IgA antibody and 
IgG generating plasma cells which develop IgG antibody, respectively (with 
permission from (54)). 
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Table ‎1-1: Main components of immune system. 
Im
m
u
n
it
y
 
Innate Immunity • Complement   
 • Natural killer   
 • Autophagy   
 • Dendritic cells   
 • Phagocytosis • Macrophages 
• Neutrophils 
• Monocytes 
 
Adaptive 
Immunity 
• Humoral • B cells • Antibodies 
• Memory cells 
 • Cellular • T cells • CD4+ 
• CD8+ 
 
Antigens entering the body are taken up by immature DCs which develop into mature 
cells. The DCs uptake, process and present antigen through major histocompatibility 
complex (MHC) class I and II pathways for identification by the T-cell receptors found 
on T-cells to start an immune response. This process is known as antigen presentation 
and typically occurs in the lymph node region (55). It is considered that soon after 
antigen presentation, the DCs go through apoptosis in the lymph nodes (36). 
Once activated, the naïve T cells initiate the adaptive immune response (acquired 
immunity) (56). Adaptive immunity (Table ‎1-1) is delayed but highly specific to a 
pathogen. The adaptive response includes the humoral immunity mediated by B cells, 
antibodies and complements and cellular immunity mediated by T cells activation. This 
immune specific response develops an immune memory for that pathogen (57). 
Recently it was found that there are approximately five different subsets of DCs in the 
murine conducting airways; resident DCs, plasmacytoid DCs, alveolar DCs, 
inflammatory DCs and interferon-producing killer DCs (58). The information available 
on these subsets of DCs in the human lung is limited due to the problem of obtaining 
lung tissue, as they cannot be recovered from the bronchoalveolar lavage (BAL) fluid. 
On the other hand, human alveolar macrophages are extensively studied because they 
are available in BAL. Immature DCs have a higher antigen presenting cells function but 
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poor phagocytic function, while the alveolar macrophages are primarily phagocytes and 
have a lower antigen presenting cell function (36).  
The lung region is composed of two main areas: the conducting airways and the lung 
parenchyma (Figure ‎1-6). The conducting airways mucosal surface includes ciliated 
epithelial cells, interspersed goblet cells, macrophages and DCs. 
The DCs in this area are mainly made up of myeloid DCs (mDCs), with a small 
percentage of plasmacytoid DCs (pDCs) (Figure ‎1-7). These mDCs have a greater 
ability for antigen uptake but lower potential to provoke the T cells. Furthermore; 
human DCs are generated from haematopoietic stem cells, mDCs from bone marrow–
derived monocyte precursors and pDCs from lymphoid progenitors. The mDCs and 
pDCs are stimulated by various groups of antigenic stimuli so their activity will be 
reflected by the expression of various cell surface receptors such as Toll-like receptors 
(TLRs).  
The lung parenchyma includes the lung interstitium, respiratory and terminal 
bronchioles, and alveoli and is primarily composed of 80% macrophages and 20% DCs 
and‎ T‎ cells.‎ The‎ ‘immature’‎ resident‎ DCs‎ have a high ability to detect, capture and 
process the encountered antigen (36). Human DCs are recognized by the over 
expression of human leukocyte antigen (HLA) DR (main histocompatibility complex 
class II). Furthermore, the specific markers to identify the mDCs involve CD11c+, 
CD1a+, BDCA-1+, BDCA-3+, HLA-DR+‎ while‎ for‎ the‎ pDCs‎ they‎ are‎ CD11c−,‎
HLADR+, BDCA-2+ and CD123+ (59; 60). 
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Figure ‎1-7: Respiratory tract DCs described in the human. BDCA, blood dendritic 
cell antigen; HLA, human leukocyte antigen. 
DCs type 
Myeloid 
(mDCs) 
DC1: CD11c+, HLA-
DR+, BDCA-1+ 
DC2: CD11c+, HLA-
DR+, BDCA-3+ 
Plasmacytoid 
(pDCs) 
CD11c-, HLA-DR+, 
BDCA-2+, CD123+ 
Figure ‎1-6: Respiratory immune system. AMDC: airway mucosal DCs, LPDC: 
lung parenchymal DCs (with permission from (59)). 
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1.6 Polymers for the pulmonary administration of vaccines  
A vaccine delivery system can be defined as a formulation or device that helps with the 
administration of a vaccine to the patient, enhancing its potency and safety and 
initiating an immune response as mentioned above (61). A wide range of polymers, both 
natural and synthetic, have previously been explored for the preparation of 
biodegradable nano/micro-particles for pulmonary vaccine delivery. Natural polymers 
e.g. albumin, cyclodextrin, collagen, gelatin, chitosan, and alginate; and synthetic 
polymers e.g. polyacrylates, polyanhydrides, and polyesters such as poly (lactic acid-co-
glycolic acid) (PLGA) and poly (L-lactic acid) (PLA) have been utilized for the 
formulation of biodegradable delivery systems (Table ‎1-2).  
Table ‎1-2: Some examples of polymer for pulmonary vaccine delivery.  
Type of polymer Examples Advantages Disadvantages 
Natural  Albumin, 
cyclodextrin, 
collagen, gelatin, 
chitosan, and 
alginate 
Biocompatible, low 
cost, high aqueous 
solubility and 
comparatively short 
duration of drug 
release. 
Presence of extraneous 
contaminants, batch 
variability, low 
hydrophobicity (40). 
Synthetic  polyacrylates, 
polyanhydrides, 
and polyesters such 
as PLGA and PLA 
Reproducible, 
controlled molecular 
weight, copolymer 
composition, and 
degradation rate. 
Limited solubility 
(40). 
Natural polymers generally have a relatively rapid release of therapeutic agent while the 
main characteristic of synthetic polymers is the ability to render sustained release of the 
active ingredient for a long period e.g. days to several weeks and can also modify the 
degradation rate based on molecular weight and polymer composition. Much research 
has been carried out to assess the potential of antigen-encapsulated microparticles for 
the preparation of a single dose vaccine through sustained release of the antigen 
avoiding the requirement for a booster dose. This would be advantageous in low and 
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middle income countries, where access to healthcare facilities and infrastructure can be 
difficult (61).  
The polyester, PLGA is one of the most extensively explored polymers for drug 
delivery due to the  FDA approval of different products that are commercially available 
in different grades and ratios of lactic and glycolic acid. However, PLGA hydrolysis 
results in the accumulation of acidic monomers, lactic and glycolic acids, thereby 
leading to a significant decrease in the pH of the environment and denaturation of the 
encapsulated proteins and local inflammation (22). 
In recent years, advances in polymer chemistry have led to the development of various 
novel biodegradable polymers as alternatives to PLGA (62). Here at Liverpool John 
Moores University poly (glycerol adipate-co-ω-pentadecalactone, PGA-co-PDL) has 
been developed as a novel delivery system (62).  
PGA-co-PDL (Figure ‎1-8) can be synthesized via the lipase, Candida antarctica, 
catalyzed combined condensation and ring opening copolymerization of activated 
diacid, glycerol and lactone monomers (63). 
 
 
 
 
 
This enzyme catalysed polymerization reaction exploits the regioselectivity of this 
lipase for primary hydroxyl groups offering protection of the secondary glycerol 
hydroxyl group that would otherwise react during the polymerization reaction. Although 
it is possible to synthesise this polymer chemically useing protecting groups this would 
involve more synthetic steps and probably lead to hydrolysis of the polymer backbone 
Figure ‎1-8: Chemical structure of PGA-co-PDL. 
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(62). Also, the enzymatic method does not require the toxic chemical or metal catalysts 
used in conventional chemical synthesis.  
PGA-co-PDL is expected to degrade through hydrolysis of ester bonds which will 
release adipic acid which is less acidic than glycolic acid and lactic acid produced by 
hydrolysis of PGLA. PGA-co-PDL has a similar but more disordered structure than 
poly-ϵ-caprolactone (PCL, semi-crystalline polymer) due to the randomly nature of 
polymerisation. Thompson et al. revealed that PGA-co-PDL was made from a random 
mixture of diacid, glycerol and lactone monomers by using 
13
C NMR hence PGA-co-
PDL should degrade quicker than PCL (62). Moreover, the presence of the pendant 
hydroxyl group enables the covalent attachment of moieties to the polymer backbone to 
modify the polymer physical and chemical characteristics (64).  
This polymer has been investigated by our group for the delivery of small molecules 
e.g. dexamethasone phosphate (63), model drugs e.g. ibuprofen (65) and sodium 
fluorescein (66),‎and‎macromolecules‎e.g.‎α-chymotrypsin (64), and DNase I (67).  
Another study proposed that PGA-co-PDL microparticles could be considered as 
carriers for pulmonary delivery. The results showed a good aerosol performance of 
PGA-co-PDL microparticles with fine particle fraction (%FPF) of 43.38±5.61% and 
mass median aerodynamic diameter (MMAD) 3.43±0.58 µm. Also, the toxicity studies 
at 5 mg/ml using human bronchial epithelial 16HBE14o- cell lines demonstrating the 
safety of PGA-co-PDL microparticles (85.57±5.44 % cell viability) compared to PLGA 
microparticles (60.66±6.75 % cell viability) after 72 h treatment (66). These results 
indicated that PGA-co-PDL could be a promising pulmonary drug delivery system 
affording a protective matrix and faster release of drug in a short period of time in 
comparison with PLGA (66). More recently we have developed PGA-co-PDL 
nanoparticles (NPs) for delivery of a model protein, bovine serum albumin (BSA) (68). 
The aerosolisation studies showed a good aerosolisation performance and deep lung 
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deposition with FPF%‎ of‎ 76.95±5.61%‎ and‎MMAD‎ of‎ 1.21±0.67‎ μm.‎ The‎ structure 
stability and integrity studies using SDS-PAGE and CD confirmed the primary and 
secondary structure of the released BSA. These results indicate that PGA-co-PDL NPs 
may be a promising carrier for pulmonary protein delivery (68). 
1.6.1 Nanoparticles for pulmonary administration of vaccine 
Nanoparticles are particles with diameters size in range of 1 to 1000 nm (62; 69). 
Polymeric NPs can improve the immune response by an adjuvant-like effect (40). When 
the antigen is encapsulated in NPs it is modified to a particulate pattern and this form 
can be more antigenic than the soluble antigen form due to the fact that these particulate 
forms have similar dimensions to pathogen to which the immune system structured to 
fight (40; 61). This particulate delivery of antigen will enhance DCs uptake and 
consequently antigen transfer to lymph node and so induce immune response (61). Most 
likely, the particulate antigen delivered to the lower respiratory tract area prevents the 
rapid clearance by alveolar macrophages and thereby enhances uptake by the epithelial 
M cells on mucosal surface. These cells, as a component of BALT, sample the 
environment for antigens and share antigenic information with DCs found in lymphoid 
tissue and induces secretory local IgA production. The NPs may then be transported to 
secondary lymph-nodes where they enhance induction of the systemic immune response 
(43). 
Another approach to enhance immune response (adjuvant-like effect) is to use chitosan 
or chitosan derivatives to prepare or to modify the surface of the NPs encapsulating 
antigen. Vila et. al. studied the use of low molecular weight chitosan (23 and 38 kDa) in 
preparation of NPs as nasal delivery system for vaccine using tetanus toxoid as a model 
antigen. The NPs sizes were in the 350 nm with a positive charge (+40 mV). These NPs 
were administered via intranasal route and produced higher and long-term IgG titres 
(humoral immune response) in comparison with the antigen solution. Moreover, the IgA 
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titres (mucosal immune response) after 6 months following administration of NPs was 
significantly more than that resulted after the antigen solution administration (70).  
Sayın et. al. prepared tetanus toxoid loaded NPs using N-trimethyl chitosan and mono-
N-carboxymethyl chitosan for mucosal vaccination. The particle size range was 40–400 
nm, and a negative surface charge for mono-N-carboxymethyl chitosan and positive 
surface charge for N-trimethyl chitosan and high loading efficacy >90 %. Immunity 
studies showed an increased in immune responses in Balb/c mice after intranasal 
administration of NPs. N-trimethyl chitosan NPs with positive surface charge produced 
high level of serum IgG titres in comparison with mono-N-carboxymethyl chitosan NPs 
with negative surface charge (71). Pawar et. al. developed hepatitis B surface antigen 
loaded PLGA microparticles coated by chitosan or trimethyl chitosan. Following 
intranasal administration of coated PLGA microparticles to mice showed a higher anti-
HBsAg titer when compared to uncoated PLGA microparticles (72). 
Table ‎1-3 shows some recent research on polymeric based particles for pulmonary 
vaccine delivery. 
Table ‎1-3: Recent research (non-exhaustive list) on polymeric nanoparticles based 
pulmonary vaccine delivery. 
Polymer  Antigen Reference 
Poly(D,L-lactide) (PLA) Hepatitis B surface antigen  (73) 
Poly(D,L-lactide-co-glycolide) (PLGA) Hepatitis B surface antigen  (73) 
N-Trimethyl chitosan (TMC) Diphtheria toxoid  (52) 
poly(lactic-co-glycolic acid) 
(PLGA)/polyethylene glycol (PEG) 
Recombinant hepatitis B surface 
antigen 
(74) 
Chitosan DNA (tuberculosis) (75) 
Poly-L-lactide (PLA) Yersinia pestis F1 and V subunit (76) 
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1.6.2 Preparation of nanoparticles 
Protein and peptide encapsulation in NPs has been achieved by various methods such as 
emulsion solvent evaporation, salting out, and solvent displacement/solvent diffusion. 
Each method of protein encapsulation has its own advantages and disadvantages and 
each protein or peptide requires its own specific conditions depending on stability, 
solubilisation, controlled release, and elimination. The method of encapsulation is 
therefore entirely based on the physicochemical activity of the protein and its intended 
application (77).  
1.6.2.1 Emulsification/Solvent Evaporation/extraction  
Water-oil-water (w/o/w) double emulsion techniques (Figure ‎1-9.A) have been 
commonly applied as parameters such as particle size and drug loading can be 
controlled by varying the type, viscosity and amount of organic and aqueous phases, stir 
rate and temperature which can easily be adjusted (78). This method is best suited to 
encapsulate water soluble drugs such as peptides, proteins, and vaccines, unlike the o/w 
method which is better for water-insoluble drugs like steroids (79). In the double 
emulsion method an aqueous solution of the active ingredient is dispersed in an organic 
phase containing polymer (e.g. PLGA in dichloromethane) to form the first w/o 
emulsion. This emulsion is then dispersed in a large volume of water containing an 
emulsifier/stabiliser such as poly (vinyl alcohol), PVA, to form the w/o/w emulsion. 
The dispersion is performed using a homogenizer, high pressure homogenizer or 
ultrasound (22). The emulsion is then subjected to solvent removal by extraction or 
evaporation processes (80). With the solvent extraction method, the double emulsion is 
added to a large amount of water or an aqueous cosolvent, (e.g. acetone in an aqueous 
solution).  
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Figure ‎1-9: Methods of preparation of nano/microparticles: (A) 
emulsification/solvent evaporation method, (B) emulsification and solvent 
diffusion method and (C) salting out method. 
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One disadvantage of the double emulsion method is the removal of the solvent from the 
emulsion during which the water/oil (w/o) emulsion droplets are exposed to a large 
amount of water and this may lead to lower antigen loading and encapsulation 
efficiency, and an initial burst release. During solvent removal from the emulsion, 
antigen molecules can diffuse out from the emulsion into the aqueous solution and can 
also accumulate on the surface of particles, as they become hardened, leading to a high 
initial burst release (78). Additionally, the antigen is exposed to a harsh environment at 
the interface between the aqueous and organic phases and the high shear force during 
nanoparticle formulation (61). To improve protein stability and integrity stabilizers such 
as carrier proteins (e.g., albumin), surfactants or molecules such as trehalose and 
mannitol can also be added to the aqueous phase (22). 
Singh et al. produced poly-(ε-caprolactone) (PCL) NPs loaded with diphtheria toxoid 
using a double emulsion solvent evaporation method to study their use as a mucosal 
vaccine delivery system. The internal aqueous phase containing diphtheria toxoid and 
0.25 ml 10%w/v polyvinyl alcohol (PVA) was emulsified with the organic phase (100 
mg of PCL in 5 mL of dichloromethane), by homogenization at 12,000 rpm for 2 min. 
This w/o emulsion was added to a 25ml of 1.25% w/v PVA solution, and then 
homogenised for 5min at 12,000 rpm. The preparations were then stirred magnetically 
at room temperature for 18 h to allow solvent evaporation and NPs formation. The NPs 
produced were approximately 267±3 nm in size and preserved diphtheria toxoid 
integrity as confirmed by sodium dodecyl sulfate poly (acrylamide) gel electrophoresis 
(SDS-PAGE) study (81). 
1.6.2.2 Emulsification/Solvent Diffusion 
In the solvent diffusion (solvent displacement) technique (Figure ‎1-9.B), the polymer 
and protein are dissolved in a partially water soluble solvent and then saturated with 
water with strong stirring. Then the polymer–water saturated solvent phase is emulsified 
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in an aqueous solution containing a stabilizer, leading to solvent diffusion to the 
external phase and elimination by evaporation leading to the production of NPs (77). 
This technique is simple, provides high encapsulation efficiency without 
homogenization, has high batch to batch reproducibility, is easy to scale up, and 
produces a narrow size distribution of protein NPs (77).  
The problem of protein hydration and the presence of hydrophobic interfaces resulted in 
protein irreversible aggregation inside the NPs. These problems can be solved by the 
addition of stabilizers such as PEO (77). BSA and immune-γ-globulin (IgG) 
encapsulated in polyethylene oxide- PLGA (PEO–PLGA) using this technique showed 
high encapsulation efficiency (58.9%) and a slow rate of in vitro release (77). 
1.6.2.3 Salting out 
In the salting out technique (Figure ‎1-9.C) the polymer is solubilised in a water miscible 
organic solvent (e.g. tetrahydrofuran) then this solution is added to an aqueous solution 
containing salting out agents (e.g. magnesium chloride and stabilizer) under continuous 
stirring leading to the formation of primary emulsion. Dilution of the primary emulsion 
through addition of a large quantity of water under mild stirring leads to a reduction in 
salt concentration and promotes the diffusion of the organic solvent into the aqueous 
phase leading to the formation of NPs. Finally the NPs formed are isolated from the 
salting out agents either by centrifugation or cross-flow filtration. The major benefit of 
the salting out method is that it reduces protein unfolding and inactivation (77). The 
main disadvantages of the salting out method are the removal of the salting out agent 
and possible interactions between the salting out agents and drugs (36). Konnan et al. 
fabricated NPs by a salting out technique. The organic phase containing PLGA and 
PLA in THF was emulsified with an aqueous solution of PVA and a salting out agent 
(magnesium chloride hexahydrate) by mechanical stirring. A large volume of water was 
added to the o/w emulsion leading to diffusion of the water-miscible organic solvent 
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into the aqueous solution forming NPs with particle size ranging from 102 to 200 nm 
(82).  
1.6.3 Factors affecting uptake of nanoparticles by dendritic cells 
To achieve an optimum immune response upon administration of particulate antigens 
through the pulmonary mucosal route, it is essential to optimize the particles for size, 
surface charge and hydrophobicity. These parameters can also influence differential 
uptake by DCs, which play an important role in developing the immune response (73). 
1.6.3.1 Hydrophobicity  
The hydrophobicity of NPs can make a difference in the cellular uptake because more 
hydrophobic NPs have a tendency to adsorb more to the cell surface compared to their 
hydrophilic counterparts, perhaps because of enhanced nonspecific interaction with the 
hydrophobic cell surface (83). 
Thomas et al prepared porous poly (L-lactic acid) (PLA) and PLGA NPs for pulmonary 
delivery of hepatitis B vaccine. They investigated the effects of particle size and 
hydrophobicity on mucosal and cell-mediated immune response. Hydrophobic NPs 
larger than 500 nm evoked a stronger increase in secretory IgA, interleukin-2 and 
interferon-γ‎levels‎in comparison with hydrophilic NPs less than 500 nm (73).  
Researchers have demonstrated that particles formulated using hydrophobic polymers 
are more prone to phagocytosis than hydrophilic polymers (84; 85). For example, 
particles prepared from poly-(ε-caprolactone), which is more hydrophobic than PLGA, 
are removed by phagocytosis more efficiently and generate a stronger immune response 
to diptheria toxoid (81). However, there are many reports that shows the PLGA with a 
hydrophilic surface are promptly taken up by the dendritic cells (55; 86).  
1.6.3.2 Surface charge 
The surface charge of the particles plays an important role in generating an immune 
response. Cationic particles are effectively taken up by DCs. The ionic interaction 
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between the positive charge on the particles surface and the negative charge on the cell 
surface generates a successful bond and promotes particle uptake (87). Thomas et al 
have shown that cationic PLGA microspheres containing HBsAg significantly enhanced 
the mucosal and cell mediated immune response in comparison with PLGA 
microspheres (88). Modifying PLGA microspheres with chitosan resulted in an increase 
in mucosal residence time and enhanced immunogenicity (41).  
Chitosan nanoparticles with encapsulated DNA plasmid encoding eight T-cell epitopes 
from M. tuberculosis were administered intratracheally to the lungs of mice and induced 
the maturation of DCs, increased levels of IFN-γ‎ secretion‎ in‎ comparison‎with DNA 
plasmid solution alone (75). The exact mechanism of action of chitosan is unclear and 
may be attributed to mucoadhesive characteristics, increased cell penetration, enhanced 
cell interaction and immune-modulating responses (39). 
1.6.3.3 Particle size  
There are contradictory studies on the effect of particle size on the initiation of immune 
responses. Some reports demonstrate that particles of about‎5‎μm can efficiently initiate 
an immune response after mucosal administration; on the other hand other reports 
revealed that particles of about 1‎ μm‎ are‎ taken‎ up by antigen presenting cells more 
efficiently than 500 and 200 nm size particles resulting in a stronger immune response 
(73). In conflict to these studies, others showed that particles of about 500 nm or less 
were optimal for DCs uptake compared to particles of 1- 5‎μm in size (89).  
DCs and macrophages are able to take up any particles of a similar size to the pathogens 
(up to 10‎μm)‎so‎it‎is expected that both micro and nano particles can be easily taken up 
by both cells. However, to target vaccine antigens to DCs, NPs are preferred over 
microparticles. This restricted level of particle uptake by DCs in comparison with 
macrophages has been attributed to the different functions that these two cell types have 
for immune response. The macrophages remove foreign particles efficiently leading to 
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clearance while DCs are responsible for antigen take-up to an extent that is necessary to 
induce an immune response (89). Some research has demonstrated that DCs more 
efficiently take up small particles of a size similar to the viral size (around 20-200 nm), 
while macrophages phagocytose larger bacterial sized particles. There is an inverted 
relationship between particle size and the ability of uptake by DCs that could be 
attributed to the large surface area of the nanoparticles which promote rapid degradation 
and faster release of the encapsulated antigens within the cells. Moreover, the large 
surface area promotes higher protein loading through adsorption (87).  
Recently Foged et al. demonstrated that particle size, surface charge, shape, and 
composition of the substance to be delivered all have a major function in controlling 
particle uptake by human DCs. Moreover, it was resolved that for the highest uptake by 
DCs‎ the‎desired‎particle‎ size‎was‎0.5‎μm (diameter). Large particles (> 1‎μm)‎uptake‎
was highly promoted when they showed a positive surface charge (89). Furthermore, 
Manolova et al. showed that upon intracutaneous injection of polystyrene beads of 
different sizes, the large particles (500–2000 nm) connected with DCs from the site of 
administration and relied extensively on them for cellular transport, while small 
particles (20–200 nm) and virus-like particles (30 nm) were transported freely to the 
lymph nodes and were present in lymph nodes resident DCs (90). 
1.6.4 Technical concerns of nanoparticle pulmonary delivery  
NPs do not deposit efficiently in the lungs leading to the exhalation of the majority of 
the inhaled dose (91). Particulate systems incorporating NPs into micron-scale 
structures have been developed to solve the problem of delivering NPs to the lungs; 
such‎ as‎ embedding‎NPs‎within‎ an‎ inert‎ ‘microcarrier’,‎ porous‎ nanoparticle-aggregate 
particles (PNAPs), agglomerated NPs (91) and nanocomposite microparticles (NCMPs) 
(92) as a dry powder. These systems are designed to dissolute in the lung lining fluid, 
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releasing the NPs from the inert carrier (93). The methods of preparation and 
administration of dry powder formulations are described below in more details. 
1.7 Methods of preparation of dry powder for inhalation 
1.7.1 Freeze drying  
Freeze drying (or lyophilisation) involves first freezing the sample then removing the 
water via sublimation under vacuum. The drawbacks of this method are; slow 
processing, expense and the production of stresses on the antigen through the freezing 
and drying phases (36). The presence of a stabilizer is essential to protect the active 
ingredient, avoid agglomeration and to confirm suitable reconstitution ability. 
Carbohydrates such as sucrose, mannitol, dextran or lactose alone, or in presence of 
surfactants e.g. poloxamer 188 or polyvinyl alcohol are often added as stabilizers to 
protect the active ingredient and avoid coalescence. The ratio of nanoparticles to sugar 
acts as a determining factor in the stability and long term storage of the final form. 
Research on long term stability of these particles demonstrated that the use of 
cryoprotective agents during freeze drying decreased the particle growth in comparison 
with non cryoprotective preparations. For example, formulations freeze-dried in the 
presence of sucrose and trehalose at 2% and 3% w/v had more controlled particle size 
and performed better than when mannitol was used at the same concentrations (36). 
However, freeze drying is technically time consuming and expensive for 
macromolecules (94). 
1.7.2 Spray drying  
Spray drying is a one-step technique which transforms liquid formulations to a dried 
form. The liquid formulation can be a suspension or an emulsion that is atomized to a 
spray form and passed through hot air leading to the rapid evaporation of the solvent to 
produce dried particles. The dried particles are then separated from the gas by means of 
a cyclone (95). The characteristics of the particles produced rely on the type of feed 
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(e.g. suspension or emulsion) as well as the spray drying parameters such as solid 
concentration, solvent type and composition, solution feed rate, inlet temperature, gas 
type and flow rate, etc. (78).  
For pulmonary drug delivery the main advantages of using spray drying is the 
possibility to manage and alter the different parameters mentioned above. This results in 
optimization of dry powder properties such as size, morphology and density, as well as 
macroscopic powder characteristics such as bulk density, flowability and dispersibility. 
Furthermore, spray dryers can be easily scaled up for industrial production (95). 
However, high inlet temperature, separation of final powder and particles loss in lab-
scale spray -dryers are disadvantageous. The spray drying technique was previously 
applied to prepare microparticles loaded with insulin, tetanus toxoid (TT), recombinant 
human erythropoietin (rhEPO), and BSA (78). 
1.7.3 Spray freeze drying 
The spray-freezedrying method includes spraying an aqueous solution of drug into a 
spray chamber containing a cryogenic liquid (such as liquid nitrogen) leading to 
formation of frozen droplets which are then lyophilized to form porous dry powder 
particles suitable for inhalation. The main advantage of the spray-freeze-drying method 
is the ability to produce particles with controllable sizes and, as it is carried out at sub-
ambient temperature, heat sensitive polymers and highly potent macromolecules can be 
formulated into dry powder preparations. The main disadvantage of this method is the 
stresses due to freezing and drying, which may lead to irreversible damage to proteins. 
This is indicated as structural denaturation, aggregation and loss of biological activity 
upon reconstitution. Furthermore, loss of stability due to unfolding and aggregation still 
present a main challenge and also it is time consuming, and expensive (95).  
Amorij et al. demonstrated that an influenza subunit vaccine powder prepared by spray-
freeze-drying using oligosaccharide inulin as a stabilizer and administered through the 
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lung to BALB/c mice stimulated systemic humoral (IgG), cell-mediated (Il-4, IFN-γ)‎
and mucosal immune responses (IgA, IgG). While vaccination with a solution subunit 
vaccine through the pulmonary or intramuscular route only lead to systemic humoral 
(IgG) immune responses concluding that powder vaccine preparations could be 
advantageous for immunization (96).  
1.7.4 Supercritical fluid 
Supercritical fluids (SCF) are compressed gases or liquids above their critical 
temperatures (Tc) and pressures (Pc), and have many advantages of both gases and 
liquids. The solvating power and density can be managed by changing the pressure and 
temperature. Commonly used SCF include carbon dioxide (CO2), acetone, propane, 
nitrous oxide (N2O), chlorodifluoromethane, propane, water, diethyl ether, or mixture. 
In addition to its low cost and non-toxicity supercritical CO2 is the most widely used 
SCF because of  its accessible critical point at 31°C and 74 bar makes it suitable for 
processing thermolabile solutes as an alternative to conventional organic solvents. There 
are two main fundamental processes for particle drying with SCF. The first uses SCF as 
a solvent and the other as an antisolvent. In the first process, the drug is dissolved in the 
SCF, suddenly decompressed and then the solution is moved through an opening and 
rapidly expanded at low pressure. Rapid Expansion of a Supercritical Solution (RESS) 
applies with this concept. In the second type of process, the solute is insoluble in SCF 
so it utilizes SCF as an antisolvent. A solute is solubilised in an organic solvent 
followed by absorption of the SCF by the organic solvent. The liquid phase then 
expands and the solvation power decreased leading to particle formation. The following 
are processes that employ this second principle. Gas Anti-Solvent (GAS), Aerosol 
Solvent Extraction System (ASES), Supercritical Fluid Antisolvent (SAS), Precipitation 
with Compressed Antisolvent (PCA), Solution Enhanced Dispersion by Supercritical 
Fluids (SEDS), and supercritical fluid extraction of emulsion (SFEE). By applying these 
 37 
 
methods the particles can be formulated with the desired shape and size and any 
drawbacks on the macromolecules can be decreased. A comprehensive discussion of 
these methods has recently been published (94).  
The dry particulate prepared by SCF techniques are often less charged than those 
prepared mechanically making them flow more easily and thus more freely dispensed 
from a DPI. Moreover, SCF techniques allow the preparation of inhalable powder that 
are more uniform in terms of particle-size, distribution, crystallinity and morphology 
than those prepared by jet milling. Regardless of its ability, SCF is still considered as a 
rising technology that is still to be fully explored for DPI preparations; with increased 
concerns about the possibility of the denaturing effects of the solvents/antisolvents used 
in this technique (36; 94).  
Amidi et al. prepared diphtheria toxoid containing microparticles by a SCF spraying 
process, resulting in dry powder microparticles with a median volume diameter between 
2‎and‎3‎μm.‎Immunization of guinea pigs with diphtheria toxoid -N-Trimethyl chitosan 
microparticles via the pulmonary route lead to a strong immune response as showed by 
the induction of IgM, IgG, IgG1 and IgG2 antibodies comparable to or significantly 
higher than those obtained with subcutaneous administration of alum-adsorbed 
diphtheria toxoid showing an effective pulmonary delivery system of diphtheria toxoid 
antigen (52). 
1.8 Aerosol as a delivery system for pulmonary vaccine  
Inhalation devices can be divided into three different categories: the nebulizer, the 
pressurized metered dose inhaler (MDIs), and the dry powder inhaler (DPIs).  
1.8.1 Nebulizer 
There are two major types of nebulizers: jet nebulizers and ultrasonic nebulizers. The jet 
nebulizer uses the movement of compressed air or oxygen through a narrow opening, 
leading to a low pressure area next to a liquid feed tube which results in pulling up the 
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drug solution from the fluid reservoir and splitting it into droplets in the gas stream. The 
ultrasonic nebulizer uses a piezoelectric crystal vibrating at a high frequency to generate 
a fountain of liquid in the nebulizer chamber (97). Nebulization provides a constant 
output with minimum patient skills, large dose can be delivered, and disposable 
nebulizers are cheap (98).  
Pulmonary vaccination research has been carried out using nebulization of live, 
attenuated organisms such as tularemia, measles, attenuated Mycobacterium bovis in 
Bacille Calmette-Guérin (BCG), and rubella. However there is a potency loss obstacle 
as demonstrated when complex molecules broke down due to the shear force of the jet 
nebulizer. For example, a measles vaccine experienced about a 71 % loss of potency 
after nebulization (98). Nebulization has many drawbacks; it is bulky, requires large 
volumes of clean water and an electricity supply, has a long-time of administration, is 
expensive, has poor efficiency, has low reproducibility, high risk of bacterial 
contamination, needs continuous cleaning, and sometimes requires the use of 
compressor or gas cylinder which are impractical in low and middle income countries 
and in vaccine campaigns (95).  
1.8.2 Pressurized-meter dose inhaler 
In pMDIs, the drug formulation is either suspended or dissolved under pressure in a 
liquefied propellant in a canister provided with a valve to measure accurate doses and a 
positioner (95). Few vaccines have been administered using pMDIs. The main reason 
being the use of a hydrophobic propellant is too harsh for most antigens. Brown et al. 
administered Streptococcus suis bacteria into the lung of swine using liquefied 
dimethylether as propellant and only approximately 30-50 % of antigenicity in the 
respirable bacteria was preserved (98). 
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1.8.3 Dry powder inhaler  
Dry powder inhalers (DPIs) are cheap, simple, efficient, compact and disposable 
devices for single dose delivery and hence are ideal devices for antigen delivery. Most 
antigens are macromolecules (e.g. proteins, peptides, and polysaccharides) and are 
highly susceptible to chemical and physical degradation in liquid preparations. 
Administration of macromolecules as dry powder aerosols through the pulmonary route 
has been widely studied as a promising non-parenteral route for drug delivery that 
affords enhanced stability in comparison with traditional liquid dosage form. Proteins 
stability can also be enhanced by preparing them in a dry, solid state with excipients 
such as lactose, inulin and L-leucine (99; 100). The excipient that is approved by FDA 
for dry powder inhalation is lactose (98; 101). Recently, D-mannitol is available in the 
form of pulmonary diagnostic DPIs as Aridol
TM
 which approved by US food and drug 
administration office and in the form of DPIs for the treatment of cystic fibrosis and 
chronic bronchitis as Bronchitol
TM
 which aapproved by approved European regulatory 
committee (102). Many studies demonstrated the stability of measles vaccine without 
refrigeration when prepared as dry powder formulations (103; 104). Furthermore, DPIs 
can reach larger deposition efficiency, do not require an external driving force, and can 
be utilized by patients more simply than liquid formulations. Also DPIs vaccines can 
overcome the need of the cold chain which is a necessity for liquid vaccine preparations 
making the shipping and handling of the vaccine cheap and easier (38). However, this 
type would not be suitable for infant and children less than 4 years old due to the 
difficulty in reliable control of breathing pattern in this group (105). 
The possibility of using dry powder aerosol vaccines has previously been investigated. 
Influenza subunit vaccines formulated as dry powder using spray-freeze-drying were 
revealed to induce superior systemic and mucosal humoral and cell-mediated immune 
responses in mice when administered via the pulmonary route in comparison with liquid 
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vaccines delivered by the pulmonary or the intramuscular route (96). The efficiency of 
spray-dried NPs administered by inhalation of Bacille Calmette-Gue´rin (BCG) in 
inducing immunity against Mycobacterium tuberculosis has been studied in guinea pigs, 
and specific immune responses have been shown in macaques after aerosol delivery of a 
measles vaccine (106).  
Lu et. al. prepared recombinant antigen 85B protein-PLGA microparticles as dry 
powder in respirable size to be administered to the guinea pig via inhalation in single or 
multiple doses of homologous and heterologous antigens to protect against tuberculosis. 
A single dose of Bacille Calmette–Guérin (BCG) administered subcutaneously was 
applied as the positive control and as part of immunisation plans. Immunized guinea 
pigs were challenged with a low-dose aerosol of Mycobacterium tuberculosis H37Rv to 
evaluate the amount of protection assessed as decrease in bacterial burden (CFU) in the 
lungs and spleens of animals. Histopathological evaluation and morphometric 
assessment of these tissues were also carried out. The heterologous strategy of BCG 
prime–Ag85B PLGA microparticles aerosol boosts showed enhanced protection against 
bacterial infection, as identified by a decrease in bacterial burden CFU in both the lungs 
and spleens of treated animals compared with untreated. However, there was no 
statistical difference in the bacterial burdens data between the BCG and BCG-BCG 
groups. The histopathological and morphometric evaluation of lung and spleen tissue 
showed the positive effect of BCG prime–Ag85B PLGA vaccination by evaluating a 
smaller area of tissue affected and number and size of granulomas noticed in the tissues 
of guinea pigs vaccinated via the lung. Hence, it was concluded that direct vaccination 
via the lung by these microparticles improved the protection provided by primary 
immunization with BCG against tuberculosis in guinea pigs. Due to the fact that a 
substantial percentage of the people around the world have been vaccinated with BCG 
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in early childhood, a boosting dose with aerosol may be a potential method to augment 
and extend the immunity due to BCG-immunisation (107). 
Recently, Agarkhedkar et al. carried out Phase I clinical study to examine the safety and 
immune responses of measles vaccine dry powder for inhalation. The study included 
three groups: the first group treated with measles vaccine dry powder using Puffhaler®, 
the second group treated with measles vaccine dry powder using Solovent
TM
, and the 
third group treated using the licensed subcutaneous measles vaccine. The results 
showed a good safety and immunogenicity profile of measles vaccine dry powder using 
Puffhaler® and Solovent
TM
 in comparison with subcutaneous measles vaccine (108). 
Moreover, it has been indicated that dry particulate antigens, in comparison with 
solubilized antigens, are taken up more efficiently by APCs, leading to a strong immune 
response (99).  
Saluja et al also demonstrated immunization through the pulmonary route using dry 
powder inhalation leading to a strong immune response in comparison with 
conventional liquid preparation administered intramuscularly or via the pulmonary route 
(38). 
The formulation of vaccines as dry powder for inhalation seems to be a promising new 
method to vaccination. 
1.9 Thesis hypothesis 
Dry powder inhaler aerosols of a pneumococcal protein PspA4Pro, encapsulated within 
nanocomposite microparticles, as a vaccine for deep lung delivery. 
1.10 Thesis Aim and objectives 
To design, formulate and characterise nanocomposite microparticles encapsulating 
pneumococcal protein PspA4Pro as a vaccine for the prevention of pneumococcal 
disease by dry powder pulmonary delivery. 
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To obtain the aim of the thesis a systematic study was designed considering the 
following objectives: 
1) Optimisation of PGA-co-PDL NPs prepared by double emulsion solvent 
evaporation technique. 
a. Optimisation of NPs in term of size and protein loading using factorial design. 
b. Investigate the effect of chitosan hydrochloride adsorption on NPs regarding 
particle size and charge. 
c. A study of NPs in vitro cell toxicity and DCs uptake. 
d. Application of the optimum NPs preparation parameters for PspA4pro 
encapsulation. 
2) Incorporation of optimum NPs into micron-scale structures NCMPs via spray 
drying with L-leucine as microcarrier. 
a. Optimisation of NCMPs formulations in term of morphology and yield%. 
b. A study of the in vitro aerosolisation behaviour, in vitro release and cell toxicity. 
c. Evaluation of the stability and integrity of protein released from optimum 
formulations and an investigation of relative antigenicity of released PspA4pro. 
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2. Materials and methods 
2.1. Materials 
Material and Properties Source 
Glycerol Sigma-Aldrich, UK 
ω-pentadecalactone (PDL) 
Myo-Inositol ≥99% 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) 
Dichloromethane (DCM) 
RPMI-1640 medium with L-glutamine and sodium hydrogen 
carbonate (NaHCO3) 
antibiotic/antimycotic solution (100x) 
Glycine 
Sodium dodecyl sulfate (SDS) 
Tris hydrochloride 
Sodium chloride 
Albumin tagged with fluorescein isothiocyanate (FITC-BSA) 
Alkaline phosphate yellow liquid substrate, number P7998  
Divinyl adipate (DVA) Fluorochem, UK 
Lactose (Lactohale, LH 230) Friesland food, 
Netherland.  
Methanol Fisher Scientific, UK 
Chloroform 
Tetrahydrofuran (THF) 
96-well flat bottom black plates 
25 and 75 cm
2
/tissue culture flask with vented cap (IWAKI 
brand) 
24-well tissue culture plates and 96-well flat bottom plates 
Paraformaldehyde 
Dimethyl sulfoxide (DMSO) 
Novozyme 435 (a lipase derived from Candida antarctica 
immobilized on a microporous acrylic resin) 
Biocatalytics, USA 
Polystyrene standards kit  Supelco, USA 
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PLGEL 5 µm MIXED-D 300 x 7.5 mm column  Varian, Polymer 
Laboratories, UK 
Bovine serum albumin (BSA, Mw 67 kDa)  Avenchem, UK 
Poly (vinyl alcohol) (PVA, Mw of 13- 23 kDa, 87-89% 
hydrolyzed) 
Clariant GmbH, 
Frankfurt amMain, 
Germany. 
QuantiPro bicinchoninic acid (BCA) protein assay kit  Sigma, UK. 
Disposable Plastic Cuvets, Catalog Number C5416 
Protogel (30% acrylamide, 0.8% Bis-acrylamide stock 
solution 37.5:1) 
Geneflow limited, UK 
Protogel resolving buffer (1.5 M Tris-HCl, 0.4% SDS, pH 
8.8) 
Protogel stacking buffer (0.5 M Tris-HCl, 0.4% SDS, pH 6.8) 
N, N, N`, N`,-tetramethyl ethylenediamine (TEMED) 
Vertical Gel Electrophoresis Units 
Protein loading buffer blue, BLUeye Prestained Protein 
Ladder  
Ammonium persulfate (APS) AGT, Bioproduct, 
Global life science 
supply, UK. 
Colloidal Coomassie Brilliant Blue Severn Biotech Ltd, 
UK 
Phosphate buffered saline tablets pH 7.3  Oxoid, UK 
Chitosan hydrochloride: molecular weight: 200,000–400,000; 
degree of deacetylation: 80% and 95%  
HEPPE MEDICAL 
CHITOSAN GmbH, 
Germany 
L-leucine ≥ 99.5%  Bioultra, Sigma, UK. 
Fluorescamine Acros Organics; 
Morris Plains, NJ 
Foetal calf serum (FCS) heat inactivated Biosera, UK. 
Adenocarcinomic human alveolar basal epithelial cell line, A 
549 (CCL-185
TM
) 
American Type 
Culture Collection 
(ATCC). Immature DCs; monocyte, mouse, JAWS II (CRL-11904
TM
). 
Fetal bovine serum Gibco by life 
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L-glutamine technologies, UK. 
Granulocyte macrophage colony-stimulating factor (GM-
CSF) 
Minimum Essential Medium (MEM) alpha-nucleosides 
8-well chambered #1 cover glass system Nunc Lab-Tek, 
Thermo Scientific, 
UK. 
4′,6-diamidino-2-phenylindole, dihydrochloride (DAPI) Invitrogen, Ltd.,UK. 
Wheat Germ Agglutinin Texas RedR-X conjugate (WGA TR) 
High binding chemistry 96-well plate Costar microplate Cole-Parmer, UK 
10x fish gelatin blocking solution number 22010 Biotium, Hayward, 
CA. 
20x TBS tween 20 buffer number 28360 was obtained from 
Thermo, UK. 
Anti-PspA monoclonal antibody clone number 22003 QED Biosciences, San 
Diego, CA. 
Aalkaline phosphatase conjugated goat anti-mouse IgG 
number 115-055 (heavy and light chain) 
Jackson 
ImmunoResearch, 
West Grove, PA. 
Recombinant PspA4Pro A kind gift from Dr 
Eliane Miyaji and Dr 
Viviane Gonçalves 
from the Insituto 
Butantan, Brazil. 
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2.2. General Methods 
2.2.1. Polymer synthesis  
The poly glycerol adipate-co-ω-pentadecalactone (PGA-co-PDL) was synthesized via 
an enzyme catalysed condensation and ring opening co-polymerization reactions 
(Figure ‎2-1) as described by Thompson et al. (62). Briefly, a 250mL two-necked round 
bottom flask equipped with a centre stirrer guide and an open top condenser (to act as an 
outlet for the acetaldehyde produced), was charged with the monomers, glycerol (125 
mmol), DVA (125 mmol), and PDL (125 mmol) and half the THF (15 ml). The flask 
was fitted with an overhead stirrer paddle and condenser, and immersed to the level of 
the‎solution,‎in‎a‎water‎bath‎(50‎˚C)‎and‎stirred‎for‎20‎min‎to‎allow‎the‎temperature‎to 
equilibrate. The Novozyme 435 (1.25 g) was added with the remaining THF (15 ml) 
and the reaction continued for 6 h. Upon completion, 300 ml of warm DCM was added 
to the flask and stirring continued to dissolve the viscous polymer. The enzyme was 
removed by Buchner filtration under vacuum. The solvent was removed by rotary 
evaporation (60‎ ˚C, Heidolph Laborota 4000). Methanol (100 ml) was added and the 
mixture agitated to precipitate the polymer and leave unreacted monomers and 
oligomers in solution. The solid polymer was obtained by filtration and air dried for 48 
h before storing in desiccator at room temperature.  
2.2.2. Polymer characterization  
2.2.2.1. Gel Permeation Chromatograph  
Polymer molecular weight was characterized by Gel Permeation Chromatography 
(GPC) using a Viscotek system employing OmniSEC 3 software, TDA Model 300. The 
system was fitted with two PLGEL 5 µm MIXED-D 300 x 7.5 mm columns stored in 
the‎detector‎oven‎at‎40‎˚C,‎and a flow rate of 1mL/min applied using chloroform as the 
mobile phase. The detector alignment and instrument sensitivity parameters had been 
previously calibrated using different molecular weight of polystyrene standard. 
 48 
 
2.2.2.2. Proton nuclear magnetic resonance  
Proton nuclear magnetic resonance (
1
H-NMR) spectroscopy was used to confirm the 
chemical structure of the synthesised polymer. The 
1
H-NMR was performed using a 
Bruker AVANCE 300 MHz, inverse probe with B-ACS 60 and autosampler with 
gradient shimming. The spectra were analysed by MestReNova software. 
2.2.2.3. Differential scanning calorimeter  
The melting point (Tm) and glass transition temperature (Tg) were determined using 
differential scanning calorimetry (DSC, Perkin Elmer 800, Pyris software). The system 
was calibrated with an indium reference standard. The polymer sample (3–5mg) was 
placed into a hermetically sealed and crimped pan. The samples were scanned at heating 
and cooling rate of 10 °C/min purged with nitrogen. Tm and Tg were reported from the 
second heating scan after previously heating to 75 ˚C followed by cooling to – 90 ˚C. 
2.2.3. Nanoparticle preparation 
BSA loaded PGA-co-PDL NPs were prepared by (w/o/w) double emulsion/solvent 
evaporation method (Figure ‎2-2). A Taguchi L36 orthogonal array design of experiment 
was used to optimise the preparation parameters to achieve NPs of optimum particle 
Figure ‎2-1: Reaction scheme for the enzymatic synthesis of poly ( glycerol adipate-
co-ω-pentadecalactone), PGA-co-PDL. 
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size and protein loading. The optimised conditions used were: internal aqueous phase 
(IAP) 0.5 ml of protein solution (1 %) containing PVA (1 %) was emulsified in 1 ml 
DCM (organic phase, OP) containing 50 mg of PGA-co-PDL, using a probe sonicator 
(VC X 500 Vibra-Cell
TM
, Sonics & Materials, Inc., Newtown, CT, USA, 13mm probe) 
at 45 % amplitude for 15 sec over an ice bath. The resulting single emulsion was 
emulsified into 25 ml of a 1% PVA solution (external aqueous phase, EAP) using the 
same probe sonicator at 45 % amplitude for 30 sec to form a w/o/w double emulsion. 
The double emulsion was stirred magnetically for 2 h at room temperature to evaporate 
the DCM. The NPs were collected by centrifugation (Sigma 3-30k, SIGMA 
Laborzentrifugen GmbH, Germany) at 40,000 xg for 1 h at 4 ⁰C, washing twice with 
distilled water. Control NPs were prepared using the same method but without protein. 
For particle uptake studies, fluorescein isothiocyanate (FITC-BSA) was added in the 
IAP. 
 
 
 
 
 
 
 
 
 
 
 
 
The adsorption of CHL was achieved by two strategies as follows: 
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Figure ‎2-2: Simple scheme shows nanoparticles preparation by double emulsion 
solvent evaporation method. 
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2.2.4. Cationic nanoparticle preparation 
The adsorption of CHL was achieved by two strategies as follows: 
1. The first strategy involved the adsorption of CHL onto the surface of the 
preformed NPs prepared as described in section ‎2.2.3 (109; 110): 
1.1. To optimise the CHL concentration, NPs were suspended in an aqueous 
solution of CHL of varying PGA-co-PDL / CHL weight ratio from 1:0, 1:1, 1:3, 
1:6, 1:8 to 1:10 with and without 1% PVA and incubated for 2 h at room 
temperature with magnetic stirring. The suspension was then centrifuged at 40,000 
x g for 1 hour at 4 ⁰C, and washed twice with distilled water.  
1.2. To optimise the amount of PVA required, NPs were suspended in an 
aqueous solution of CHL containing PGA-co-PDL /CHL weight ratio 1:6 with 0, 
0.5 or 1% PVA and incubated for 2 h at room temperature with magnetic stirring. 
The suspension was then centrifuged at 40,000 x g for 1 hour at 4 ⁰C, and washed 
twice with distilled water.  
1.3. To optimise the adsorption time, NPs were suspended in an aqueous 
solution of CHL (PGA-co-PDL / CHL weight ratio 1:6) without PVA and incubated 
for 2h, 4 h, 6h, 24h at room temperature with magnetic stirring. The suspension was 
then centrifuged at 40,000 x g for 1 hour at 4 ⁰C, and washed twice with distilled 
water.  
2. The second strategy involved the addition of CHL to EAP during the NPs 
preparation process as described in section ‎2.2.3 (41; 72; 111). CHL was dissolved 
at various concentrations (2, 4, 6, 8, 10, 16, 20 mg/ml) in the EAP. The suspension 
was then centrifuged at 40,000 x g for 1 hour at 4 ⁰C, and washed with distilled 
water. The supernatants were further assessed for CHL adsorption to NPs. 
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2.2.5. Quantification of chitosan hydrochloride adsorption 
The amount of CHL adsorbed on the surface of cationic NPs was determined by 
fluorescamine due to its high sensitivity and specificity (111). Fluorescence was 
produced by the reaction of fluorescamine with the primary amino groups of CHL. 
Fluorescamine in DMSO solution (100 µL of 0.2%) was added to the supernatant 
(collected from section 2 of the section ‎2.2.4, 20 µL) in a black 96-well fluorescent 
detection microplate. This was incubated for 3 h protected from light, and the 
fluorescence measured at an excitation wavelength of 390 nm and emission wavelength 
of 515 nm using a microplate reader (Clariostar BMG LABTECH, Germany). A CHL 
calibration curve was prepared for each experiment. The mass CHL adsorbed onto the 
NPs was calculated by subtracting the free CHL in the supernatant from the initial 
amount of CHL added, equation 2-1: 
𝒒 =
(𝑪𝒊−𝑪𝒆 ) 
𝑾
𝑽            Equation ‎2-1 
where q is the amount (mg) of adsorbed CHL on NPs, V is the volume of suspension 
(ml), W is the mass (mg) of NPs, and Ci and Ce are the initial feed concentration of 
CHL and the free CHL concentration (mg/ml) at equilibrium, respectively (111). 
2.2.6. Adsorption isotherm models 
The adsorption mechanism of CHL on NPs could be explained by using isotherm 
models: the Langmuir, (equation 2-2); BET (Brunauer–Emmett–Teller), (equation 2-3); 
Freundlich, (equation 2-4); and Halsey, (equation 2-5). The isotherm models were 
plotted in a linear form using the measured adsorption values. Listed below are the 
equations of isotherm models where, q is the weight of adsorbed CHL per unit weight 
of NPs, Ce is the equilibrium concentration of unadsorbed CHL, qm, and k are constants 
referred to the adsorption capacity, and b and n are constant referred to the intensity of 
adsorption (111). 
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𝑪𝒆
𝒒
=  
𝟏
𝒃 𝒒𝒎
+
𝑪𝒆
𝒒𝒎
   Equation ‎2-2 
𝑪𝒆
𝒒−(𝟏−𝑪𝒆)
=  
𝟏
𝒃 𝒒𝒎
+
𝒃−𝟏
𝒃 𝒒𝒎
  Equation ‎2-3 
𝐥𝐨𝐠 𝒒 = 𝐥𝐨𝐠 𝒌 +  
𝟏
𝒏 
𝐥𝐨𝐠 𝑪𝒆  Equation ‎2-4 
𝒍𝒏 𝒒 =
𝟏
𝒏
𝒍𝒏 𝒌 −  
𝟏
𝒏 
𝒍𝒏 (−𝒍𝒏 𝑪𝒆)  Equation ‎2-5 
2.2.7. Characterization of nanoparticles 
2.2.7.1. Particle Size and zeta potential 
Particle size, polydispersity index (PDI) and zeta potential were measured by laser 
differaction using a Zetasizer Nano ZS (Malvern Instruments Ltd, UK). An aliquot of 
200 µl of the suspension was diluted with 3ml of deionized water. The diluted samples 
were placed into a cuvette and the measurements were conducted at ambient 
temperature (25 °C) (n=3). 
2.2.7.2. Encapsulation efficiency and protein loading of nanoparticles 
The amount of protein loaded in the NPs was determined by indirect and direct 
methods.  
Direct method: the amount of protein loaded in the NPs was determined after 
extraction from the NPs. Ten milligrams of protein-loaded NPs was dissolved in 4 mL 
of DCM followed by the addition of 2 mL of distilled water. The mixture was vortexed 
at 1000 rpm and then placed on the shaker for extraction overnight. After centrifugation 
(Sigma 3-30k, SIGMA Laborzentrifugen GmbH, Germany) at 40,000 xg for 1 h at 4 ⁰C 
the supernatant was removed for analysis.  
Indirect method: the amount of protein loaded in the NPs was determined by 
measuring the amount of protein remaining in the supernatant and wash after 
centrifugation.  
Both methods carried out using a QuantiPro bicinchoninic acid (BCA) protein assay kit 
(n=3). This assay is based on colorimetric detection. Protein concentration was 
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determined by UV spectroscopy at 562 nm (Genesys 5 spectrophotometer, Thermo 
Fisher Scientific Inc, Waltham, MA).  
In order to eliminate any source of interfering with BCA assay in the direct method an 
unloaded NPs was treated as the BSA loaded NPs and used as a blank while in the 
indirect method the supernatant of unloaded NPs was used as a blank. A calibration 
curve was obtained with BSA standard solutions (2.5-30 µg/ml). The encapsulation 
efficiency (EE %) and drug loading (DL) were calculated according to equations 2-6 
and 2-7:  
𝑬𝑬 % =  
𝒂𝒎𝒐𝒖𝒏𝒕 𝒐𝒇 𝑩𝑺𝑨 𝒂𝒅𝒅𝒆𝒅−𝒇𝒓𝒆𝒆 𝒂𝒎𝒐𝒖𝒏𝒕 𝒐𝒇 𝑩𝑺𝑨
𝒂𝒎𝒐𝒖𝒏𝒕 𝒐𝒇 𝑩𝑺𝑨 𝒂𝒅𝒅𝒆𝒅
× 𝟏𝟎𝟎                     Equation ‎2-6 
 
𝑫𝑳 =  
𝒂𝒄𝒕𝒖𝒂𝒍 𝒂𝒎𝒐𝒖𝒏𝒕 𝒐𝒇 𝒆𝒏𝒄𝒂𝒑𝒔𝒖𝒍𝒂𝒕𝒆𝒅 𝑩𝑺𝑨 (µ𝒈)
𝒂𝒄𝒕𝒖𝒂𝒍 𝒂𝒎𝒐𝒖𝒏𝒕 𝒐𝒇 𝒏𝒂𝒏𝒐𝒑𝒂𝒓𝒕𝒊𝒄𝒍𝒆𝒔  (𝒎𝒈)
                                          Equation ‎2-7 
2.2.8. Preparation of nanocomposite microparticles by spray drying  
Spray drying was used to incorporate the NP formulation into nanocomposite 
microparticles (NCMPs). NCMPs were prepared by spray drying NPs suspended in 
aqueous L-leucine solutions (at polymer-to-carrier ratio of 1:1.5 w/w) using a Büchi, B-
290 mini-spray dryer (Büchi Labortechnik, Flawil, Switzerland) with a standard two-
fluid nozzle (0.7 mm diameter). A Taguchi L27 orthogonal array design of experiment 
was used to optimise the parameters to achieve NCMPs of highest yield %. The 
optimised condition used were: feed rate 10%, aspirator capacity 100%, atomizing air 
flow rate 400 L/h, inlet drying temperature 100ºC (corresponding outlet temperature of 
approximately 42-46‎ ˚C), and the feed concentration 12.5 mg/ml.  The dried powder 
was collected from the particle collecting vessel and stored in a desiccator at room 
temperature prior to characterization.  
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2.2.9. Characterization of nanocomposite microparticles 
2.2.9.1. Particle size and zeta potential 
Five milligram of NCMPs were suspended in 7 ml deionized water and the 
measurements recorded at 25°C (n=3) to determine the geometric particle size and zeta 
potential by laser diffraction using a Zetasizer Nano ZS (Malvern Instruments, UK). 
2.2.9.2. Morphology of nanocomposite microparticles 
Spray dried NCMPs samples were mounted on aluminum stubs (pin stubs, 13mm) 
layered with a sticky conductive carbon tab and coated with palladium (10-15 nm) 
(EmiTech K 550X Gold Sputter Coater, 25mA for 3 min), and visualized by scanning 
electron microscopy (SEM) (FEI – QuantaTM 200 ESEM, Holland).  
2.2.9.3.  Yield of spray dried nanocomposite microparticles 
 The yield of spray dried NCMPs (dry powder) was quantified as a percentage mass of 
expected total powder yield according to equation 2-8: 
𝒀𝒆𝒊𝒍𝒅 % =  
𝑾𝒆𝒊𝒈𝒉𝒕 𝒐𝒇 𝒅𝒓𝒚 𝒑𝒐𝒘𝒅𝒆𝒓 𝒄𝒐𝒍𝒍𝒆𝒄𝒕𝒆𝒅 𝒂𝒇𝒕𝒆𝒓 𝒔𝒑𝒓𝒂𝒚 𝒅𝒓𝒚𝒊𝒏𝒈
𝑾𝒆𝒊𝒈𝒉𝒕 𝒐𝒇 𝒕𝒐𝒕𝒂𝒍 𝒅𝒓𝒚 𝒎𝒂𝒔𝒔 𝒖𝒔𝒆𝒅 𝒇𝒐𝒓 𝒕𝒉𝒆 𝒑𝒓𝒆𝒑𝒂𝒓𝒂𝒕𝒊𝒐𝒏
× 𝟏𝟎𝟎            Equation ‎2-8 
2.2.9.4. Moisture content 
A thermogravimetric analyser (TGA) was used to evaluate the moisture content of dry 
powder after spray drying. Moisture content was measured using TGA Q50, UK 
equipped with TA universal analysis 2000 software. Approximately 10–15 mg of 
sample was weighed in a platinum pan and heated over the temperature range 25– 
650°C using a scanning rate of 10 °C/min purged under nitrogen at 20 ml/min. The 
moisture content was analysed for data collected between 25 to 120 °C.  
2.2.9.5. Powder density and primary aerodynamic diameter 
The powder density of selected NCMPs powders was determined by adding 
approximately 0.2 g of powder to a 5 ml graduated cylinder and recording the volume. 
The tapped density was determined by tapped density measurements on the same 
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samples in a 5 ml graduated measuring cylinder until constant volume was obtained 
(n=3).  
Theoretical primary aerodynamic diameter (dae) was calculated using data acquired 
from geometric particle size (d) and tapped‎density‎(ρ)‎according‎to‎equation 2-9. 
𝒅𝒂𝒆 = 𝒅 √
𝝆
𝝆𝟏
               Equation ‎2-9 
ρ1 = 1 g/cm
3 
2.2.10. In vitro aerosolisation studies 
The aerodynamic particle size of the NCMPs was assessed using a Next Generation 
Impactor (NGI) (NGI is specified in the USP Chapter <601> as Apparatus 5 and Ph. 
Eur. Chapter 2.9.18 as Apparatus E for their use in measuring the mass distribution of 
pharmaceutical aerosols by aerodynamic diameter) (112). The NGI have a range of cut-
off diameters at 60 L/min (Table ‎2-1), with particles captured on any specific stage 
having an aerodynamic diameter less than the preceding stage, assuming ideal collection 
behaviour on each stage. Optimum NCMPs samples were weighed (4- 6 capsules, each 
corresponding to 10-15 mg spray-dried powder) and manually loaded into 
hydroxypropyl methylcellulose capsules (size 3) and aerosolised via a Cyclohaler® 
(Teva pharma) into NGI. The capsule was punctured using the actuator of the 
Cyclohaler® prior to inhalation and a pump (Copley HCP5, Nottingham, UK) was used 
to simulate an inspiration (the flow rate was 60L/min for 4s). Prior to testing, the pre-
separator was filled with 15ml of 0.15 M NaCl as washing media. The NGI stages were 
coated with 1% tween 80: acetone solution to eliminate particle bounce (113). Four to 
six capsules were emptied in each run (3 runs). Following aerosolisation, the samples 
were collected from each stage of the NGI, pre-separator, throat, mouth piece, inhaler, 
and capsule by washing with a DCM/0.15 M NaCl mixture (2:1) to dissolve the 
polymer and the encapsulated BSA, which was determined by QuantiPro BCA protein 
assay as described in section 2.2.4.2. (n=3). The emitted dose (ED) was determined as 
 56 
 
the sum of powder deposited in mouthpiece, throat, pre-separator, NGI stages and 
micro-orifice collector of the NGI (MOC), the fine particle dose (FPD) was determined 
as the sum of powder deposited in NGI stages and MOC with aerodynamic diameters 
less than 4.6 μm,‎the‎fine‎particle‎fraction‎(FPF%) was determined as the fraction of ED 
deposited in the NGI and MOC with aerodynamic diameters less than 4.6 μm,‎and‎the‎
mass median aerodynamic diameter (MMAD) was calculated from log-probability 
analysis. 
 
 
Table ‎2-1: Effective cut-off diameters for NGI impactor at 60 L/min (with 
permission from (113)). 
 
Stage Aerodynamic cut-off diameter (µm) 
1 8.1 
2 4.5 
3 2.9 
4 1.7 
5 1 
6 0.6 
7 0.3 
MOC < 0.3 
MOC: micro-orifice collector of the NGI. 
2.2.11. In vitro release study  
Spray dried NCMPs samples (10 - 15 mg) were placed in micro tubes and dispersed in 
1.2 ml of PBS (pH 7.4). The samples were incubated at 37 °C and left rotating at 20 
RPM in a sample mixer (HulaMixer, Invitrogen Dynal AS, Life Technologies).  At 
predetermined time intervals up to 48 h, the samples were centrifuged (13,000 rpm for 
30 min) and 0.5 ml of the supernatant removed and replaced with fresh buffer. The 
supernatant was analysed by the QuantiPro BCA protein assay as described above 
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(n=3). The percentage cumulative protein released was calculated according to equation 
2-10. 
% 𝑪𝒖𝒎𝒖𝒍𝒂𝒕𝒊𝒗𝒆 𝒑𝒓𝒐𝒕𝒆𝒊𝒏 𝒓𝒆𝒍𝒆𝒂𝒔𝒆𝒅 =
𝒄𝒖𝒎𝒖𝒍𝒂𝒕𝒊𝒗𝒆 𝒑𝒓𝒐𝒕𝒆𝒊𝒏  𝒓𝒆𝒍𝒆𝒂𝒔𝒆𝒅
𝒑𝒓𝒐𝒕𝒆𝒊𝒏 𝒍𝒐𝒂𝒅𝒆𝒅
× 𝟏𝟎𝟎        Equation ‎2-10
  
The % cumulative protein release data was assessed using different release models, 
namely‎ zero‎ order,‎ first‎ order‎ and‎ Higuchi’s‎ square‎ root‎ plot,‎ and‎ a‎ correlation‎
coefficient close to unity was used as the mechanism and order of release (114). The 
following plots were made: cumulative % drug release vs. time (zero order kinetic 
model); log cumulative of % drug remaining vs. time (first order kinetic model); 
cumulative % drug release vs. square root of time (Higuchi model). 
2.2.12. Investigation of protein structure  
2.2.12.1. SDS-PAGE analysis of protein integrity 
The primary structure of the proteins was characterized by sodium dodecyl sulfate poly 
(acrylamide) gel electrophoresis (SDS-PAGE). NPs and spray dried NCMPs (10-20 mg) 
were suspended in 0.5-1.5 ml of phosphate buffer saline (PBS, pH 7.4). The samples 
were incubated at 37 °C and left rotating at 20 RPM on a sample mixer (HulaMixer, 
Invitrogen Dynal AS, Life Technologies) for 24 h. This was followed by centrifugation 
(Sigma 3-30k, SIGMA Laborzentrifugen GmbH, Germany) at 40,000 xg for 1h, and 50 
µl of supernatant was withdrawn to perform SDS-PAGE. The standard was 75 µg/ml of 
protein in water. The SDS-PAGE was performed on a CVS10D omniPPAGE vertical 
gel electrophoresis system (Geneflow Limited, UK). 
Sodium dodecyl sulfate poly (acrylamide) gels (10 cm W × 8 cm L × 0.5 mm thick) 
were freshly cast for all experiments as described in appendix- 1. Protein samples and 
standard were treated with protein loading buffer in a ratio (1:1) for 3 min at 95°C. The 
protein molecular weight marker, standard, and samples were loaded into the wells (25 
µl per well). Electrophoresis was performed at a constant voltage of 100 V for 2.3 h. 
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Then the gel was stained with colloidal Coomassie Brilliant Blue stain (as described in 
appendix- 1). A Molecular Imager® Gel‎ Doc™‎ XR+‎ System‎ with Quantity One 
Software was used for the gel imaging and documentation.  
2.2.12.2. Circular dichroism spectroscopy 
The secondary structure of standard protein (as a control), and protein released after 48 
h was determined via circular dichroism (CD) spectra using a J-815 spectropolarimeter 
(Jasco, UK) at 20 °C  (115). Five scans were performed per sample using a 10 mm path-
length cells at far-UV wavelengths from 260-180 nm at a data pitch of 0.5 nm, band 
width of 1 nm and a scan speed 50 nm/min. Far-UV CD spectra were collated for 
standard protein and protein released in PBS after 48 h. For all spectra, the baseline 
acquired in the absence of sample was subtracted (116). The secondary structure of the 
samples was estimated using the CDSSTR method (117) protein reference set 3 from 
the DichroWeb server (118; 119). 
2.2.13. Production and purification of PspA4Pro 
Recombinant PspA4Pro was produced, purified, and provided by Dr. Eliane Miyaji and 
Dr. Viviane Gonçalves from Centro de Biotecnologia, Instituto Butantan, São Paulo, 
Brazil. 
The PspA4Pro was produced and purified using published methods with modifications 
(120; 121). PspA4Pro was produced in 5 L bioreactors by; fed-batch cultivation with 
defined medium including glycerol as carbon source and lactose as inducer (120) or 
batch cultivation with complex medium including glucose, glycerol and lactose for 
auto-induction (122). The purification procedure includes cell disruption in a continuous 
high pressure homogenizer at 500 bar for 8 min, precipitation of the homogenate with 
0.1% cationic detergent cetyltrimethylammonium bromide, pellet removal by 
centrifugation, anion exchange chromatography in Q-Sepharose, cryoprecipitation at pH 
4 and cation exchange chromatography in SP-Sepharose (121). The desired protein 
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purity of > 95% was reached with good yield (14-30 %). The established procedure also 
removed lipopolysaccharides (LPS), producing an acceptable concentration of 
endotoxin (0.3-0.6 EU/ml) in the final product (123). The purified protein was identified 
by‎ antibodies,‎ capable‎ to‎ bind‎ lactoferrin‎ and‎ displayed‎ the‎ characteristics‎ α-helical 
secondary structure. 
2.2.14. In vitro antigenicity study of protein 
The antigenicity of PspA4Pro was defined by the capability of anti-PspA antibody to 
bind to the released PspA4Pro. The antigenicity of PspA4Pro was measured using an 
enzyme-linked immunosorbent assay (ELISA) as described previously by Haughney et 
al. with modifications (30). The concentration of released PspA4Pro was adjusted to 
0.5µg/ml and used to coat a high binding chemistry 96-well plate then incubated 
overnight at 4°C. The PspA solution was removed and PBS with 1% fish gelatin 
blocking buffer was added and incubated for 2 h at room temperature. Then, the fish 
gelatin blocking buffer was removed and the plates were washed three times with PBS 
containing 0.5% Tween 20 (PBS-TN). Anti-PspA monoclonal antibody (1 µg/ml) was 
added and the plates were incubated overnight at 4°C. Plates were washed three times 
with PBS-TN then alkaline phosphatase conjugated goat anti-mouse IgG (0.1 µg/mL) 
was added, and incubated for 2 h at room temperature before developing. For the 
development of the ELISA, alkaline phosphatase substrate was added (1 mg/mL). After 
15 min incubation at room temperature, the colorimetric assay was carried out at an 
absorbance of 405 nm using a microplate reader (Epoch, BioTek Instruments Ltd, UK) 
and the data was described as relative antigenicity, which is presented as the ratio of 
absorbance between the released PspA4Pro and the native protein. 
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2.2.15. Cytotoxicity study 
2.2.15.1. Normal human bronchial epithelial (A 459) cells 
2.2.15.1.1. Cell culture 
Adenocarcinomic human alveolar basal epithelial cell line (A 549) cells were cultured 
in RPMI-1640 medium supplemented with 10% FCS/1% Antibiotic/Antimycotic 
solution (complete medium) incubated at 37°C into 5%CO2 incubator. The medium was 
changed every four days and cells were passed weekly using Trypsin. 
2.2.15.1.2. Cells viability study  
The toxicity profiles of NPs and NCMPs were evaluated over 24 h in adenocarcinomic 
human alveolar basal epithelial cell line (A549) cells (passage No. 44) using 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Cells were 
cultured in 96-well plates with 100 µl (2.5X105 cells /ml) RPMI-1640 medium 
supplemented with 10% FCS/1% Antibiotic/Antimycotic solution for 24 h at 37°C into 
5% CO2 incubator. The wells were replaced with fresh medium (100 µl) containing NPs 
or NCMPs (0–2.5 mg/ml) (n=3) and 10% dimethylsulfoxide (DMSO) as a positive 
control and incubated for a further 24 h as above, followed by the addition of 40 µl 
MTT solution (5 mg/ml in PBS, pH 7.4) to each well. After incubation for a further 2 h, 
the medium was gently removed, and any formazan crystals generated were solubilized 
with‎ 100‎ μl‎ of‎DMSO.‎The absorbance of solubilised dye, which correlates with the 
number of living cells, was measured using a microplate reader (Epoch, BioTek 
Instruments Ltd, UK) at 570 nm. The cell viability (%) in each well was calculated as 
the absorbance ratio between NPs or NCMPs-treated and untreated control cells. 
2.2.15.2. Dendritic cells 
2.2.15.2.1. Cell culture 
DCs were cultured in MEM alpha medium containing ribonucleosides, 
deoxynucleosides, 4 mM L-glutamine,1 mM sodium pyruvate, supplemented with 20 % 
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fetal calf serum, 5 ng/ml murine growth GM-CSF, and 1% Antibiotic/Antimycotic 
solution (complete growth medium) and incubated at 37°C and 5%CO2 incubator in 25 
cm
2
 tissue culture flask. The medium was changed every four days and cells were 
passed weekly using Trypsine. 
2.2.15.2.2. Cells viability  
Cells were cultured in 96-well plates with 100 µl (2.5X105 cells /ml) complete growth 
medium for 24 h at 37°C in a 5% CO2 in an incubator. Then, complete growth medium 
(100 µl) containing NPs (0–5 mg/ml) (n=3) and 10% DMSO as a positive control were 
added to the wells and incubated for a further 4 h as above, followed by the addition of 
40 µl MTT solution (5 mg/ml in PBS, pH 7.4) to each well. After a further 2 h 
incubation, the 96-well‎plate‎was‎centrifuged‎at‎1300‎g‎for‎7‎min‎at‎4‎˚C‎to‎pellet‎ the‎
suspended cells then the medium was gently removed, and any formazan crystals 
generated‎were‎solubilized‎with‎100‎μl‎of‎DMSO.‎The‎absorbance of solubilised dye, 
which correlates with the number of living cells, was measured using a microplate 
reader (Epoch, BioTek Instruments Ltd, UK) at 570 nm. The cell viability (%) in each 
well was calculated as the absorbance ratio between treated and untreated control cells. 
2.2.16. NPs cellular uptake by DCs  
DCs uptake of FITC-BSA loaded anionic and cationic NPs was visualized using 
Confocal Laser Scanning Microscopy (CLSM) (Carl Zeiss lsm 710, UK). The DCs 
2x105 cells/400 µl were plated into an 8-well chambered borosilicate cover glass 
system, and incubated at 37 °C and 5% CO2 for 48 h prior to treatment with NPs.  
Different concentrations of FITC-BSA loaded NPs (10-40 µg/40 µl) were added to each 
well and incubated at 37°C and 5% CO2 for 1 h. The suspension in each well was 
removed and washed using PBS. Cells were fixed for 15 min with 300‎ μL‎ of 4% 
paraformaldehyde in PBS followed by washing with PBS. The cell membranes were 
counterstained with WGA TR: 100 µl WGA TR (5µg/ml) was added to each well and 
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incubated at 37°C and 5% CO2 for 10 min followed by washing with PBS. The nuclei 
were counterstained with DAPI: 100 µl of DAPI was added to each well and incubated 
at 37°C and 5% CO2 for 10 min. Followed by washing with PBS. The cells were 
examined using a Zeiss 510 Meta laser scanning microscope mounted on a Axiovert 
200 M BP computer-controlled inverted microscope. Cells were imaged by excitation at 
a wavelength of 595 nm (red channel for WGA TR), and 358 nm (blue channel for 
DAPI), and 488 nm (green channel for FITC-BSA), using a Plan Neofluar 63×/0.30 
numerical aperture (NA) objective lens. Image analysis was carried out using the Zeiss 
LSM software. 
2.2.17. Statistical analysis 
Minitab 16 Statistical Software
®
 (Minitab Inc., PA, USA) was employed for statistical 
analysis and graph plotting. The data obtained were analysed statistically by one-way 
analysis of variance (ANOVA) with the Tukey’s‎ comparison‎ using‎ Minitab‎ 16 
Statistical Software
®
 (Minitab Inc., PA, USA). Statistically significant differences were 
assumed when p < 0.05. All values are expressed as their mean ± standard deviation. 
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3.1. Introduction 
Pulmonary vaccination would stimulate both mucosal and systemic immune responses. 
The substantial networks of DCs lining the epithelium submucosa of the respiratory 
tract and on the alveolar surface play a significant role in inducing both systemic and 
local immune responses. Furthermore, s-IgA antibodies in the respiratory tract have 
important roles in the avoidance and control of infection at the respiratory mucosa by 
preventing the adherence of the pathogen and neutralizing antigen on the respiratory 
mucosal surfaces (52). 
Immune response can be improved by using polymeric NPs containing antigen because 
of NPs adjuvant-like effect where the particulate pattern can be more antigenic than the 
soluble antigen form (40). Also, it could enhance uptake by the epithelial M cells on 
mucosal surface by delivering the antigen to the lower respiratory tract area and 
prevents the rapid clearance by alveolar macrophages. M cells share antigenic 
information with DCs found in lymphoid tissue and induces secretory local IgA 
production. Then, the NPs may be transported to secondary lymph-nodes where they 
enhance induction of the systemic immune response (43). 
However, to gain a reliable and strong immune response upon application of particulate 
vaccines via the pulmonary route, it is essential to optimize the size of the delivery 
system (73). Studies reported that particles of ∼500 nm size are more suitable for 
uptake than particles of 1-5‎μm‎size (124). However, an inverse relationship had been 
reported between particle size and the efficiency of uptake by DCs (87). 
In this study PGA-co-PDL, biodegradable polyester, was used to prepare NPs. The most 
common method for the encapsulation of proteins in polymer NPs is the water/oil/water 
(w/o/w) double-emulsion solvent evaporation method (79) and it is best suited to 
encapsulate water soluble drugs such as peptides, proteins, and vaccines (80).  
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NPs do not deposit efficiently in the lungs leading to the exhalation of the majority of 
the inhaled dose (91). NPs can be formulated into dry powder microparticle carriers to 
produce NCMPs as DPIs via spray-drying (92). This system is designed to disperse in 
the lung lining fluid, releasing the NPs from the inert carrier (93).  
Biocompatible excipients (carbohydrates, amino acids, and lipids) are typically added to 
the formulation feed to afford dry powders with bulk (i.e. from microparticle carrier) 
and to promote the production of a desirable aerodynamic particle size and allow a rapid 
release of the NPs in the lung fluid lining upon inhalation. In addition, the excipients are 
added to the formulation to afford some level of protection to both the NPs and 
encapsulated drug during spray drying, especially against shear forces and increased 
temperatures (38).  
L-leucine is one of the amino acid excipients that is commonly used in the 
pharmaceutical industry because of its potential to improve dispersibility and 
bioavailability of aerosols (125). Pure spray dried L-leucine shows hollow particles with 
low density, proving its ability to enhance aerosolisation (125).  
To design a new dosage form in the pharmaceutical field, it is very important to identify 
the formulation (e.g. concentration of drug, polymer, surfactant, etc.) and preparation 
(e.g. homogenisation speed, time, etc.) parameters because these variables will affect 
the properties of the final dosage form. The use of design of experiment (DOE) is the 
most common method of determining the influence of different parameters on the 
characteristics of the dosage form being studied and to optimise the parameters to 
achieve the desired properties (126). Due to parameter interactions and the large number 
of factors implicated, optimizing these parameters by conventional DOE (e.g. factorial 
designs) would be considered highly exhausting and uneconomical (127). The efficient 
analyses of complex formulations process using statistical experimental design have 
been proposed by‎ “Taguchi‎ Orthogonal‎ Array‎ Design” (127). This design is a 
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combination of mathematical and statistical approaches included into an empirical study 
developed by Dr. Genichi Taguchi (128). It aims to investigate how different factors 
affect the mean and variance of a process performance property that defines how well 
the process is functioning. A number of implemented trials are proposed to find out the 
optimum combination of parameters that have the highest effect on the product and with 
the least variation from the design target (129).  
The Taguchi design is a useful inexpensive method for the study of a large number of 
parameters and interactions within an acceptable number of trials. Also, it has the ability 
to optimise many extract qualitative parameters simultaneously and extraction much 
quantitative data with only a few experiments (129). Taguchi has conceptualised a new 
method to carry out the design of experiments using a special set of arrays called 
orthogonal arrays. The orthogonal array is a matrix of numbers arranged in columns and 
rows (128). These standard arrays specify a way to carry out the minimal number of 
experiments to give full information on all factors that affect the performance over a 
specific region of interest (levels). Rather than having to try all possible combination 
e.g. factorial design, Taguchi design test pairs of combinations (126). For example, a 
single replicate of 4 parameters and 3 level experiments would require 81 runs for a full 
factorial analysis. On the other hand, Taguchi method will require 9 runs only. Taguchi 
approach has previously been used in the improvement of dosage forms (126; 127). 
The Taguchi method employs a signal to noise (S/N) ratio to quantify variations. These 
ratios are meant to be used as measures of the effect of noise (uncontrollable) factors on 
performance characteristics. S/N ratios take into account both amount of variability in 
response data and closeness of average response to the target (130). In Taguchi design, 
𝑆/𝑁 ratio can be defined as the measure of the deviation of the response from the 
desired‎value.‎So,‎ “signal”‎ presents‎ the‎mean‎value‎and‎“noise”‎presents the standard 
deviation. It means that lower variability in the process is ensured through maximizing 
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the S/N ratio (131). The variability of a characteristic is due to the noise factor such as 
environmental factors.  Thus, optimizing process parameters by the Taguchi design 
leads to bringing the average quality near to the target value, and also to simultaneously 
decrease the variation in quality (132). The experimental condition having the 
maximum S/N ratio is considered the optimum condition, as the variability of 
characteristics is in inverse proportion to the S/N ratio (133).  
There are several S/N ratios available depending upon the type of characteristics: 
smaller the better (equation 3-1), e.g. particle size; larger the better (equation 3-2), e.g. 
drug loading. In some cases, a nominal S/N ratio is the best (equation 3-3) (130).  
Smaller is better: 
𝑺
𝑵
= −𝟏𝟎 𝐥𝐨𝐠 ∑
𝒚𝒊
𝟐
𝒏
𝒏
𝒌=𝟏                    Equation ‎3-1 
Larger is better: 
𝑺
𝑵
= −𝟏𝟎 𝐥𝐨𝐠 ∑
𝟏
𝒚𝒊
𝟐  𝒏
𝒏
𝒌=𝟏                 Equation ‎3-2 
Nominal S/N ratio is the best: 
𝑺
𝑵
= −𝟏𝟎 𝐥𝐨𝐠 ∑
𝝁
𝝈𝟐  
𝒏
𝒌=𝟏                  Equation ‎3-3 
Where 
 𝝁 =
𝟏
𝒏
 ∑ 𝒚𝒊
𝒏
𝒌=𝟏        Equation ‎3-4 and 𝝈
𝟐 = (
𝟏
𝒏−𝟏
) ∑ (𝒚𝒊 − 𝝁)
𝟐𝒏
𝒌=𝟏         Equation ‎3-5 
And 𝑦𝑖 donates‎response‎variables‎and‎“𝑛”‎represents‎the‎number‎of‎experiments (131). 
The Taguchi design method was applied in this study to examine the effects of different 
formulation and process parameters on the size and drug loading of NPs and yield % 
and morphology of NCMPs.  
Bovine serum albumin (BSA) has been widely used as a model antigen mainly because 
of its well-recognized secondary structure (Figure ‎3-1) (134; 135; 136; 137). It has a 
molecular weight in the range of 66-69 kDa and is composed of a single long chain of 
about 582 amino acid residues (138). It has been used in this study as a model antigen to 
optimize NPs formulation for DCs uptake. 
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3.2. Aim 
The aim of this study was to formulate PGA-co-PDL NPs encapsulating bovine serum 
albumin (BSA), a model protein, using Taguchi design to optimize formulation 
parameters: particle size and drug loading. The PGA-co-PDL NPs were then 
incorporated into microparticle carriers (L-leucine) via spray drying to produce NCMPs 
carriers suitable for pulmonary delivery via DPIs.  
To obtain the aim of the study a systematic study was designed considering the 
following aspects: 
1. Formulation of NPs using double emulsion solvent evaporation technique. 
2. Evaluation of the influence of formulation parameters on the particle size, 
encapsulation efficiency, and drug loading of BSA using Taguchi design. 
3. Formulation of NCMPs via spray drying technique.  
4. Evaluation of the influence of spray drying parameters on the morphology, and 
yield% of NCMPs using Taguchi design. 
5. Examination of BSA integrity, in vitro aerosolisation performance, in vitro 
release, cells toxicity of optimum NCMPs. 
Figure ‎3-1: Bovine serum albumin structure includes three α-helical domains 
(I, II, III). Each domain contains two subdomains (A and B) (with permission 
from (137)). 
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3.3. Methods 
3.3.1. Polymer synthesis and characterisation 
The PGA-co-PDL was synthesised and characterised as described in section ‎2.2.1 and 
section ‎2.2.2 respectively. 
3.3.2. Nanoparticle preparation 
BSA loaded PGA-co-PDL NPs were prepared by a (w/o/w) double emulsion/solvent 
evaporation method. Various concentrations of aqueous BSA solutions (0.2 – 1 %) 
containing PVA as surfactant (1 – 10 %) were prepared. The protein solution (IAP) was 
emulsified in DCM (OP) containing PGA-co-PDL (50 - 200 mg), by sonication using a 
probe sonicator (VC X 500 Vibra-Cell
TM
, Sonics & Materials, Inc., Newtown, CT, 
USA, using the 13 mm probe) for 5 - 20 seconds over an ice bath. The resulting single 
emulsion was emulsified into 25 ml of a 1 % PVA solution (EAP) using the same probe 
sonicator for 10 - 30 seconds to form a w/o/w double emulsion. The double emulsion 
was stirred magnetically for 2 h at room temperature to evaporate the DCM. The NPs 
were collected by centrifugation (Sigma 3-30k, SIGMA Laborzentrifugen GmbH, 
Germany) at 40,000 xg for 1 h at 4 ⁰C, and washed twice with distilled water.  
3.3.2.1. Experimental design by Taguchi method 
The Taguchi design was applied in this study to evaluate the influence of IAP volume, 
BSA concentration, polymer amount, OP volume,  PVA concentration, sonication time 
of IAP, sonication time of EAP, and sonication amplitude on the NPs particle size, BSA 
encapsulation efficiency %, and loading. The design was composed of 8 variables set at 
2 levels (IAP volume, and OP volume) or 3-levels each (BSA concentration, polymer 
mass, PVA concentration, sonication time of IAP, sonication time of EAP, and 
sonication amplitude), where the mean particle size, BSA encapsulation efficiency % 
and loading were the dependent variables (Table ‎3-1). The design was constructed using 
L36 orthogonal array as shown in Table ‎3-2. The optimum conditions were indicated by 
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high signal-to-noise (S/N) ratios. Where the signal factor (S) is the outcome, i.e. particle 
size, BSA encapsulation efficiency %, or loading and noise factors (N) include room 
temperature and humidity and researcher experience etc. 
Optimization‎of‎the‎size‎was‎carried‎out‎using‎the‎Taguchi’s‎‘smaller-is-better’‎criterion 
while optimization of the BSA encapsulation efficiency % and loading was carried out 
using‎ the‎ Taguchi’s‎ ‘higher-is-better’ criterion (128). The different values for the 
variables summarized in Table ‎3-1 were chosen on the basis of the tested lower and 
upper values for each variable following pre-formulations studies. The Taguchi design 
was constructed and analysed in Minitab 16 Statistical Software
®
 (Minitab Inc., PA, 
USA). 
 
Table ‎3-1: Double emulsion solvent evaporation processing variables, units, and 
levels for BSA-loaded PGA-co-PDL NPs. 
Code Variables Unit 
Levels 
1 2 3 
A IAP volume ml 0.25 0.5 - 
B OP volume ml 1 2 - 
C BSA concentration % (w/v) 0.2 0.5 1 
D Polymer mass  mg 50 100 200 
E PVA concentration % (w/v) 1 5 10 
F Sonication time IAP sec 5 10 15 
G Sonication time EAP sec 10 15 30 
H Sonication Amplitude % 30 45 65 
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Table ‎3-2: Double emulsion solvent evaporation processing variables for BSA-
loaded PGA-co-PDL NPs using Taguchi design method (L36 Orthogonal Array). 
Run A B C D E F G H 
1 1 1 1 1 1 1 1 1 
2 1 1 2 2 2 2 2 2 
3 1 1 3 3 3 3 3 3 
4 1 1 1 1 1 1 2 2 
5 1 1 2 2 2 2 3 3 
6 1 1 3 3 3 3 1 1 
7 1 1 1 1 2 3 1 2 
8 1 1 2 2 3 1 2 3 
9 1 1 3 3 1 2 3 1 
10 1 2 1 1 3 2 1 3 
11 1 2 2 2 1 3 2 1 
12 1 2 3 3 2 1 3 2 
13 1 2 1 2 3 1 3 2 
14 1 2 2 3 1 2 1 3 
15 1 2 3 1 2 3 2 1 
16 1 2 1 2 3 2 1 1 
17 1 2 2 3 1 3 2 2 
18 1 2 3 1 2 1 3 3 
19 2 1 1 2 1 3 3 3 
20 2 1 2 3 2 1 1 1 
21 2 1 3 1 3 2 2 2 
22 2 1 1 2 2 3 3 1 
23 2 1 2 3 3 1 1 2 
24 2 1 3 1 1 2 2 3 
25 2 1 1 3 2 1 2 3 
26 2 1 2 1 3 2 3 1 
27 2 1 3 2 1 3 1 2 
28 2 2 1 3 2 2 2 1 
29 2 2 2 1 3 3 3 2 
30 2 2 3 2 1 1 1 3 
31 2 2 1 3 3 3 2 3 
32 2 2 2 1 1 1 3 1 
33 2 2 3 2 2 2 1 2 
34 2 2 1 3 1 2 3 2 
35 2 2 2 1 2 3 1 3 
36 2 2 3 2 3 1 2 1 
Note: A: IAP volume, B: OP volume, C: BSA concentration, D: polymer mass, E: PVA 
concentration, F: sonication time IAP, G: sonication time EAP, H: sonication amplitude. 
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3.3.3. Nanoparticle characterization 
The NPs were characterised for particle size, PDI, encapsulation efficiency and protein 
loading as described in section ‎2.2.7.1 and ‎2.2.7.2 respectively. 
3.3.4. Nanocomposite microparticles preparation by spray drying  
NCMPs were prepared by spray drying selected NPs formulation as described in 
section ‎2.2.8 
3.3.4.1. Experimental design by Taguchi method 
The Taguchi method was applied to evaluate the influence of the air flow rate, inlet 
drying temperature, aspirator capacity, pump rate, and feed concentration (total amount 
of L-leucine and NPs in the feed suspension) on the NCMPs properties. The design was 
composed of 5 variables each set at 3-levels (Table ‎3-3), where the morphology and 
percentage yield were the dependent variables. The design was constructed using L27 
orthogonal array design (Table ‎3-4). The different values for the factors, summarized in 
Table ‎3-3  were chosen on the basis of the tested lower and upper values for each 
variable following pre-formulations studies. The Taguchi design was constructed in 
Minitab 16 Statistical Software
®
 (Minitab Inc., PA, USA).  
Furthermore, the optimum spray drying condition was carried out without L-leucine and 
with lactose or myo-inositol as alternative excipient to L-leucine. 
Table ‎3-3: Spray drying processing variables, units, and levels for BSA-loaded 
PGA-co-PDL NCMPs. 
Code Variable Unit 
Level 
1 2 3 
A Air flow L/h 400 535 670 
B Inlet Temperature C 50 75 100 
C Aspirator capacity % 50 75 100 
D Feed rate % 5 10 15 
E Feed concentration mg/ml 12.5 6.25 4.17 
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Table ‎3-4: Spray drying processing variables for NCMPs using Taguchi design 
method (L27 Orthogonal Array). 
Runs A B C D E 
1 1 1 1 1 1 
2 1 1 1 1 2 
3 1 1 1 1 3 
4 1 2 2 2 1 
5 1 2 2 2 2 
6 1 2 2 2 3 
7 1 3 3 3 1 
8 1 3 3 3 2 
9 1 3 3 3 3 
10 2 1 2 3 1 
11 2 1 2 3 2 
12 2 1 2 3 3 
13 2 2 3 1 1 
14 2 2 3 1 2 
15 2 2 3 1 3 
16 2 3 1 2 1 
17 2 3 1 2 2 
18 2 3 1 2 3 
19 3 1 3 2 1 
20 3 1 3 2 2 
21 3 1 3 2 3 
22 3 2 1 3 1 
23 3 2 1 3 2 
24 3 2 1 3 3 
25 3 3 2 1 1 
26 3 3 2 1 2 
27 3 3 2 1 3 
H 1 3 3 2 1 
Note: A: air flow, B: inlet temperature, C: aspirator %, D: pump rate, E: feed 
concentration. Numeric values 1-27 indicate experimental run number, H indicate 
optimum spray drying condition that produce highest yield %. 
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3.3.5. Characterization of nanocomposite microparticles 
NCMPs were characterised as described in section ‎2.2.9. 
3.3.6. In vitro Aerosolisation studies 
The in vitro aerosolisation studies were carried out as described in section ‎2.2.10. 
3.3.7. In vitro release study  
The in vitro release studies were carried out as described in section ‎2.2.11. 
3.3.8. Investigation of BSA structure  
The released BSA stability of primary and secondary structure were evaluated as 
described in section ‎2.2.12. 
3.3.9. Cytotoxicity study 
The cytotoxicity of NPs and NCMPs were determined as described in section ‎2.2.15.1. 
3.4. Results  
3.4.1. Polymer characterization 
PGA-co-PDL (monomer ratio, 1:1:1) was a white powder with an average molecular 
weight of 16.72±0.4 KDa (n=3) as determined by GPC. The GPC chromatographs 
(Figure ‎3-2) show symmetric molecular weight distribution with small or no low 
molecular weight impurities and, so, low polydispersity. This was expected as the 
polymers were re-precipitated from methanol and any low molecular weight material 
would have been washed. The structure of the polymer (Figure ‎3-3) was confirmed from 
the integration pattern of peaks obtained from 
1
H-NMR spectra (Figure ‎3-4) (δH‎
CDCl3, 300 MHz): 1.34 (s, 22 H, H-g), 1.65 (m, 8 H, H-e,‎e′,‎h),‎2.32‎(m,‎6‎H,‎H-d,‎d′,‎
i), 4.05 (q)-4.18 (m) (6 H, H-a, b, c, f), 5.2 (s, H, H-j). The Tm of the polymer was 
measured by DSC (Figure ‎3-5) and was detected to be 59.79 ˚C‎which‎ is similar to 
previous report (66). 
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Figure ‎3-3: Chemical structure of PGA-co-PDL. 
Figure ‎3-2:  Gel Permeation Chromatography (GPC) chromatograph of PGA-co-
PDL. 
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Figure ‎3-5: Differential scanning calorimetry (DSC) thermograms of PGA-co-
PDL. 
 
Figure ‎3-4: Nuclear magnetic resonance (1H-NMR) spectra of PGA-co-PDL. 
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3.4.2. Optimization of the BSA-loaded NPs prepared by the double 
emulsion solvent evaporation method using Taguchi design 
The Taguchi L36 orthogonal array design required 36 runs to be carried out to identify 
the important factors that could affect the particle size and DL of NPs and to produce 
the optimum conditions for each variable to achieve the smallest particle size NPs (SPS 
NPs), and highest drug loading NPs (HDL NPs). In Taguchi design, S/N ratio is the 
determination of the deviation of the response from the target value. In this study, 
“signal”‎ represents the mean‎ value‎ while‎ “noise”‎ represents the standard deviation 
value. The highest the S/N ratio the lowest the variability in the process applied (131). 
Table ‎3-5 represents the measured values of particle size, DL, and EE % of NPs. The 
measured values were converted into S/N ratio (using Minitab 16 statistical software) 
which was utilized for the analysis of the results. The calculated S/N ratio at different 
levels for each parameter were plotted in Figure ‎3-6 which‎ favoured‎ a‎ ‘smaller‎ –is-
better’‎S/N‎ ratio for particle size. Also, the calculated S/N ratio at different levels for 
each parameter were plotted in Figure ‎3-7 and Figure ‎3-8 which‎favoured‎a‎‘larger-is-
better’‎S/N‎ratio for DL and EE %. In order to determine which parameter had a critical 
impact on the particle size, DL, or EE% the range and rank were calculated. The range 
is the difference between the maximum and minimum S/N ratios for the parameter 
while the rank is the rank of each range, where rank 1 is the largest range. The factor 
with largest range and corresponding rank (indicating the relative importance compared 
to other factors) was considered as the critical factor affecting the particle size, DL, or 
EE % of NPs.  
Analysis of results following the Taguchi design indicated particle sizes ranging from 
216.17 to 2168.78 nm were obtained (Table ‎3-5). Based on the range, rank, and S/N 
response graph (Figure ‎3-6) for the production of SPS NPs‎ using‎ the‎ Taguchi’s‎
“smaller-is-better”‎criterion‎in‎Minitab® 16 statistical software, the optimal conditions  
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Table ‎3-5: The experimentally measured values of particle size, polydispersity 
index, EE %, and DL of NPs. Data represent mean ± S.D., n=3. 
Runs 
Particle size 
(nm) 
Polydispersity 
Index 
EE (%) DL (µg/mg) 
1 574.4±120.6 0.395±0.15 36.6±1.6 3.6±0.2 
2 648.5±10.5 0.209±0.1 56.3±3.3 6.9±0.4 
3 1165.9±337.9 0.1805±0.2 57±0.8 7±0.1 
4 498.7±4.6 0.311±0.01 23.9±3.8 2.4±0.4 
5 1032.9±41.9 0.1845±0.3 45.9±4.5 5.7±0.5 
6 1534.7±1484 0.1715±0.2 39.8±28 4.9±3.4 
7 577.8±107.4 0.236±0.1 41.2±6.3 4.1±0.6 
8 550.4±93.9 0.1455±0.2 37.5±7 4.6±0.9 
9 1836.4±864 0.273±0.2 75.3±1.7 9.3±0.2 
10 357.5±102 0.1585±0.03 8.4±5.9 0.8±0.6 
11 349±68.9 0.124±0.1 52.1±7.2 6.4±0.9 
12 325±73.3 0.162±0.03 34.5±8 4.3±0.9 
13 270.8±81 0.1325±0.004 27.4±9.8 1.4±0.5 
14 416.4±100.8 0.083±0.1 62.9±4.6 3.9±0.3 
15 319.7±41.9 0.1415±0.002 11.4±11 5±4 
16 493.1±36.1 0.243±0.06 38.9±3.8 1.9±0.2 
17 443.6±47 0.1355±0.1 69.1±2.6 4.3±0.2 
18 230.7±46.7 0.1005±0.01 32.9±10 15.7±4.8 
19 420.8±75.9 0.081±0.1 50.7±1 5±0.1 
20 1375.8±392.2 0.005±0 57.3±1.2 7.1±0.1 
21 467.3±104.4 0.005±0 21.1±6.6 19.2±5.9 
22 1204.7±450.6 0.342±0.1 56.1±0.36 5.6±0.04 
23 2168.9±1553 0.0035±0.002 42.8±1.5 20.4±0.7 
24 267±10.2 0.0615±0.07 29.5±6.3 26.8±5.8 
25 554.1±88.7 0.111±0.09 56.8±2.9 2.8±0.1 
26 468.2±50 0.005±0 33.2±0.7 15.8±0.3 
27 493.1±104 0.046±0.05 51.4±6.6 24.5±3.1 
28 535.1±3.4 0.175±0.1 53.6±0.4 2.7±0.02 
29 216.2±39.9 0.1045±0.04 32.5±1.9 15.5±0.9 
30 343.4±54.3 0.194±0.03 37.3±2.6 17.7±1.2 
31 729.9±54.6 0.269±0.05 44.8±8.4 2.2±0.4 
32 246.5±32.2 0.103±0.02 39.5±2.6 18.8±1.2 
33 316.7±59.8 0.2125±0.02 38±0.3 18.1±0.1 
34 430.1±207.8 0.233±0.1 62.8±3.5 3.1±0.2 
35 301.5±19.6 0.095±0.12 45.2±4 21.5±1.9 
36 463.5±123.4 0.246±0.03 60.9±4.5 19.2±2.1 
Note: EE%: encapsulation efficiency %, DL: BSA loading. 
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Figure ‎3-6: Mean signal-to-noise (S/N) graph for particle size response. Letters (A-
H) indicate the experimental parameters and numeric value indicates the 
parameter‎ levels,‎◊‎ indicate maximum S/N value, A: IAP volume, B: OP volume, 
C: BSA concentration, D: polymer mass, E: PVA concentration, F: IAP sonication 
time, G: EAP sonication time, H: sonication amplitude. 
 
Figure ‎3-7: Mean signal-to-noise (S/N) graph for BSA loading response. Letters 
(A-H) indicate the experimental parameters and numeric value indicates the 
parameter levels, ◊‎ indicate‎maximum‎S/N‎value,‎A: IAP volume, B: OP volume, 
C: BSA concentration, D: polymer mass, E: PVA concentration, F: IAP sonication 
time, G: EAP sonication time, H: sonication amplitude. 
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Figure ‎3-8: Mean signal-to-noise (S/N) graph for EE% response. Letters (A-H) 
indicate the experimental parameters and numeric value indicates the parameter 
levels,‎ ◊‎ indicate‎ maximum‎ S/N‎ value,‎ A:‎ IAP‎ volume,‎ B:‎ OP‎ volume,‎ C:‎ BSA‎
concentration, D: polymer mass, E: PVA concentration, F: IAP sonication time, G: 
EAP sonication time, H: sonication amplitude. 
were A2B2C3D1E1F1G2H2. When the suggested optimized run was carried out the 
measured particle size obtained was 203±5.4 nm, which is lower than the minimum 
particle size of 216.2±39.9 nm prepared using run 29. The measured particle size 
obtained for unloaded SPS NPs was 224.4±10 nm. It is also worth to mention that the 
measured BSA loading of SPS NPs was 35.9±2.4 µg/mg using the indirect method. 
Also, when the direct method used to calculate DL, it was 30.02±8.1 µg/mg. 
Regarding BSA loading and EE% the results (Table ‎3-5) of the present Taguchi design 
showed that DL ranged from 0.8±0.6 to 26.84± 5.8µg/mg and EE % ranged from 8.42 
to 75.31%.  
Based on the range, rank, and S/N response graph (Figure ‎3-7) for the production of 
HDL‎ NPs‎ using‎ the‎ Taguchi’s‎ “Larger-is-better”‎ criterion‎ in‎ Minitab® 16 statistical 
software, the optimal conditions were A2B1C3D1E1F3G3H2. When the suggested 
optimized run was carried out the measured DL obtained was 43.67±2.3 µg/mg, which 
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is higher than the maximum DL of 26.8±5.8 µg/mg prepared using run 24. It is also 
worth to mention that the particle size of HDL NPs was 287±24.4 nm and for unloaded 
HDL NPs was 291.86±8.8 nm. Also, the drug loading measured using the direct method 
was 39.30±11.2 µg/mg.  
The DL value calculated by the indirect method based on the assumption that there was 
no BSA loss during the preparation so this could explain the difference (non-significant, 
p‎ >‎ 0.05,‎ ANOVA/Tukey’s‎ comparison)‎ between‎ the‎ DL‎ calculated‎ by‎ direct‎ and‎
indirect methods.  
3.4.3. Optimization of the spray drying process 
Spray drying was applied to incorporate the selected NPs formulation into NCMPs 
using L-leucine as a carrier and to enhance powder dispersion.  
The Taguchi L27 orthogonal array design required 27 runs to be carried out to produce 
the optimum condition for each factor to achieve the highest yield % of dry powder. 
Table ‎3-6 represents the structure of the Taguchi L27 orthogonal array design and the 
corresponding dry powder yield ranged from no yield to 49.78±0.17 %.  
Figure ‎3-9 presents the mean S/N graph of the yield for each factor level. The factor 
with the largest range and corresponding rank (indicating the relative importance 
compared to other factors) was considered the critical factor affecting that yield. 
Optimum conditions were suggested by high S/N ratios. Therefore, based on the range, 
rank, and S/N response graph for production of highest yield of dry powder using the 
Taguchi’s‎ “larger-is-better” criterion in Minitab 16 statistical software suggested 
combinations A1B3C3D2E1 (run H - Table ‎3-6) which produced dry powder yield of 
50.96±2.26 %.  
When the optimum condition carried out without the use of L-leucine there was no 
yield. Furthermore, when lactose used the yield was 13 % and when myo-inositol used 
the yield was decreased dramatically to 1 %. 
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Table ‎3-6: The experimentally measured value of yield % of NCMPs after spray 
drying. Data represent mean ± S.D., n=3. 
Runs Yield (%) 
1 34.1±2.2 
2 30.5±4.5 
3 27.8±0.3 
4 26.5±3.9 
5 37.7±0.7 
6 29.4±7.9 
7 43.1±2.4 
8 41.9±2.1 
9 37±0.95 
10 0.01±0 
11 0.01±0 
12 0. 01±0 
13 49.8±0.2 
14 41.2±0.1 
15 40.8±3.5 
16 38.2±1.2 
17 33.3±0.8 
18 26.6±1.2 
19 48.6±2.5 
20 35.8±2.7 
21 35.7±3.1 
22 0.01±0 
23 0.01±0 
24 0.01±0 
25 38±1.1 
26 21.9±0.9 
27 24±1.5 
H 50.9±2.3 
Note: Numeric values 1-27 indicate experimental run number, H indicate optimum 
spray drying condition that produce highest yield %. 
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Figure ‎3-9: Mean signal-to-noise (S/N) graph for yield % response. Letters (A-E) 
indicate the experimental parameters and numeric value indicates the parameter 
levels,‎ ◊‎ indicate‎ maximum‎ S/N‎ value,‎ A:‎ airflow,‎ B:‎ inlet‎ temperature,‎ C:‎
aspirator %, D: feed rate %, E: feed concentration.  
 
The shape and surface texture of NCMPs were investigated using scanning electron 
microscopy (Figure ‎3-10). Photomicrographs of NCMPs showed irregular and porous 
microparticles. Figure ‎3-11 showed photomicrograph of run H. 
From 27 spray-drying conditions run 16 and run H were selected for primary 
aerodynamic diameter calculation and in vitro aerosolisation studies. Run H had the 
highest yield while run 16 produced particles more porous in nature. So the selected 
HDL NPs and SPS NPs spray dried using run 16 and run H parameters to produce 
NCMPs. The formulations were given the following codes HDL 16 NCMPs, SPS 16 
NCMPs, HDL H NCMPs, and SPS H NCMPs respectively. 
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Figure 3-10: SEM images of NCMPs prepared by different spray drying conditions 
(numeric values 1-27 indicates run experimental number). The scale bar represents 1 
µm. 
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3.4.4. Powder density and primary aerodynamic diameter 
NCMPs formulations had a geometric particle size between 1.23±0.07- 4.69±0.77 µm 
(Table ‎3-7) suitable for pulmonary delivery. The tapped densities of all formulations 
were similar (0.091±0.004–0.145±0.002 g cm-3; Table ‎3-7) and were used together with 
the geometric particle size to calculate the theoretical aerodynamic diameter (dae). As 
shown in Table ‎3-7, the dae for all formulations was between 0.399±0.08– 1.71±0.30 
µm.  
Table ‎3-7: The geometric particle size, tapped density and theoretical aerodynamic 
diameter (dae) of spray-dried NCMPs. Data represent mean ± S.D., n=3. 
NCMPs 
Formulation 
Geometric 
particle size 
(µm) 
Tapped density 
(g/cm
3
) 
dae 
(µm) 
SPS 16 NCMPs 1.23±0.07 0.091±0.004 0.399±0.08 
HDL 16 NCMPs 2.62±0.11 0.093±0.004 0.811±0.01 
SPS H NCMPs 4.69±0.77 0.132±0.007 1.71±0.30 
HDL H NCMPs 3.89±0.37 0.145±0.002 1.45±0.14 
SPS 16 NCMPs, HDL 16 NCMPs: SPS NPs and HDL NPs spray dried using run 16. 
SPS H NCMPs, HDL H NCMPs: SPS NPs and HDL NPs spray dried using run H. 
 
B A 
Figure ‎3-11: SEM images of NCMPs spray dried with run H (HDL H NCMPs) (A) 
and L-leucine alone spray dried with run H (B). 
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3.4.5. In vitro aerosolisation studies for SPS and HDL nanocomposite 
microparticles 
The percent mass of BSA recovered from the NGI was approximately 76 %, which is 
within pharmacopeia limit (75 – 125 %) of the average delivered dose (139). BSA 
deposition data obtained from NCMPs (Table ‎3-8) indicated there was no significant 
difference in FPD, FPF % and MMAD between SPS 16 NCMPs and SPS H NCMPs 
and between HDL 16 NCMPs and HDL H NCMPs (p˃0.05, ANOVA/Tukey’s 
comparison). But run H produced the highest yield% of powder (50%). So run H was 
applied as spray drying condition for the rest of this study. Formulations SPS H NCMPs 
and HDL H NCMPs were further investigated.  
Table ‎3-8: The Fine particle dose (FPD), fine particle fraction (FPF), and mass 
median aerodynamic diameter (MMAD) of NCMPs. Data represent mean ± S.D, 
n=3. 
Code FPD (µg) FPF (%) MMAD (µm) Yield % 
SPS 16 NCMPs 49.12±12.5 70.97±4.7 1.5±0.40 36.0±2.7 
HDL 16 NCMPs 59.26±6.00 79.60±7.0 1.6±0.20 38.2±1.2 
SPS H NCMPs 38.04±2.80 64.32±1.6 1.49±0.13 46.4±7.9 
HDL H NCMPs 45.00±7.40 78.57±0.1 1.71±0.10 50.9±2.3  
SPS 16 NCMPs, HDL 16 NCMPs: SPS NPs and HDL NPs spray dried using run 16. 
SPS H NCMPs, HDL H NCMPs: SPS NPs and HDL NPs spray dried using run H. 
3.4.6. In Vitro Release Studies 
In vitro release studies comparing SPS H NCMPs and HDL H NCMPs formulations 
were performed (Figure ‎3-12). Both formulations showed biphasic release profiles with 
a first initial burst release followed by a second continuous sustained release phase over 
48h. A significant difference (p<0.05,‎ ANOVA/Tukey’s)‎ was‎ noted‎ in‎ the release 
profile (24 – 48 h) of HDL H NCMPs and SPS H NCMPs, with HDL H NCMPs 
achieving 38.77±3% release after 48 h compared to SPS H NCMPs with (20.84±4.2%).  
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In this study, BSA was released from SPS H NCMPs and HDL H NCMPs formulations 
according to the Higuchi diffusion model (r
2
 value of 0.981 and 0.955, respectively), 
and the release rate constant were k1 (h
-½
) 2.7021 and 5.3653, respectively (Table ‎3-9). 
Therefore, the sustained release of BSA from spray-dried NCMPs appears to be a 
diffusion-limited process. Accordingly HDL H NCMPs was selected for further 
investigation in this study. 
 
 
Table ‎3-9: Release parameters of BSA from NCMPs. 
Formulation Zero Order First order Higuchi 
r
2
 ko (h
-1
) r
2
 k1 (h
-1
) r
2
 k1 (h
-½
) 
HDL H NCMPs 0.842 0.72 0.886 -0.004 0.955 5.3653 
SPS H NCMPs 0.881 0.366 0.899 -0.0018 0.981 2.7021 
SPS H NCMPs, HDL H NCMPs: SPS NPs and HDL NPs spray dried using run H. 
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Figure ‎3-12: Cumulative in-vitro release of BSA from NCMPs in PBS buffer at 
37°C. Data represent mean ± S.D., n=3. 
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3.4.7. Moisture content 
The moisture content in HDL NCMPs was reported using TGA and the thermogram 
(Figure ‎3-13) demonstrates that the dry powder formulation had a residual moisture 
content of 0.2±0.03 % w/w. 
 
3.4.8. Investigation of BSA structure 
The primary structure of BSA released from NPs or NCMPs was analysed by SDS-
PAGE followed by Coomassie brilliant blue staining. According to Figure ‎3-14, BSA 
standard and the molecular weight marker shown in Lanes 1 and 5, respectively, 
revealed a clear band at about 66 KDa. The BSA released from HDL NPs lanes 2 and 
from HDL H NCMPs lanes 3, and 4, respectively, also showed similar clear banding 
patterns to the BSA standard (Figure ‎3-14). The single lines in the gels provided 
Figure ‎3-13: Thermogram of NCMPs reported using thermal gravimetric 
analysis. 
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evidence that the BSA released did not suffer a significant covalent aggregation or 
fragmentation during the preparation methods used. 
 
 
 
 
 
 
 
 
 
 
 
 
The secondary structure of BSA was analysed using CD spectroscopy. Figure ‎3-15 
shows CD spectra of the secondary structure of standard BSA and BSA released. The 
CD spectra present minima at 221 - 222 and 209 – 210 nm and a maximum at 195 nm 
for both samples, which is characteristic of an α-helical structure. In support of this data, 
structural analysis showed that BSA was predominantly helical displaying 51.5% 
helicity (Table ‎3-10), which is in good agreement with previous reports (140). 
Structural analysis of BSA released displayed double minima at 210 and 222 nm and a 
further spectra analysis showed‎a‎reduced‎level‎of‎α-helical conformation (circa 48.5% 
helical) (Table ‎3-10). Furthermore, a comparison of BSA released with standard BSA, 
showed‎ that‎ the‎ α-helical‎ content‎ decreased‎ by‎ 3%,‎ the‎ β-sheet content increased by 
3.5%,‎the‎turns‎content‎decreased‎by‎2.5%,‎and‎the‎random‎coils’‎content‎increased‎by‎
2%, respectively. 
 
 
   Lane    1       2      3       4                                      5 MW 
KDa 
205 
129 
116 
97.4 
84 
 
66  
 
45 
 
36 
 
 
20 
17.5 
7.1 
 Figure ‎3-14: SDS-PAGE behaviour of BSA released for the assessment of BSA stability. 
Lanes represent, BSA standard (1), BSA released from HDL NPs (2), BSA released 
from HDL H NCMPs (3, 4), and molecular weight (MW) standard markers, BSA (MW 
66,000), (5). Difference in band intensity was due to different loading. 
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Table ‎3-10: The percentage of secondary structure conformation for BSA released 
from the selected formulation and BSA standard (means±SD, n=3). 
 
 
 
Sample Helix Strands Turns Unordered 
BSA standard 51.5 ± 0.007 21.50 ± 0.007 9.0 ± 0 17.50 ± 0.007 
BSA released 48.50 ± 0.007 25.0 ± 0 6.50 ± 0.007 19.5 ± 0.007 
Figure ‎3-15: The CD spectra of BSA released from HDL NPs (grey) and BSA 
standard (black). 
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3.4.9. Cytotoxicity study 
The NPs and NCMPs appear to be well tolerated by the A549 cell line, with a cell 
viability of 77.7±19.6% for NPs and 79±4.7% for NCMPs (Figure ‎3-16) at 2.5 mg/ml 
concentration after 24 h exposure. There was no significant difference between cell 
viability of cells treated with NPs and cells treated with NCMPs (p > 0.05, ANOVA, 
Tukey’s‎comparison).‎The‎cell‎viability‎study‎indicates‎a good toxicity profile.  
 
 
 
 
 
 
 
 
 
 
 
3.5. Discussion 
3.5.1. Preparation and characterization of NPs 
The BSA loaded PGA-co-PDL NPs were prepared by a modified (w/o/w) double 
emulsion/solvent evaporation method (141). The aim of the Taguchi design was to 
determine the formulation parameters that have the greatest impact on the particles size, 
BSA encapsulation and loading within NPs and to optimise NPs formulation in term of 
particle size and BSA loading.  
Also, Taguchi design uses orthogonal array saved time and decreased cost of 
experiments while reproducibility and consistency were maintained (142). 
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Figure ‎3-16: A549 cell viability measured by MTT assay after 24 h exposure to NPs 
and NCMPs. Data represent mean ± S.D., n=3. 
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3.5.1.1. Effects of the double emulsion solvent evaporation method parameters 
on the size of the nanoparticles 
Analysis of results following the Taguchi design indicated that the particle size of NPs 
was influenced by different parameters in the following order: polymer mass > OP 
volume > sonication amplitude>surfactant concentration> EAP sonication time and IAP 
sonication time > IAP volume > BSA concentration (Figure ‎3-6). 
It can be seen that the polymer mass followed by the OP volume had the greatest 
influence on the particle size of NPs (i.e. rank 1 and 2, Figure ‎3-6). It could be noticed 
from Table ‎3-5, that four out of the thirty-six experimental runs (i.e. runs 3, 6, 9, and 
23) had a particle size range of 1165.9 to 2168.9 nm These four runs shared a common 
parameters, which was 200mg polymer mass and 1 ml OP in the preparations. On the 
other hand, it could be seen from Table ‎3-5 that runs 10, 15, 18, 29, 32, and 35 had 
much smaller particle size ranging from 216.2 to 357.5 nm. These runs shared a 
common parameters, which was 50mg polymer mass and 2 ml OP in the preparations. 
In general, an increase in the mass of substances used will increase the particle size, and 
this was illustrated by the observation that the mass of PGA-co-PDL is the primary 
parameter responsible for the changes in particle size. This size increase was also 
observed with PLGA protein-loaded NPs or/and microparticles, when using a double 
emulsion solvent evaporation method (143). This effect of the polymer mass on the 
particle size can be attributed to the increased viscosity of the OP leading to a less 
efficient stirring of the medium and to increased NPs coalescence (144).  
The third factor affecting particle size was sonication amplitude (i.e. rank=3, 
Figure ‎3-6) while EAP sonication time and IAP sonication time occupied the fifth and 
sixth rank, respectively (Figure ‎3-6). The rate of size reduction decreased considerably 
when sonication was carried out beyond the duration of 5 s for IAP or 15 s for EAP or 
above an amplitude of 45 %. For example, it could be noticed from Table ‎3-2 that runs 
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10 and 29 shared the important parameters: the polymer mass 50 mg, OP 2 ml and PVA 
concentration 10 % but differ in amplitude (65 % and 45 %, respectively) and duration 
of sonication for IAP (10 sec and 15 sec, respectively) and EAP (10 sec and 30 sec, 
respectively). These difference led to change in particle size measured (run 10: 
375.5±102 nm and run 29: 216.2±39.9). Increasing amplitude lead to more fluid 
cavitation, this inhibited the efficiency of energy transmission and decreased the 
ultrasonic effect (145). 
PVA concentration was directly proportional to size with 1< 5< 10% PVA (rank=4, 
Figure ‎3-6). For example, it could be noticed from Table ‎3-2 that runs 4 and 7 shared 
the important parameters  (i.e. polymer mass 50 mg , OP 1 ml and sonication amplitude 
45 %) but differ in PVA concentration (run 4: 1 % and run 7: 5% ). This increase in 
PVA concentration led to increase in particle size (run 4:498.7±4.6 nm and run 7: 
577.8±107.4 nm). This was associated with an increase in viscosity with an increase in 
PVA concentration from 1 to 5 or 10% of the IAP. This resulted in a reduced net shear 
stress, decreasing the diffusion speed and consequently increasing particle size. 
Moreover, further addition of PVA lead to an increase in NPs size because of the 
accumulation of excess molecules at the particle surface leading to bridging between the 
primary particles (146).  
IAP volume and BSA concentration had minimum effect on the particle size of NPs 
(rank=7 and 8, respectively Figure ‎3-6) which have also been previously reported in 
literature (143). For example, it could be noticed from Table ‎3-2 that runs 16 and 36 
shared the first 4 important parameters (i.e. polymer mass 100 mg, OP 2 ml, sonication 
amplitude 30 % and PA concentration 10%) but differ in BSA concentration and IAP 
volume (run 16: 0.2 % and 0.25 ml and run 36: 1 % and 0.5 ml, respectively). This 
change in BSA concentration and IAP volume led minimal change in particle size (run 
16: 493.7±36.1 nm and run 36: 463.8±123.4 nm). 
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3.5.1.2. Effects of the double emulsion solvent evaporation method parameters 
on the loading of BSA 
The loading capacity of NPs is a critical aspect as the higher the loading, the higher the 
bioavailability of drug per particle absorbed (143). A successful drug delivery system 
should have a high loading capacity in order to decrease the amount of drug and 
excipients used for manufacturing the delivery system. However, with proteins it is 
generally not necessary to achieve very high drug loading, because most therapeutic 
proteins are active at low doses (143). BSA loading expresses the ratio of the weight of 
BSA encapsulated to the weight of NPs. 
The influence of different parameters on the DL of NPs had the following order: BSA 
concentration>IAP volume > polymer mass > PVA concentration > OP volume > EAP 
sonication time and IAP sonication time > sonication amplitude (Figure ‎3-7).  
BSA concentration had the greatest influence on the DL (rank=1, Figure ‎3-7). The DL 
increased profoundly as the BSA concentration increased from 0.2 to 1%. This was 
expected from predictions based on equation 2-7 in which DL was positively 
proportional to the amount of BSA and also as reported in literature (143). For example, 
run 7 and run 18 shared three dominant factors affecting DL (i.e. rank 2, 3, and 4, 
Figure ‎3-7) which were IAP volume, polymer mass, and PVA concentration and differ 
in the BSA concentration (i.e. rank 1, Figure ‎3-7). The DL obtained when run 7 carried 
out was 4.1±0.6 µg/mg while run 18 produced NPs with DL 15.7±4.8 µg/mg. The 
difference in DL could be attributed mainly to the increased BSA concentration from 
0.2 (run 7) to 1% (run 18). 
IAP volume was the second factor affecting DL (i.e. rank 2, Figure ‎3-7), such that, the 
larger volume of the IAP the higher the BSA loading. This effect has been reported 
(141; 143; 147) and is thought to be due to a decrease in the concentration gradient 
between IAP and EAP. For example, run 13 and run 19 although they have an equal 
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BSA concentration (0.2 %) and polymer mass (100 mg) but differ in IAP volume (0.25 
ml and 0.5 ml, respectively). The DL obtained with run 13 was 1.4±0.5 µg/mg and with 
run 19 was 5±0.1 µg/mg. 
The third factor affecting DL was the polymer mass (rank=3, Figure ‎3-7). DL decreased 
substantially with increasing polymer mass from 50 to 100 to 200 mg, as predicted 
based on equation 2-7, in which DL is inversely proportional to the polymer mass (147). 
For example, run 22 and run 25 shared the predominant factors affecting DL (i.e. rank 
1, and 2, Figure ‎3-7) which were BSA concentration and IAP volume and also have the 
equal PVA concentration and OP volume and differ in the polymer mass (rank= 3, 
Figure ‎3-7). The DL obtained with run 22 (polymer mass 100 mg) was 5.6±0.04 µg/mg 
and with run 25 (polymer mass 200 mg) was 2.8±0.1 µg/mg. 
The factors that had the least effect on DL were PVA concentration, OP volume, 
sonication time of the EAP, sonication amplitude and sonication time of the IAP (i.e. 
rank= 4, 5, 6, 7, and 8, Figure ‎3-7). 
Among the PVA concentrations used, 1% PVA was found to result in a considerably 
high BSA loading with no added benefit of any further increase in PVA concentration 
(5, and 10 %). For example, run 19 and run 22 shared the predominant factors affecting 
DL (i.e. rank 1, 2, and 3, Figure ‎3-7) which were BSA concentration, IAP volume and 
polymer mass and differ in the PVA concentration (1 and 5 %, respectively). The DL 
obtained were similar with run 19 was 5±0.1 µg/mg and with run 22 was 5.6±0.04 
µg/mg. Similar observation was reported previously (148). 
OP volume has an enhancing effect on DL of BSA (rank=5, Figure ‎3-7). The results 
showed that decreasing the OP volume increased DL. This could be explained by that 
increasing the viscosity of the OP lead to a further stabilization of the primary emulsion 
and lowering the diffusion of BSA through the OP (141). 
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Moreover, increasing the sonication time of IAP and EAP or increasing the sonication 
amplitude from 30 to 45 to 65% had almost no beneficial effect on the BSA loading. 
This has been reported previously and has been associated with BSA precipitation 
within the sonication probe due to high pressure and increased fluid cavitations during 
sonication (136; 149). For example, run 1 and run 4 shared the predominant factors 
affecting DL (i.e. rank 1, 2, 3, 4, and 5, Figure ‎3-7) which were BSA concentration, IAP 
volume, polymer mass, PVA concentration, and OP volume. The DL obtained with run 
1 was 3.6±0.2 µg/mg and with run 4 was 2.4±0.4 µg/mg. 
3.5.1.3. Effects of the double emulsion solvent evaporation method parameters 
on the encapsulation efficiency % of BSA 
The EE % was studied because BSA is a hydrophilic compound which can easily 
diffuse into an EAP during the double emulsion solvent evaporation method (150). 
The effect of different parameters on the EE% had the following order: polymer mass > 
PVA concentration > BSA concentration > IAP volume > OP volume > EAP sonication 
time and IAP sonication time > sonication amplitude (Figure ‎3-8). It is obvious from the 
ranking that the first four important factors affecting EE% and DL of BSA are the same 
but with a different order. 
The polymer mass had the greatest influence on EE % of BSA. For example, run 11 and 
run 17 shared the predominant factors affecting EE % (i.e. rank 2, 3, 4 and 5, 
Figure ‎3-8) which were PVA concentration, BSA concentration, IAP volume, and OP 
volume and differ in the polymer mass (100 and 200 mg, respectively). The EE% 
obtained with run 11 was 52.1±7.2% and with run 17 was 69.1±2.6%. This could be 
correlated with the increased mass of the polymer resulting in a further stabilization of 
the primary emulsion and limiting the diffusion of BSA through and out of the OP due 
to higher viscosity of the OP (141; 151).  
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The second important factor affecting EE % of BSA was PVA concentration (i.e. 
rank=2, Figure ‎3-8). Among the PVA concentrations used, 1% PVA was found to result 
in a considerably high EE% of BSA. For example, runs 28, 31, and 34 shared the 
predominant factors affecting EE % (i.e. rank 1, 3, 4 and 5, Figure ‎3-8) which were 
polymer mass, BSA concentration, IAP volume, and OP volume and differ in the PVA 
concentration (5, 10 and 1 %, respectively). The EE% obtained were 53.6±0.4, 44.8±8.4 
and 62.8±3.5 %, respectively. One possible explanation is that 1 % PVA concentration 
provides sufficient covering of the organic/aqueous interface so as to reduce possible 
leaching of the BSA. Consequently, any further increase in PVA concentration (5 and 
10 %) resulted in more BSA molecules portioning into the aqueous phase during the 
emulsification procedure (129; 152). 
BSA concentration was the third factor that affected EE % (i.e. rank= 3, Figure ‎3-8). 
The EE % of BSA increased when BSA concentration increased from 0.2 to 0.5% but 
interestingly it decreased as the BSA concentration increased further to 1%. For 
example, runs 19 and 27 shared the predominant factors affecting EE % (i.e. rank 1, 2, 4 
and 5, Figure ‎3-8) which were polymer mass, PVA concentration, IAP volume, and OP 
volume and differ in the BSA concentration (0.2 and 1 %, respectively). The EE% 
obtained were 50.7±1 and 51.4±6.6 %, respectively. In fact, an increase in BSA 
concentration to high levels (1 %) is not always beneficial; this trend has been explained 
by the mass of polymer used being insufficient to completely encapsulate the BSA 
(143). Furthermore, higher concentration of BSA provide a higher BSA concentration in 
IAP droplets and thus increase the concentration gradient between the IAP droplets and 
the EAP and so increases the amount of BSA transported into the EAP (153; 154).  
IAP volume was the fourth factor affecting EE % (i.e. rank=4, Figure ‎3-8), such that, 
the larger volume of the IAP the higher the BSA EE %. This effect has been reported 
previously (141; 143; 147) and is similar to those observed for DL. For example, run 13 
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and run 19 although they have an equal BSA concentration (0.2 %) and polymer mass 
(100 mg) but differ in IAP volume (0.25 ml and 0.5 ml, respectively). The EE% 
obtained with run 13 was 27.4±9.8 % and with run 19 was 50.7±1 %. 
In contrast reducing OP volume has positive effect on EE % of BSA (rank=5, 
Figure ‎3-8). The results showed that reducing the OP volume increased EE %. This 
could be due to the higher viscosity of the OP leading to a further stabilization of the 
primary emulsion and minimizing the diffusion of BSA through the OP (141). For 
example, run 25 and run 28 shared the predominant factors affecting EE % (i.e. rank 1, 
2, 3 and 4, Figure ‎3-8) which were polymer mass, PVA concentration, BSA 
concentration, and IAP volume and differ in the OP volume (1 and 2 ml, respectively). 
The EE% obtained were 56.8±2.9 and 53.6±0.4 %, respectively. 
The sonication time of the IAP and EAP exerted similar effects on EE % (i.e. rank= 7 
and 6, respectively, Figure ‎3-8). The results indicated that increasing the sonication time 
of IAP and EAP resulted in higher EE % (155). Walter et al. reported that when 
preparing PLGA microparticles the reduction in the sonication time of IAP from 20 to 
10 s lead to decrease in EE% of DNA which may be due to the decrease in dispersion 
efficiency of the W/O emulsion (155). 
Moreover, increasing the sonication amplitude from 30 to 45 to 65% had almost no 
beneficial effect on the BSA EE % (rank= 8, Figure ‎3-8). This has been reported 
previously and has been associated with BSA precipitation within the sonication probe 
due to high pressure and increased fluid cavitations during sonication (136; 149). 
For example, run 14 and run 17 shared the predominant factors affecting EE % (i.e. rank 
1, 2, 3, 4 and 5, Figure ‎3-8) which were polymer mass, PVA concentration, BSA 
concentration, IAP volume and OP volume with different sonication amplitude and 
time. The EE% obtained were 62.9±4.6 and 69.1±2.6 %, respectively. 
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3.5.1.4. Optimized Conditions for BSA-loaded PGA-co-PDL nanoparticles 
prepared by double emulsion solvent evaporation method 
A precise adjustment of the various formulation and processing parameters is important 
to obtain NPs of a desired size and BSA loading. In‎this‎study,‎a‎particle‎size‎of‎≤‎500‎
nm was desired to facilitate uptake of NPs by DCs (43; 98; 156) and at least 30 µg/mg 
proteins loading to be suitable for dosage purpose when the protein of interest, PspA, is 
used (30; 35; 157). 
Optimum conditions were suggested by high S/N ratios. The greater the S/N ratio, the 
smaller is the variance of target (particle size and BSA loading) around the desired 
value. When the suggested optimized run was carried out the measured particle size 
obtained 203±5.4 nm was considered suitable for DCs uptake (158; 124; 159). 
Concerning the DL, the suggested optimized run produced NPs (HDL NPs) with DL 
43.67±2.3 µg/mg which is considered suitable for vaccination (7; 26; 160).  
When the DL was determined using the direct method for both SPS and HDL NP there 
was no significant difference although the DL value decreased in comparison with 
indirect method. 
3.5.2. Optimization of the spray drying process 
Spray-drying was applied to incorporate the selected HDL NPs into NCMPs using L-
leucine as a carrier and to enhance powder dispersion.  
Most of the runs produced low yields (Table ‎3-6) due to the difficulties in dry powder 
collection associated with condensation inside the drying chamber and collecting vessel 
and the sticking tendency of dry powder to the walls of the drying chamber and 
collecting vessel so cannot be collected efficiently (161). Utilizing the Taguchi design 
revealed that the feed rate, aspirator capacity, air flow, and inlet temperature had the 
greatest effects on the yield of dry powder while the change in the concentration of total 
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solid in the spray dried suspension showed no improvement in the yield of dry powder 
(Figure ‎3-9).  
The most important factor was feed rate with a negative effect on powder yield % (rank 
= 1, Figure ‎3-9). At higher feed rates of 15%, the atomizing air may not be able to break 
the liquid flow. Consequently, insufficient atomization and drying may cause deposition 
of a large amount of NCMPs on the walls of the drying chamber and the cyclone 
separator (161). Similar observation was reported by Motlekar et. al. (161). They found 
that the high feed rate (25 %) of the spray suspension lead to almost no yield of dry 
powder (161). 
The second important factor was aspirator capacity (i.e. rank=2, Figure ‎3-9). A high 
aspirator flow rate created greater centrifugal force leading to an increase in the 
collection efficiency (162). Airflow was the third factor affecting dry powder yield (i.e. 
rank=3, Figure ‎3-9). Higher spray flow produced smaller droplet so collected less 
efficiently by the centrifugal force (162). 
Shi and Hickey optimised spray drying condition to prepare PLGA microparticles 
suitable for inhalation. They found that the airflow and aspirator capacity had 
significant effect on the yield of dry powder. Where the airflow had negative effect, 
showing that powder yield decreased with the increase of the airflow while the aspirator 
capacity had positive effect, showing that powder yield increased with the increase of 
the aspirator capacity (162).  
The inlet temperature of drying air ranged from 50 to 100 ºC typically resulting in the 
spray dryer outlet temperature of approximately 22 to 46 ºC, respectively. The inlet 
temperature of drying air had considerable effects on the yield of dry powder (rank=4, 
Figure ‎3-9). It was noticed that as inlet temperature increased from 50 to 100 ºC this 
resulted in an increased powder yield. It has been reported that high inlet temperature 
can reduce the drying time and inhibit particle aggregation (163). Furthermore, a higher 
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inlet temperature promotes a decrease of residual moisture by enhancing water 
evaporation resulting in less particles stick in the drying chamber (164).  
Also, it was observed that the change in the concentration of total solid in the spray 
dried suspension showed no improvement in the yield of dry powder. This observation 
was in contrast to the results reported by Jensen et al. were they found that as the 
concentration of solid in the suspension increased the yield of dry powder increased 
(92). 
It could be noticed from Table ‎3-6 that runs 10, 11, 12, 22, 23, and 24 had no yield. 
They shared the predominant factor (i.e. rank=1, Figure ‎3-9) affecting yield which is 
feed rate although they differ in other factors which are aspirator capacity, air flow and 
inlet temperature (Table ‎3-4). The feed rate was 15 % at this high rate the atomizing air 
may not be able to break the flow of the suspension also this high feed rate accompanied 
by lower level of aspirator capacity (50 and 75%), higher level airflow (535 and  670 
L/h) and lower level of inlet temperature (50‎and‎75‎˚C).‎At‎these‎levels‎ these factors 
had negative effect on yield as explained above. When these parameters adjusted to 
their positive level in run 7, 8, and 9 (i.e. level that produced higher yield, Table ‎3-4 and 
Table ‎3-6) the yield increased up to 43 %.  
Optimum conditions used for the production of highest yield% (Table ‎3-4) of dry 
powder resulted in 50.96±2.26 % of NCMPs which was considered reasonable (92).  
Photomicrographs of NCMPs (Figure ‎3-10) showed irregular and porous microparticles. 
This occurred due to an excessive build-up of vapour pressure during water evaporation 
in the spray drying process and typically occurs with hydrophobic amino acids, such as 
L-leucine, for improved aerosolisation performance (66; 134; 165; 166; 167; 168; 169; 
170).  
From 27 spray-dried formulations run 16 and run H were selected for in vitro 
aerosolisation studies. Run H had the highest yield % while run 16 produced particles 
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more porous in nature as presented by SEM photograph and the tapped density 
suggesting highly porous particles (66). 
SPS H NCMPs and HDL H NCMPs formulations had a geometric particle size double 
of that obtained with SPS 16 NCMPs and HDL 16 NCMPs (Table ‎3-7). This could be 
due to the difference in the airflow between the run H and run 16 (400 and 535 L/h, 
respectively). The higher airflow produces smaller droplet size and enhancing 
evaporation rate and thus produces smaller particle size. This observation was reported 
previously with PLGA microparticles prepared by spray drying as the airflow increased 
the particle size decreased (162). 
The theoretical aerodynamic diameters (Table ‎3-7) of tested formulation HDL H 
NCMPs, SPS H NCMPs, HDL 16 NCMPs, and SPS 16 NCMPs indicate that the spray 
dried NCMPs generated are suitable for pulmonary delivery. 
3.5.3. In vitro aerosolisation and moisture content studies 
BSA deposition data obtained from spray-dried formulations indicated similarity in 
aerosolisation performance between run 16 and run H for FPD, FPF % and MMAD 
(Table ‎3-8). SPS 16 NCMPs and HDL 16 NCMPs produced higher FPD and FPF % and 
this was attributed to the more porous structure of the NCMPs prepared by run 16 (134; 
165). In run 16, the aspirator capacity was adjusted to 50 % which is lower than the 
aspirator capacity of run H (100 %). Consequently this resulted in a slower movement 
of the particles through the system and a longer action of the drying air upon them 
(171). Moreover, in run 16 the air flow was adjusted to a higher value (535 l/h) than for 
run H (400 l/h) which resulted in a smaller droplet size to which amphiphillic small 
leucine molecules can easily diffuse (163). However, the conditions associated with run 
H produced significantly greater yield hence run H conditions were applied for spray 
drying for the rest of this study.  
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Therefor high residual moisture content can promote particle aggregation leading a 
variation in particle size distribution (157). The low moisture content reported from the 
TGA thermogram presents a good drying efficiency therefor the dry powder 
formulations (HDL H NCMPs) are likely to show high storage stability.  
3.5.4. In Vitro Release, structure stability of BSA, and cytotoxicity 
studies 
In vitro release studies comparing SPS H NCMPs and HDL H NCMPs formulations 
were performed in PBS (pH=7.4). Both formulation showed biphasic release profile 
with a first initial burst release followed by a second continuous sustained release phase 
over 48h (Figure ‎3-12). The noticeable change in release profile at 24h after the initial 
burst release could be due to the distribution of BSA inside NPs or a change in 
degradation rate due to changed surface porosity.  
In this study, BSA was released from SPS H NCMPs and HDL H NCMPs formulations 
according to the Higuchi diffusion model (Table ‎3-9). Therefore, the sustained release 
of BSA from spray-dried NCMPs appeared to be a diffusion-limited process. 
Accordingly from in vitro aerosolisation and release studies HDL H NCMPs was 
selected for further investigation in this study. 
The primary structure of BSA released from HDL NPs and HDL H NCMPs was 
analysed by SDS-PAGE followed by Coomassie brilliant blue staining. The BSA 
released showed similar clear banding patterns to the BSA standard providing evidence 
that the released BSA did not suffer a significant covalent aggregation or fragmentation 
during the preparation methods used (Figure ‎3-14). 
The secondary structure of BSA in the formulation was analysed using CD 
spectroscopy, a valuable technique for analysing protein structure (115). CD of the BSA 
released samples (Figure ‎3-15) confirmed the‎presence‎of‎α-helix‎and‎β-sheets although 
these were slightly decreased in comparison with standard BSA (140; 172). But, in 
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protein secondary structure, this decrease (3%) considered minor and it is believed that 
the‎β-sheet‎structure‎is‎sometimes‎noticed‎as‎a‎special‎α-helix only with two amino acid 
residues through stretching resulting from the breakage of hydrogen bond (140; 172). 
The aerosolisation data suggests a deposition mainly in the deep lung region thus 
cytotoxicity studies were performed on A549 cell line (adenocarcinomic human alveolar 
basal epithelial cells). The NPs and NCMPs appear to be well tolerated by the cells. 
3.6. Conclusion 
PGA-co-PDL NPs with appropriate size (203±5.4 nm) to target DCs and therapeutic 
BSA loading (43.67±2.3 µg/mg) were successfully prepared using the Taguchi L36 
orthogonal array design of experiment. The selected NPs formulations were 
incorporated into NCMPs using L-leucine as a carrier and to enhance powder 
dispersion. The highest yield % of dry powder (50%) was obtained using the Taguchi 
L27 orthogonal array design of experiment. The NCMPs had irregular and porous 
surface. The in vitro release studies showed BSA maintains its primary and secondary 
structure. Furthermore, aerosolisation deposition data (FPF 78.57±0.1 % and MMAD 
1.71±0.1 µm) indicates deep lung deposition. Cell viability studies on A549 cells and 
DCs showed a low toxicity profile. This study suggests that PGA-co-PDL NCMPs 
should be further investigated for modification of particle surface to improve uptake by 
DCs and to encapsulate PspA as a therapeutic antigen to be delivered through the lung.  
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4.1. Introduction 
Pulmonary vaccine delivery has recently been explored as an alternative for parenteral 
immunization. The extensive network DCs lining the respiratory submucosa and on the 
alveolar surface plays important roles in generating both mucosal and systemic immune 
responses (52). 
The surface charge of NPs plays an important role in determining uptake of NPs by DCs 
and cationic particles have been shown to be more effectively taken up by DCs (75; 87; 
88; 41). The ionic interaction between the positive charge on the particles surface and 
the negative charge on cell surface generates a successful bond and promotes particle 
uptake (87). Furthermore, cationic NPs have greater ability to interact with the 
proteoglycans on the surface of macrophages and DCs (173). 
Incorporation of cationic polymers such as chitosan or chitosan derivatives have been 
shown to enhance the uptake of antigens by DCs and subsequently induce strong 
immune responses (174). Recently published researches on the use of chitosan and its 
derivatives as mucosal vaccine delivery systems are summarised in Table ‎4-1. 
Thomann-Harwood et al. have reported that chitosan nanogels carrying a model 
antigen, ovalbumin, have a higher association of the positively charged nanogel 
compared with the more neutral (mannosylated alginate coated) or negatively charged 
(alginate coated) nanogels (175). Also, Slütter et al. have demonstrated that N-trimethyl 
chitosan (TMC) NPs were superior over PLGA NP and PLGA/TMC NP in stimulating 
the maturation of DCs after nasal administration (156). 
Many research groups have documented techniques of modifying NPs charge by using 
didodecyldimethylammoniumbromide (DMAB) as a surfactant (173; 176; 177). Jensen 
et al. have demonstrated that addition of cationic lipid 
dioleoyltrimethylammoniumpropane (DOTAP) into PLGA matrix during preparation of 
NPs resulted in cationic NPs and they further showed the use of these NPs loaded with 
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small interfering RNA prepared as a dry powder of RNA NPs for pulmonary delivery 
(178). 
Table ‎4-1: Recently published studies on Chitosan and chitosan derivatives as 
mucosal vaccine deliver systems. 
Polymer Antigen Delivery 
system 
Model Route Ref. 
Chitosan  Bacillus anthracis 
protective antigen 
Nanoparticles In vivo Nasal  (179) 
Chitosan  measles antigen Nanoparticles In vivo Oral (180) 
Chitosan PsaA protein Nanoparticles In vivo Intranasal (181) 
Chitosan Human 
papillomavirus 
Nanoparticles In vivo Intranasal (182) 
Mannose/ chitosan Pseudomonas 
aeruginosa protein 
Microspheres In vivo Intranasal (183) 
Chitosan/gold  Tetanus toxoid Nanoparticles In vivo Oral (184) 
Chitosan Influenza whole 
virus 
Nanospheres In vivo Nasal (185) 
Chitosan Yeast-derived 
PCV2 virus-like 
particles 
Microparticles In vivo Oral (186) 
Chitosan Recombinant 
enterovirus 71 
Mixture In vivo Oral (187) 
Glucomannosylated 
chitosan 
Tetanus toxoid Nanoparticles In vitro Oral (188) 
Chitosan DNA Complex In vivo Intranasal (189) 
Chitosan CPE30 peptide, C 
terminal 30 amino 
acids of clostridium 
perfringens 
enterotoxin 
Nanoparticles In vivo Oral  (190) 
Glycol chitosan  Hepatitis B surface 
antigen 
Nanoparticles In vivo Intranasal (191) 
N-trimethylamino-
ethylmethacrylate 
chitosan 
Thiolated 
ovalbumin 
Soluble 
conjugate 
In vivo Intranasal (192) 
Chitosan Recombinant HIV- Solution In vivo Intranasal (193) 
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1 envelope 
glycoprotein and 
tetanus toxoid  
and 
sublingual 
Mannosylated 
chitosan 
DNA Nanoparticles In vivo Intranasal  (194) 
Chitosan DNA Solution In vivo Intranasal (195) 
Glucomannosylated 
chitosan  
Model antigen Nanoparticles In vivo Oral (196) 
Chitosan Diphtheria toxoid In situ forming 
gel  
In vivo Intranasal (197) 
Chitosan hemagglutinin 
(HA)-split 
influenza virus 
product 
Nanoparticles In vivo Intranasal (198) 
PLGA/Chitosan membrane protein 
B of Brachyspira 
hyodysenteriae 
Microparticles In vivo Oral (199) 
Chitosan high-mobility 
group box 1 
Microparticles In vivo Intranasal (200) 
Chitosan/liposome DNA Nanoparticles In vivo Intranasal (201) 
Chitosan  P1-P30 chimeric 
recombinant 
protein 
Solution In vivo Intranasal (202) 
PLGA/Chitosan Model antigen Nanoparticles In vivo Intranasal (203) 
PLGA/Chitosan or 
glycol chitosan  
Hepatitis B surface 
Antigen 
Nanoparticles In vivo Intranasal (204) 
Chitosan Hepatitis B. Nanoparticles In vivo Oral (205) 
Methylated N-(4-N,N-
dimethylaminocinnam
yl) chitosan- 
Ovalbumin Microparticles In vivo Oral (206) 
Chitosan Ovalbumin Microparticles In vivo Intranasal (207) 
Chitosan and trimethyl 
chitosan 
Hepatitis B surface 
antigen 
Nanoparticles In vivo Intranasal (208) 
N-[(2-hydroxy-3-
trimethylammonium) 
propyl] chitosan 
chloride and‎ α,‎ β-
glycerophosphate 
adenovirus based 
Zaire Ebola virus 
glycoprotein 
antigen 
hydrogel In vivo Intranasal (209) 
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Here, we focused on the use of natural polymer chitosan and its derivatives. Chitosan is 
a biodegradable, biocompatible, cationic polysaccharide, with low toxicity and can be 
formulated in a number of different ways, as a solution, gel, powder, microparticles and 
nanoparticles. The potential application of chitosan is restricted by its low aqueous 
solubility but it can be chemically modified to enhance polymer processing, solubility, 
antimicrobial activity, and the ability to interact with other substances (71). 
Recently, water-soluble chitosan hydrochloride (CHL) has been reported as a model 
positively charged polyelectrolyte, which may overcome the low water solubility of 
chitosan at neutral pH (210). However, like other cationic polymers, the strong positive 
charge contributes to the toxicity of the polymer. The amount of CHL can be 
substantially decreased by adsorbing CHL to anionic NPs. This is particularly true due 
to the large surface-to-volume ratio of the NPs (111). These cationic NPs could be 
incorporated into microparticles to produce cationic NPs/NCMPs with an aerodynamic 
size between 1 and 5 µm which upon inhalation can deposit deep in the lung and have 
access to the alveoli and the broncho associated lymphoid tissue (BALT) and are, 
therefore, attractive antigen carriers (52).  
PGA-co-PDL has previously been used to produce NPs with negative surface charge (as 
described in section ‎2.2.3 and chapter 3) utilising PVA as a surfactant. 
4.2. Aim 
The aim of this study was to adsorb CHL onto PGA-co-PDL NPs with encapsulated 
BSA as a model protein, and optimize the preparation method and formulation 
parameters: particle size and zeta potential. The cationic NPs were incorporated into 
microcarriers (L-leucine) via spray drying to produce cationic NPs/NCMPs suitable for 
pulmonary delivery via DPIs.  
To obtain the aim of the study a systematic study was designed considering the 
following aspects: 
 110 
 
1. Formulation of cationic NPs using double emulsion solvent evaporation 
technique. 
2. Evaluation of the influence of formulation parameters on the particle size and 
charge. 
3. Formulation of cationic NPs/NCMPs via spray drying technique.  
4. Examination of BSA integrity, in vitro aerosolisation performance, in vitro 
release, in vitro cells toxicity of optimum cationic NPs/NCMPs. 
4.3. Methods 
4.3.1. Cationic nanoparticle preparation 
The adsorption of CHL was achieved as described in section ‎2.2.4. 
4.3.2. Cationic nanoparticle characterization 
The cationic NPs were characterised for particle size, PDI, zeta potential, encapsulation 
efficiency and protein loading as described in sections ‎2.2.7.1 and ‎2.2.7.2 respectively. 
4.3.3. Quantification of chitosan hydrochloride adsorption 
The amount of CHL adsorbed on the surface of cationic NPs was evaluated as described 
in section ‎2.2.5. 
4.3.4. Adsorption isotherm models 
The adsorption mechanism of CHL on NPs was determined as described in 
section ‎2.2.6. 
4.3.5. Chitosan Hydrochloride nanocomposite microparticles 
preparation by spray drying  
Cationic NPs/NCMPs were prepared by spray drying cationic NPs using the spray 
drying conditions for run H as described in section ‎2.2.8.  
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4.3.6. Characterization of Chitosan Hydrochloride nanocomposite 
microparticles 
Cationic NPs/NCMPs morphology, yield %, moisture content and powder density and 
primary aerodynamic diameter were characterised as described in section ‎2.2.9.  
4.3.7. In vitro aerosolisation studies 
The in vitro aerosolisation studies were carried out as described in section ‎2.2.10. 
4.3.8. In vitro release study  
The in vitro release studies were carried out as described in section ‎2.2.11. 
4.3.9. Investigation of BSA structure  
The stability of the primary and secondary structure of released BSA was evaluated as 
described in section ‎2.2.12. 
4.3.10. Cytotoxicity study 
The cytotoxicity of cationic NPs and cationic NPs/NCMPs was determined as described 
in section ‎2.2.15.1. 
4.4. Results 
4.4.1. Cationic nanoparticles characterisation  
4.4.1.1. Effect of different concentrations of CHL and PVA on particle size 
and zeta potential  
The adsorption of CHL on NPs was carried out using two strategies: the first after the 
formation of NPs and resuspending in CHL solution the second during the preparation 
of NPs with CHL added to EAP. 
In the first strategy, different concentrations of CHL were used with and without 1% 
PVA. When 1% PVA was used the zeta potential significantly changed from negative (- 
17.44±1.3 mV) to around neutral (0.06±0.34 to -0.71±0.63 mV) (Figure ‎4-1.A) 
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regardless of CHL concentration (p < 0.05,‎ANOVA/Tukey’s‎comparison). The particle 
size (445±46.87 nm) increased significantly (p‎<‎0.05,‎ANOVA/Tukey’s‎ comparison)‎
when the CHL concentration increased to 4, 8 and 30 mg/ml (Figure ‎4-1.B). However, 
at a CHL concentration of 20 and 34 mg/ml there was no significant (p > 0.05, 
ANOVA/Tukey’s‎comparison)‎change in particle size (Figure ‎4-1.B).  
When PVA was not included during the NPs preparation, the zeta potential was neutral 
at lower CHL concentrations of 4 and 8 mg/ml (p < 0.05,‎ ANOVA/Tukey’s‎
comparison) while at higher CHL concentrations of 20 and 30 mg/ml the zeta potential 
was positive 11.79±2.5 and 16.73±0.98 mV respectively‎ (p‎<‎ 0.05,‎ANOVA/Tukey’s‎
comparison) (Figure ‎4-1.A). At the highest concentration of CHL 34 mg/ml the NPs 
surface charge once again became neutral.  
The particle size increased significantly when the concentration of CHL increased to 4, 
and 8 mg/ml (Figure ‎4-1.B). However, at higher concentrations of CHL (20, 30 and 34 
mg/ml) there was no significant (p>0.05,‎ANOVA/Tukey’s‎ comparison) difference in 
particle size at different concentration of CHL but it was significantly (p<0.05, 
ANOVA/Tukey’s‎comparison) larger than the anionic NPs (Figure ‎4-1.B).  
In order to use lower amount of CHL concentration of 20 mg/ml was selected to 
investigate the effect of PVA% on zeta potential and particle size.  
Figure ‎4-2.A and B shows the effect of % PVA added to the CHL solution (20 mg/ml) 
on particle size and zeta potential of NPs. Three concentrations of PVA were compared 
0, 0.5, and 1%. 
Anionic NPs had a negative surface charge (-17.44±1.2 mV) but following the addition 
of CHL (20 mg/ml) with various amount of PVA the zeta potential changed 
significantly‎(p‎<‎0.05,‎ANOVA/Tukey’s‎comparison)‎from‎negative‎(-17.44±1.3 mV) 
to positive (11.8±2.5 mV) then neutral (-0.41±0.89 M). When the PVA concentration 
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was 0 and 0.5%, the particle size showed significant difference (p < 0.05, 
ANOVA/Tukey’s‎comparison)‎from anionic NPs (Figure ‎4-2 B). 
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Figure ‎4-1: Effect of CHL (mg/ml) concentration on: A) zeta potential and B) 
particle size of NPs. Data represent means ±SD, n=3,* is p < 0.05,‎ANOVA/Tukey’s‎
comparison. 
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4.4.1.2. Effect of adsorption time 
Figure ‎4-3.A and B shows the effect of adsorption time on zeta potential and particle 
size. The zeta potential changed significantly (p<0.05, ANOVA/Tukey,s comparison) 
from negative (- 17.44±1.3 mV) to positive 2 and 6 h and became neutral after 4 and 24 
h. The particle size (455± 46.87 nm) increased‎significantly‎(p<0.05,‎ANOVA/Tukey’s‎
Figure ‎4-2: Effect of PVA % concentration on: A) zeta potential and B) particle 
size of NPs. Data represent means ±SD, n=3, * is p < 0.05,‎ ANOVA/Tukey’s‎
comparison. 
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comparison) after CHL adsorption in comparison with anionic NPs regardless of 
adsorption time.  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* 
* 
* 
0
200
400
600
800
1000
1200
1400
1600
1800
Anionic NPs 2 4 6 24
P
ar
ti
cl
e
 s
iz
e
 (
n
m
) 
Time (h) 
* 
* 
* 
* 
* 
-25
-20
-15
-10
-5
0
5
10
15
20
Anionic NPs 2 4 6 24
Ze
ta
 P
o
te
n
ti
al
 (
m
V
) 
Time (h) 
A) 
B) 
Figure ‎4-3: Effect of adsorption time on: A) zeta potential and B) particle size of 
NPs. Data represent means ±SD, n=3, * is p < 0.05,‎ANOVA/Tukey’s‎comparison. 
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4.4.1.3. Effect of method of addition CHL  
In the second strategy CHL was added to the EAP in different concentrations (0 to 20 
mg/ml) during the preparation of cationic NPs. The NPs had an electronegative (-
17.44±1.2 mV) zeta potential, while all CHL - NPs were electropositive (p < 0.05, 
ANOVA/Tukey’s‎comparison). The zeta-potential of cationic NPs increased with CHL 
feed concentrations up to +24 mV when produced from a CHL concentration of 
approximately 16–20 mg/ml (Figure ‎4-4.A).  
The particle size (Figure ‎4-4.B) of anionic NPs was 445± 46.8 nm and it increased 
(3934±1533.7 and 2148±352.6 nm) significantly (p < 0.05,‎ ANOVA/Tukey’s‎
comparison) with low concentrations of CHL ranging from 2 to 4 mg/ml (Figure ‎4-4.B). 
Whilst at higher concentrations of CHL the particle size did not significantly change (p 
> 0.05,‎ANOVA/Tukey’s‎comparison).  
The CHL concentration of 10 mg/ml in EAP was selected for further investigations in 
this study because it had similar size to anionic NPs with positive charge (Table ‎4-2). 
Furthermore, there was no significant difference (p‎ >‎ 0.05,‎ ANOVA/Tukey’s‎
comparison) between particle size and surface charge of unloaded and BSA loaded 
cationic NPs at the selected concentration of CHL (10 mg/ml in EAP) Table ‎4-2. 
4.4.2. Chitosan adsorption 
The amount of CHL per mg of NPs increased significantly with the concentrations of 
CHL in the EAP over the entire range (0–20 mg/ml) of CHL concentrations examined 
(Figure ‎4-5). The mass of adsorbed CHL was 0.69±0.01, 1.45±0.02, 2.32±0.01, 
3.44±0.38, 3.99±0.02, and 8.97±0.03 mg CHL/ mg of NPs obtained with initial CHL 
concentrations of 2, 4, 6, 8, 10 and 20 mg/ml, respectively. The largest mass of 
adsorbed CHL was obtained at 20 mg/ml CHL initial concentration with 8.97 mg CHL 
per mg of NPs (p < 0.05, ANOVA/Tukey’s‎ comparison;‎ all‎ values‎ are‎ significantly‎
different to each other). 
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Figure ‎4-4: Effect of CHL concentration in EAP on: A) zeta potential and B) 
particle size of NPs, Data represent means ±SD, n=3, * is p < 0.05, 
ANOVA/Tukey’s‎comparison. 
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Table ‎4-2: Particle size and zeta potential of selected anionic and cationic NPs with 
and without BSA loading. Data represent mean ± SD, n=3. 
 
Unloaded NPs BSA loaded NPs 
Anionic NPs* 
  
Particle size (nm) 
Zeta Potential (mV) 
PDI 
403±7.80 
-20.33±2.1 
0.244±0.03 
445±46.8
 
 
-17.44±1.20 
0.209±0.05 
Cationic NPs*   
Particle size (nm) 
Zeta Potential (mV) 
PDI 
470.22±45.77 
+16.88±3.10 
0.328±0.09 
480.23±32.2 
+14.20±0.72 
0.380±0.03 
*NPs characterised after centrifugation. 
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Figure ‎4-5: Effect of CHL concentration on the amount of CHL absorbed onto 
NPs. Data represent mean±SD, n=3, where * significantly different (p < 0.05, 
ANOVA/Tukey’s‎comparison). 
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4.4.3. Adsorption isotherm model  
The adsorption of CHL onto NPs did not fit with the Langmuir model over the range of 
CHL concentration examined (Figure ‎4-6.A). Even though, it had a good fit at low 
initial chitosan concentrations. The adsorption of CHL had a poor fit with the BET 
model (Figure ‎4-6.B). The multiplayer adsorption models including the Freundlich 
(Figure ‎4-6.C), and Halsey (Figure ‎4-6.D), models both had a good fit with good 
agreement (r
2 
> 0.9), and the corresponding adsorption parameters were calculated 
(Table ‎4-3). 
 
 
 
Table ‎4-3: Parameters derived from adsorption isotherm models by linear 
regression. 
Isotherm 
equations 
Adsorption 
capacity 
Adsorption 
intensity 
Regression 
coefficient 
Langmuir* qm=1.2366 b=-0.2149 0.9167 
Langmuir qm=2.28 b=0.146 0.8415 
BET qm=0.4288 b=0.8561 0.0015 
Freundlich k=0.2893 n=0.5434 0.9988 
Halsey k=1.9422 n=0.5406 0.9974 
*PGA-co-PDL NPs made at 0-8 mg/ml CHL initial concentration. 
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Figure ‎4-6: Linear representation of the four isotherm models of CHL adsorption 
onto NPs. Ce is the residual CHL concentrations in the suspension at equilibrium 
(mg/ml) and q is the amount of adsorbed CHL per unit weight of NPs. The (A) 
Langmuir model was fit with two regression lines plotted for low (0–8 mg/ml) (—) and 
the entire range of concentrations‎ (….),‎ respectively.‎ The‎ (B)‎BET,‎ (C)‎ Freundlich,‎
and (D) Halsey models were fit using whole range of concentrations. Data represent 
mean±SD, n= 3. 
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4.4.4. BSA loading and EE% 
The BSA loading of anionic NPs (43.67±2.3 µg/mg) decreased significantly (p<0.05, 
ANOVA/Tukey’s comparison) in comparison with cationic NPs (7.28±1.3 µg/mg) and 
the BSA EE% (48±2.6 %) decreased significantly (p<0.05,‎ ANOVA/Tukey’s 
comparison) in comparison with cationic NPs (4.9±2.1 %), Table ‎4-4.  
 
Table ‎4-4: BSA loading (µg/mg) and EE % of anionic NPs, anionic NPs/NCMPs, 
cationic NPs and cationic NPs/NCMPs. Data represent mean±SD, n=3. 
 
BSA loading (µg/mg) EE (%) 
Anionic NPs 43.67±2.3* 48.04±2.6* 
Anionic NPs/NCMPs 5.37±1.7**  
Cationic NPs 7.29±1.4* 4.9±1.3* 
Cationic NPs/NCMPs 1.09±0.03**  
 * (Anionic vs Cationic NPs) and ** (Anionic vs Cationic NPs/NCMPs) is p < 0.05, 
ANOVA/Tukey’s‎comparison. 
4.4.5. Characterisation of nanocomposite microparticles 
Spray-drying was applied to incorporate the selected cationic NPs into NCMPs using L-
leucine as a carrier and to enhance powder dispersion.  
The size of anionic NPs after recovery from spray-dried anionic NPs/NCMPs and 
cationic NPs/NCMPs in distilled water were 453.6± 19.7 nm and 490±17 nm 
confirming the recovery of NPs from NPs/NCMPs. 
4.4.5.1. Morphology of nanocomposite microparticles 
The shape and morphology of cationic NPs/NCMPs were investigated using SEM 
(Figure ‎4-7). Photomicrographs of cationic NPs/NCMPs showed irregular and porous 
microparticles.  
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Figure ‎4-7: SEM images of cationic NPs/NCMPs: 1 µm scale (A) and 2 µm scale 
(B). 
 
 
4.4.6. Powder density and primary aerodynamic diameter 
Cationic NPs/NCMPs formulation had a geometric particle size of 5.52±0.64 µm 
(Table ‎4-5). The tapped density was 0.08±0.002g cm-3; and this was used together with 
the geometric particle size to calculate the theoretical aerodynamic diameter (dae). The 
cationic NPs/NCMPs had the theoretical aerodynamic diameter within the respirable 
range. 
Table ‎4-5: The geometric particle size, tapped density and theoretical aerodynamic 
diameter of cationic NPs/NCMPs. Data represent mean ± S.D., n=3. 
NCMPs 
Formulation 
Geometric 
particle 
size 
(µm) 
Tapped density 
(g/cm
3
) 
Carr’s index 
 dae 
(µm) 
% Flowability 
Cationic 
NPs/NCMPs 
5.52±0.64 0.08±0.002 36.71±0.83 Very poor 1.56±0.19 
 
 
B A 
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4.4.7. In vitro aerosolisation studies  
The percent mass of BSA recovered from the NGI was approximately 89 %, which is 
within the pharmacopeia limits (75 – 125 %) of the average delivered dose (139). BSA 
deposition data obtained from anionic NPs/NCMPs and cationic NPs/NCMPs 
formulations (Table ‎4-6) indicated there was a significant difference in aerosolisation 
performance between these formulations for FPD, and FPF% (p<0.05, 
ANOVA/Tukey’s comparison). Anionic NCMPs produced a higher FPD 45.00±4.70 
µg, and FPF% 78.57±0.1% than cationic NPs/NCMPs 32.51±6.67 µg and 
46.79±11.21%, respectively. 
 
Table ‎4-6: The Fine particle dose (FPD), percentage fine particle fraction (FPF), 
and mass median aerodynamic diameter (MMAD) of cationic NPs/NCMPs. Data 
represent mean ± S.D., n=3. 
 
 
FPD (µg) 
 
FPF (%) 
 
MMAD (µm) 
Cationic 
NPs/NCMPs 
32.51±6.67 46.79±11.21 1.49±0.29 
 
 
4.4.8. Investigation of BSA structure 
The primary structure of BSA released from cationic NPs and cationic NPs/NCMPs was 
investigated using SDS-PAGE analysis. According to Figure ‎4-8, the BSA standard and 
the molecular weight marker had shown in Lanes 1 and 2, respectively, revealed a clear 
band at around 66 KDa. The BSA released from cationic NPs and cationic NPs/NCMPs 
(Lanes 3 and 4, respectively), showed similar clear banding patterns to the BSA 
standard. The single lines in the gels provided evidence that the entrapped BSA in the 
cationic NPs and cationic NPs/NCMPs samples was stable. 
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The secondary structure analysis of released BSA was carried out using CD. Figure ‎4-9 
shows the structure of standard BSA and BSA released. The CD spectra show minima 
at 221 - 222 and 209 – 210 nm and a maximum at 195 nm for both samples, which is 
characteristic of an α-helical structure. In support of these data, structural analysis 
showed that BSA was predominantly helical displaying 51.5% helicity (Table ‎4-7). In 
contrast to standard BSA, structural analysis of BSA released showed a reduced level of 
α-helical conformation (circa 43 % helical) (Table ‎4-7). Furthermore, a comparison of 
BSA released with standard BSA, showed that the α-helical content decreased by 8.5 %, 
the β-sheet content increased by 8%, the turns content decreased by 2%, and the random 
coils’‎content‎increased‎by‎3%, respectively. 
 
 
 
 
  1                     2      3     4                                  
MW  
KDa 
205 
129 
116 
97.4 
84 
66  
 
45 
 
 
36 
 
20 
17.5 
7.1 
Figure ‎4-8: SDS-PAGE behaviour of BSA released from NPs for the 
assessment of BSA stability. Lanes represent, molecular weight (MW) 
standard markers, BSA (MW 66,000) (1), BSA standard (2), BSA released 
from cationic NPs (3), and BSA released from cationic NPs/NCMPs (4). 
Difference in band intensity was due to different loading. 
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Table ‎4-7: The percentage of secondary structure conformation for BSA standard 
and BSA released from cationic NPs/NCMPs (n=3).  
 
4.4.9. In Vitro Release Studies 
In vitro release studies were performed on cationic NPs/NCMPs formulations and 
reported as cumulative percentage BSA released over time (Figure ‎4-10). Cationic 
NPs/NCMPs formulations showed a biphasic release profile. The % cumulative BSA 
released at time zero was considered as surface-associated BSA, the % cumulative BSA 
 
 
Helix Strands Turns Unordered 
BSA standard 51.5 ± 0.007 21.50 ± 0.007 9.0 ± 0 17.50 ± 0.007 
BSA released 43 ± 0.007 29 ± 0.014 7 ± 0 20.5 ± 0.007 
Figure ‎4-9: The CD spectra of BSA released from cationic NPs/NCMPs (grey) 
and BSA standard (black) (n=3). 
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released at the end of 4 h was considered as the initial burst phase of BSA release, and 
followed by a second continuous sustained release phase over 48h (Figure ‎4-10).  
The anionic NPs/NCMPs formulations showed a lower cumulative release achieving 
38.77±3% release after 48 h (Figure ‎3-12). The cationic NPs/NCMPs formulations 
showed a higher cumulative releases, with nearly 88.93 ±14.8% of BSA released after 
48 h (p<0.05,‎ANOVA/Tukey’s comparison) (Figure ‎4-10).  
In vitro release kinetics were used to determine the mechanism of BSA release. 
Comparison of the rates of release using zero, first order and the Higuchi rate equations 
are shown in Table ‎4-8.  
BSA was released from cationic NPs/NCMPs formulations according to a dual pattern 
first order model with an r
2
 value of 0.919. The release rate constant k1 (h
-½
) was -0.016, 
the Higuchi diffusion model r
2
 value was 0.928, and the release rate constant k1 (h
-½
) was 
9.316 (Table ‎4-8).  
 
 
 
Figure ‎4-10: % Cumulative in-vitro release of BSA from cationic NPs/NCMPs in 
PBS buffer at 37°C. Data represent mean ± S.D., n=3. 
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Table ‎4-8: Release parameters of BSA from cationic NPs/NCMPs. 
Formulation Zero Order First order Higuchi 
r
2
 ko (h
-1
) r
2
 k1 (h
-1
) r
2
 k1 (h
-½
) 
Cationic 
NPs/NCMPs 
0.777 1.218  0.919 -0.016 0.928 9.316 
 
 
 
4.4.10. Cytotoxicity study 
The A549 cell line toxicity studies (Figure ‎4-11) of cationic NPs and cationic 
NPs/NCMPs showed a cell viability of 63.91±0.87% for cationic NPs and 78.85±9.96% 
for cationic NPs/NCMPs at a concentration of 2.5 mg/ml after 24 h exposure indicating 
a good toxicity profile.  
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Figure ‎4-11: A549 cell viability measured by MTT assay after 24 h exposure to 
cationic NPs and cationic NPs/NCMPs. Data represent mean ± S.D., n=3. 
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4.5. Discussion 
Adsorption of CHL was investigated in order to modify the particles surface charge, 
favouring potential interactions with negatively charged cell membranes and facilitating 
uptake by DCs (156). 
4.5.1. Cationic nanoparticles characterisation  
Effect of different concentrations of CHL and PVA on zeta potential and particle 
size  
In the first strategy, different concentrations of CHL were used with and without 1% 
PVA. When 1% PVA was used, upon addition of CHL, the zeta potential changed from 
negative to neutral regardless of CHL concentration (Figure ‎4-1.A). This was due to the 
ability of the PVA layer to screen CHL charges leading to an almost neutral zeta 
potential value (211). 
When PVA was not included the zeta potential changed from negative to neutral at 
lower CHL concentrations (4 and 8 mg/ml) but at higher CHL concentrations (20 and 
30 mg/ml) the zeta potential changed to positive (Figure ‎4-1.A). Chronopoulou et al. 
reported a similar pattern with chitosan coated PLGA NPs (110). They found that in the 
case of lower concentrations, the relative PLGA and chitosan concentrations 
corresponded to a concentration close to the one of the isoelectric condition, justifying 
the finding that the zeta potential of the resulting coated PLGA NPs was very close to 
zero and then at higher concentration inverts its charge, indicating that the adsorbed 
chitosan reversed the NPs charge (110). At the highest concentration of CHL tested (34 
mg/ml) the NPs surface charge was neutral again, probably because of the high 
viscosity which would decrease the efficiency of adsorption (111). This decrease in 
efficiency of adsorption is evident by particle size of NPs. where the increase in particle 
size could be attributed to particle aggregation due to absence of PVA and only small 
amount of CHL adsorbed. 
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The particle size increased significantly when the concentration of CHL increased to 8 
mg/ml (Figure ‎4-1.B). The increase in particle size has been attributed to either the 
increased viscosity of the CHL solution, which lowered the shear stress on NPs during 
stirring, and/or the increasing amounts of CHL on the surface of the NPs (212). 
However, at CHL concentration of 20 and 34 mg/ml there was no significant change in 
particle size. This indicated a complete coating of CHL on the surface leading to CHL 
molecules repelling each other, preventing particle aggregation and hence an increase in 
particle size (111). 
At the same concentration of CHL with highest PVA concentration used (1%, 
Figure ‎4-2.B) the particle size decreased significantly this is because the PVA is known 
to prevent particle aggregation (80). 
Effect of adsorption time 
Figure ‎4-3.A and B shows the effect of adsorption time on zeta potential and particle 
size. The zeta potential changed significantly from negative to positive at 2 and 6 h and 
became neutral after 4 and 24 h. This pattern of change in zeta potential could be 
attributed to interfering by BSA released from NPs which could be adsorbed by CHL on 
NPs surface. At 2-6 h incubation it is positive with CHT charge dominating and some 
aggregation of NPs. At other time points the neutral charge could be due to the release 
of BSA into media and aggregation of BSA which dominates the CHT adsorbed on 
NPs. Moreover, this was confirmed by increased particle size significantly after CHL 
adsorption in comparison with anionic NPs regardless of adsorption time.  
Effect of method of addition CHL  
In the second strategy CHL was added to EAP in different concentrations (0 to 20 
mg/ml) during the NPs preparation process. Anionic NPs produced were electronegative 
-17.44±1.2 mV, while all cationic NPs were electropositive this confirmed the presence 
of CHL on NPs. The zeta-potential of cationic NPs increased with CHL feed 
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concentrations until a zeta-potential plateau was reached at approximately +24 mV 
(CHL concentration of approximately 16–20 mg/ml, Figure ‎4-4.A). This could be 
indicative of saturation in adsorption of CHL on the NPs (111; 72; 212). 
The particle size of cationic NPs was heterogeneous with two populations of particles 
present regardless of the concentrations of CHL (Figure ‎4-4.B). The particle size of 
cationic NPs increased significantly at lower concentrations of CHL ranging from 2 to 4 
mg/ml. This could be attributed to the increased viscosity of CHL, lowering the shear 
stress of the OP during sonication producing larger emulsion droplets and subsequently 
larger NPs (212). At higher concentrations of CHL (6, 10, 16 mg/ml) the particle size 
did not change significantly. This has been attributed to a complete coating of the NPs 
by CHL molecules so additional CHL would repel each other (due to similar charge) 
and prevent particles aggregation. Also, the pattern of change in particle size when CHL 
was added to the EAP was similar to that when CHL was added after NPs formation. It 
was observed that all cationic NPs regardless of preparation method displayed a neutral 
or positive charge that could be due to electrostatic interactions between the negatively 
charged groups (-OH) of PGA-co-PDL and the positively charged CHL inducing 
adsorption of CHL onto the NPs surface. Only a fraction of the amino groups would be 
required to neutralize the negative charges of PGA-co-PDL, whereas the remaining free 
amino groups could be responsible for the resulting change in the measured zeta 
potential (211). 
The second strategy was selected to examine CHL adsorption onto NPs and to explain 
the mechanism of adsorption because it had positive zeta potential over the entire range 
of CHL concentrations examined. The cationic NPs prepared at a CHL concentration of 
10 mg/ml was selected for further investigations in this study because these particles 
had a similar size to the anionic NPs. 
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The amount of adsorbed CHL per mg of NPs increased with initial CHL concentrations 
over the entire range (0–20 mg/ml) of CHL concentrations examined and no plateau of 
adsorption was reached. The continued adsorption of CHL onto NPs did not affect the 
apparent zeta-potential at high concentrations (greater than approximately 16–20 
mg/ml). As a possible model, multiple layers of CHL only allow a small amount of 
CHL to influence the measured zeta-potential. Layers beyond the first few do not 
increase the zeta-potential because the apparent surface charge per unit area (amine 
groups) is constant (111). 
Adsorption isotherm model 
Different presumptions of the parameters of adsorption, such as the characteristics of 
compositions and interaction between adsorbate (CHL) and adsorbent (PGA-co-PDL) 
influenced the analysis of adsorption isotherms. The mechanism of adsorption can be 
predicted from the model that fits best with the experimental results. (111).  
The first model tested was Langmuir model (Figure ‎4-6.A). This model described 
monolayer adsorption of adsorbate on the adsorbent where there is no interaction 
between adsorbate molecules, the adsorption is not governed by surface occupation, and 
equivalent adsorption sites (111).  
The adsorption of CHL onto NPs did not comply with the Langmuir model at the range 
of CHL concentration investigated. However, the Langmuir monolayer model was valid 
at low concentrations (0–8 mg/ml). The monolayer adsorption capacity (qm) was found 
to be 1.2366 mg/mg NPs, which corresponded to the initial concentration of CHL at 8 
mg/ml. However, the Langmuir monolayer model could not explain adsorption at high 
concentrations of CHL. 
The second model tested was BET model (Figure ‎4-6.B). This model did not describe 
the results in the concentrations range investigated. The BET model was a development 
of the Langmuir model (monolayer model) to include multilayer adsorption. Depending 
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on the BET type, the following layers are the condensed adsorbate molecules. Also, it 
assumed that the energies of adsorption are equal for layers after the monolayer, which 
is property of a uniform surface. Moreover, this model bears in mind little interactions 
between adsorbate and adsorbent. The adsorption model demonstrated in this study did 
not fit the BET type due to the ideal characteristic of this type (111). 
The adsorption results for CHL were in good agreement with the Freundlich model 
(Figure ‎4-6.C). The nonlinear adsorption model was commonly described by Freundlich 
model. This model is applicable for multilayer adsorption with a uniform surface or a 
greatly non-uniform surface (111). The slope 1/n, ranging between (0.33-1.18), is a 
measure for the adsorption intensity or surface heterogeneity, becoming more 
heterogeneous as its value gets closer to zero. The calculated value of 1/n is above 1 
which is an indication of a cooperative adsorption (213).  
The Halsey isotherm model (Figure ‎4-6.D) illustrates multilayer adsorption of an 
adsorbate (at relatively far distances from a heterogeneous surface) which fit with the 
exponential relationships between the mass of adsorbate (q) and free concentration of 
adsorbateat equilibrium (Ce). Accordingly, the typical multilayer isotherm consisted of 
three sections where in the first section the adsorption is non-cooperative on a highly 
non-uniform surface; in the second section the adsorption is cooperative on a still non-
uniform surface; and in the last section the multilayer adsorption is cooperative 
provoked by little van der Waals force influences at some length from the surface (111). 
It was found that the adsorption of CHL on NPs complied with multilayer adsorption 
pattern irrespective of which model was examined. The leading factor particularly in the 
development of the first adsorption layer was electrostatic force between CHL (with 
positive charge) and PGA-co-PDL surface (with negative charge). When the CHL 
concentration increased it is likely that the following layers of CHL adsorbed on the 
first layer of CHL without interaction with the NPs surface. When more CHL layers 
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adsorbed the CHL molecules would repel each other because of the same charge 
however CHL molecules interacted via hydrogen bonds, hydrophobic interactions, and 
van‎ der‎Waal’s‎ forces.‎Mainly,‎ the‎NPs‎ great‎ surface‎ energy‎ and‎ surface‎ area‎ had‎ a‎
significant function in CHL multilayer adsorption (111). 
BSA loading and EE % 
The EE% of BSA in anionic NPs was (48±2.6 %) but this decreased significantly after 
CHL adsorption (4.9±2.1 %). This could be explained by electrostatic interactions 
between the negative charge of BSA and positive charge of CHL. The isoelectric point 
of BSA is 4.8 indicating it was negatively charged at pH>4.8, so could potentially 
adsorb cationic CHL in an aqueous solution (measured 1% in water pH =6) (214). The 
CHL may adsorbs some of the BSA to the surface of the NPs during the preparation and 
hardening process, significantly decreasing the encapsulation efficiency (109). This was 
confirmed by the first initial burst release phase (section 4.4.9) at time 0 h which was 
the result of loss of surface BSA. However, DL decreased substantially with increasing 
polymer amount (PGA-co-PDL and CHL), as it was expected from predictions based on 
the respective equation 2-2 in which DL is inversely proportional to the amount of 
polymer (147). 
4.5.2. Cationic nanocomposite microparticles characterisation 
Photomicrographs of cationic NPs/NCMPs showed irregular and porous microparticles 
(see section ‎3.5.2 for more detail and explanations). Furthermore, the size of anionic 
and cationic NPs after dispersing anionic and cationic NPs/NCMPs in distilled water 
confirmed the recovery of NPs with suitable size for uptake by DCs (89). 
The cationic NPs/NCMPs formulations had a geometric particle size of 5.52±0.64 µm 
suitable for pulmonary delivery. The tapped density was 0.08±0.002g cm
-3
; suggesting 
highly porous particles. The cationic NPs/NCMPs showed the theoretical aerodynamic 
diameter was in the respirable range despite having a larger geometric particle size than 
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anionic NPs/NCMPs. This is because the density of cationic NPs/NCMPs was lower 
than that of the anionic NPs/NCMPs (66). 
Anionic NPs/NCMPs produced a higher FPD 45.00±4.70 µg, and FPF% 78.57±0.1% than 
cationic NPs/NCMPs 32.51±6.67 µg and 46.79±11.21%, respectively. This could be 
explained by the observation that the cationic NPs/NCMPs aggregate more and have a 
poorer powder flow as‎indicated‎by‎Carr’s‎index. This could be attributed to incomplete 
powder de-aggregation as van der Waals forces between particles were not completely 
overcome upon inhalation despite the low density of the particles. In addition, powder 
aggregation of cationic NPs/NCMPs was confirmed with a Carr’s index of ≥32, 
indicating the flow was very poor (66). 
In the cationic NPs/NCMPs formulation the observed high-burst release at time zero 
(22.41±6.7%) could be explained by the majority of the BSA being adsorbed onto the 
surface (110). Also, the cationic NPs/NCMPs formulations showed a higher cumulative 
BSA release at the end of 48 h compared to anionic NPs/NCMPs. These differences in 
release patterns may be due to a combination of factors, such as BSA loading, and 
presence of CHL on the surface of the NPs (141). For both formulations the notable 
change in release profile at 20-24h after the initial burst release could be due to the 
distribution of BSA inside NPs or a change in degradation rate due to changed surface 
porosity (141). Also, it is worth noting that CHL adsorbed on NPs dissolves in water 
and therefore does not hinder drug diffusion from the NPs (156; 110). 
A study of the in vitro release kinetics was carried out to determine the mechanism of 
BSA release. BSA was released from anionic NPs/NCMPs formulations according to 
the Higuchi diffusion model (for details see section ‎3.5.4).  
However, BSA was released from cationic NPs/NCMPs formulations according to a 
dual pattern first order model and Higuchi diffusion model. A first order kinetics 
equation described the release of BSA which was not efficiently encapsulated in 
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cationic NPs and is available for dissolution from cationic NPs surface. This takes place 
immediately after introducing the formulation into the release medium (215). The 
Higuchi model describes the second and third part of the BSA release which appears to 
be a diffusion-limited process. 
The primary structure of BSA released from cationic NPs and cationic NPs/NCMPs was 
analysed by SDS-PAGE. BSA standard and the BSA released from anionic NPs and 
cationic NPs/NCMPs showed similar clear banding patterns in the gels providing 
evidence that the BSA entrapped in cationic NPs and cationic NPs/NCMPs samples 
maintained its primary structure during the preparation methods used. 
The secondary structure of BSA in the formulation was analysed using CD 
spectroscopy. Structural analysis showed that BSA was predominantly helical which is 
in good agreement with previous reports (172). The BSA released samples confirmed 
the‎presence‎of‎α-helix‎and‎β-sheets although these were decreased in comparison with 
standard BSA (140).   
The aerosolisation studies indicated that the cationic NPs/NCMPs would reach the 
bronchial-alveolar region in the lung so cytotoxicity studies were carried out on A 549 
cell line. The cationic NPs and cationic NPs/NCMPs appear to be well tolerated by the 
cell line at 2.5 mg/ml concentration indicating a good toxicity profile. The difference in 
cell viability between cationic NPs and cationic NPs/NCMPs at the same concentration 
could be due to dilution of cationic NPs with L-leucine for spray drying. Also, the 
possibility of reaching a high local concentration can be ruled out because after 
inhalation the dose would be spread over different part of the lungs and not be 
concentrated in certain area (216). Furthermore, cationic NPs have a greater ability to 
interact with negatively charged proteoglycans on the cell surface of macrophages and 
DCs (173). Kwon et al. have showed higher delivery of cationic NPs with ovalbumin as 
model antigen to bone marrow DCs in comparison with neutral NPs while the cell 
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viability of both cationic and neutral NPs were comparable at concentrations of 125-250 
µg/mg (217). This provides an indication of the feasibility of using cationic 
NPs/NCMPs as safe carriers for pulmonary drug delivery (68). 
4.6. Conclusion 
Adsorption of CHL on PGA-co-PDL NPs can be used as a successful strategy to 
produce cationic NPs. Two strategies were used. The first strategy involved attachment 
of CHL onto the surface of the preformed NPs by physical adsorption. The second 
strategy involved addition of CHL to EAP during the process of NPs preparation by 
double emulsion solvent evaporation method. The second strategy successfully 
produced cationic NPs with a positive charge in the whole range of CHL concentrations 
examined while the first strategy failed. The adsorption of CHL on NPs complied with 
multilayer adsorption behaviour as indicated by Freundlich model. 
The cationic NPs prepared at a CHL concentration of 10 mg/ml was selected for further 
investigations in this study because it has a similar size to anionic NPs with a positive 
zeta potential. The BSA loading for this selected formulation was 7.28±1.3 µg/mg. 
After spray drying, the photomicrographs of cationic NPs/NCMPs showed irregular and 
porous microparticles. In vitro aerosolisation performance of cationic NPs/NCMP FPD, 
and FPF% were 32.51±6.67 µg and 46.79±11.21%, respectively. The cationic 
NPs/NCMPs formulations showed high BSA cumulative releases, with nearly 88.93 
±14.8% of BSA released at the end of 48 h. Further cell viability studies on A549 cells 
showed a low toxicity profile. This study suggests that cationic NPs/NCMPs could be 
further investigated for encapsulation of PspA as therapeutic antigen to be delivered 
through the lung. 
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5.1. Introduction 
Over the last decades, many researchers have explored the use of pneumococcal 
proteins as possible replacements for current pneumococcal vaccines (PPV and PCV). 
A protein-based vaccine can overcome the limitations of PPV and PCV and provide 
protection against nasopharyngeal carriage upon mucosal delivery. One of the most 
promising pneumococcal proteins is pneumococcal surface protein A (PspA) which has 
an important role in preventing the accumulation of complement on the surface of the 
bacterium which leads to inhibition of clearance and phagocytosis of S. pneumoniae 
(157). 
PspA is a surface protein located on the cell wall of all strains of pneumococci 
(Figure ‎5-1.A), and has an N-terminal‎α-helical domain exposed on the bacterial surface 
and a C-terminal choline-binding repeat region responsible for the attachment to the cell 
wall (Figure ‎5-1.B) (218). PspA sequences are variable, especially in the N-terminal 
domain, and have been classified into three families based on sequence homologies. 
Ninety-five percent of pneumococcal strains carry PspA of family 1 (PspA1) or family 
2 (PspA2), and there is a significant serological cross-reactivity between the different 
families (29). Moreover, PspA has been shown to provoke protective antibodies in 
humans (157).  
Recombinant protein based vaccines are often poorly immunogenic alone or in 
combination. Encapsulating PspA in polymer based particle or nanogel has been 
documented to improve its immunogenicity (35; 157). In previous chapters, the 
biodegradable PGA-co-PDL successfully encapsulated in NPs and released stable BSA.  
The mucosal surface of the respiratory system is the main entrance for S. pneumoniae. 
Delivery of a vaccine through the pulmonary route has been proposed for evoking an 
immune response at mucosal and systemic level against airborne pathogens and 
consequently may prevent colonization at mucosal surfaces (43; 42). Furthermore, the 
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stimulation of the immune system requires the successful delivery of the antigen to DCs 
which process the antigen and generate the immune response (217). Therefore 
encapsulating PspA into polymeric NPs followed by incorporation into microparticle 
carriers to produce NCMPs as DPIs is a promising vaccine delivery system.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎5-1: A. alignment of PspA on the cell wall of pneumococci. B. Model of 
PspA structure (with permission from (218)). 
A B 
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5.2. Aim 
The aim of this study was to formulate anionic and cationic NPs (optimum formulations 
from chapters 3 and 4) encapsulating PspA followed by incorporation into microparticle 
carriers to produce anionic and cationic NPs/NCMPs as DPIs via spray-drying suitable 
for pulmonary vaccine delivery.  
5.3. Methods 
5.3.1. Production and purification of PspA4Pro 
Recombinant PspA4Pro was produced as described in section ‎2.2.13. 
5.3.2. Anionic and cationic NPs preparation 
PspA4Pro loaded PGA-co-PDL anionic NPs were prepared by a previously optimised 
(w/o/w) double emulsion/solvent evaporation method as described in section ‎2.2.3 and 
section ‎2.2.4. Briefly, IAP containing 1% PspA4Pro and 1% PVA was emulsified in OP 
(DCM and 50 mg PGA-co-PDL), by sonication using a probe sonicator at 45% 
amplitude for 15 seconds over an ice bath. The resulting single emulsion was emulsified 
into 25 ml of a 1% PVA solution (EAP) using the same probe sonicator for 30 seconds 
to form a w/o/w double emulsion. The double emulsion was stirred magnetically for 2 h 
at room temperature to evaporate the DCM. The anionic NPs were collected by 
centrifugation (Sigma 3-30k, SIGMA Laborzentrifugen GmbH, Germany) at 40,000 xg 
for 1 h at 4 ⁰C, and washed with distilled water twice. Cationic NPs were prepared 
using the same method except CHL 10 mg/ml was added to the EAP. Control NPs were 
prepared using the same method but without protein. For particle uptake studies, 
fluorescein isothiocyanate (FITC-BSA) was added in the IAP. 
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5.3.3. Anionic and cationic NPs characterization 
The particle size and zeta potential, EE % and PspA4Pro loading of anionic and cationic 
NPs were characterised as described in section ‎2.2.7. 
5.3.4. Preparation and characterisation of NCMPs 
The anionic and cationic NPs were dispersed into L-leucine solution (1:1.5 w/w) and 
spray dried according to the spray drying condition described in section ‎2.2.8 to produce 
NCMPs as a dry powder for inhalation. The produced NCMPs were characterised for 
morphology as described in section ‎2.2.9.2. 
5.3.5. In vitro release study  
The in vitro release studies were performed as described in section ‎2.2.11. 
5.3.6. Investigation of PspA4Pro structure 
The released PspA4Pro was examined for primary structure stability by SDS-PAGE 
analysis and for secondary structure by circular dichroism spectroscopy analysis as 
described in section ‎2.2.12. 
5.3.7. In vitro antigenicity study of PspA4Pro 
The antigenicity of PspA4Pro was examined as described in section ‎2.2.14. 
5.3.8. Cytotoxicity study 
The DCs viability of anionic and cationic NPs was determined as described in 
section ‎2.2.15.2. 
5.3.9. NPs cellular uptake by DCs  
DCs uptake of FITC-BSA loaded anionic and cationic NPs was evaluated as described 
in section ‎2.2.16. 
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5.4. Results  
5.4.1. Characterisation of anionic and cationic NPs 
The encapsulation of PspA4Pro into anionic and cationic NPs was carried out using the 
processing parameters optimised in chapters 3 and 4. PspA4Pro loading into cationic 
particles (9.84±1.4 µg/mg) was significantly less (p<0.05,‎ ANOVA/Tukey’s‎
comparison) than in anionic particles (65.73±5.6 µg/mg). The EE % of PspA4Pro into 
the anionic NPs was 75.3±6.2% which was significantly (P<0.05,‎ ANOVA/Tukey’s‎
comparison) higher than the EE% of cationic particles (50.2±7.1%).The particle size of 
anionic and cationic NPs were 328.4±56.16 nm and 409.7±49.5 nm respectively, 
indicating a significantly increased particle size (p<0.05,‎ ANOVA/Tukey’s‎
comparison). Table ‎5-1 presents the particle size, PDI, zeta potential, EE % and 
PspA4Pro loading of anionic and cationic NPs.  
 
Table ‎5-1: Particle size, PDI, zeta potential, EE % and PspA4Pro loading of PGA-
co-PDL NPs. Data represent mean ± SD, n=3. 
 
Anionic NPs
a
 Cationic NPs
a
 
Particle size (nm) 310.4±25.3* 409.4±49.5* 
PDI 0.302±0.02 0.418±0.06 
Zeta potential (mV) -29.20±0.9 21.30±1.3 
EE (%) 75.3±6.2* 50.2±7.1* 
PspA4Pro loading (µg/mg) 65.73±5.6* 9.84±1.4* 
a
 NPs characterised after centrifugation, * significantly different (p<0.05, 
ANOVA/Tukey’s‎comparison). 
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5.4.2. Characterisation of NCMPs 
The shape and surface texture of anionic and cationic NPs/NCMPs were investigated 
using SEM (Figure ‎5-2). Photomicrographs for both formulations showed irregular and 
corrugated microparticles. 
 
 
 
 
 
 
 
 
5.4.3. In Vitro Release Studies 
In vitro release studies comparing anionic and cationic NP/NCMPs formulations were 
performed (Figure ‎5-3) and reported as the % cumulative PspA4Pro released. Anionic 
NPs/NCMPs formulation showed a biphasic release profile with an initial burst release 
(14.56±1.6%) followed by a second continuous sustained release phase over 48h. 
Cationic NPs/NCMPs formulation showed a biphasic release profile with the PspA4Pro 
released at time zero (12.76±0.11 %) considered to be surface-associated PspA4Pro, the 
PspA4Pro released at the end of 4 h (66.93±1.2%) was considered as the initial burst 
phase of PspA release, followed by a second continuous sustained release phase over 
48h. The anionic NPs/NCMPs formulations showed a significantly (p<0.05, 
ANOVA/Tukey’s comparison) lower cumulative release achieving only 21.01±1.5% 
release after 48 h compared to  the cationic NPs/NCMPs formulations with nearly 
83.13±0.84% of PspA4Pro released at the end of 48 h.  
A B 
Figure ‎5-2: The SEM image of anionic NPs/NCMPs (A) and cationic NPs/NCMPs 
(B). 
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An in vitro release kinetics study was performed to determine the PspA4Pro release 
mechanism. Comparison of the rates of release using zero and first order and the 
Higuchi rate equations are shown in Table ‎5-2. PspA4Pro was released from anionic 
NPs/NCMPs formulations according to the Higuchi diffusion model (r
2
 value of 0.836, 
and the release rate constant k1 (h
-½
) was 2.1 (Table ‎5-2). For cationic NPs/NCMPs 
formulations, PspA4Pro was released according to a first order model r
2
 value of 0.944, 
and the release rate constant k1 (h
-½
) was 8.1 (Table ‎5-2).  
 
Figure ‎5-3: Cumulative in-vitro release of PspA4Pro from anionic and cationic 
NPs/NCMPs formulation in PBS buffer at 37°C. Data represent mean ± S.D., n=3. 
 
 
Table ‎5-2: Release parameters of PspA4Pro from anionic and cationic 
NPs/NCMPs formulations. 
Formulation Zero Order First order Higuchi 
r
2
 ko (h
-1
) r
2
 k1 (h
-1
) r
2
 k1 (h
-½
) 
Anionic 
NPs/NCMPs 
0.671 0.27 0.699 -0.0014 0.836 2.1 
Cationic 
NPs/NCMPs s 
0.519 0.98 0.944 -0.0097 0.723 8.1 
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5.4.4. Investigation of PspA4Pro structure 
The primary structure of PspA4Pro was investigated using SDS-PAGE analysis. 
According to Figure ‎5-4, the molecular weight markers are represented in Lanes 2 and 
7, and PspA4Pro standard in lane 1 revealed a clear band at about 55 KDa. The 
PspA4Pro released from anionic NPs, anionic NPs/NCMPs, cationic NPs/NCMPs and 
cationic NPs Lanes 3, 4, 5 and 6, respectively, also showed similar clear banding 
patterns to the PspA4Pro standard (Figure ‎5-4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
The secondary structure analysis of PspA4Pro standard and PspA4Pro released from 
anionic and cationic NPs/NCMPs was performed using CD spectral data. Figure ‎5-5 A 
and B shows the structure of standard PspA4Pro and PspA4Pro released from anionic 
and cationic NPs/NCMPs respectively. The CD spectra show two characteristics 
minima at 222 and 208 nm which are known to be associated with an α-helical structure 
(30). In support of these data structural analysis showed that the predominant structure 
of standard PspA4Pro, and, PspA4Pro released from anionic and cationic NPs/NCMPs 
was helical displaying 50, 51 and 45 % helicity respectively (Table ‎5-3). Comparing the 
    Lane   1     2     3                4     5                6     7 
MW 
KDa 
 
205 
129 
116 
97.4 
84 
 
66  
 
45 
 
 
36 
 
20 
17.5 
7.1 
 
Figure ‎5-4: SDS-PAGE behaviour of PspA4Pro released. Lanes represent, 
PspA4Pro standard (1), molecular weight standard markers (2, 7), PspA4Pro 
released from anionic NPs (3), PspA4Pro released from anionic NPs/NCMPs (4), 
PspA4Pro released from cationic NPs/NCMPs (5), and PspA4Pro released from 
cationic NPs (6). Difference in band intensity was due to different loading. 
 146 
 
CD results of PspA4Pro released from anionic and cationic NPs/NCMPs with that of 
standard‎PspA4Pro,‎the‎content‎of‎α-helix increased by 1 and 5 %, respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B 
Figure ‎5-5: The CD spectra of PspA4Pro released from anionic 
NPs/NCMPs (grey) and PspA4Pro standard (black) (A) and PspA released 
from cationic NPs/NCMPs (grey) and PspA4Pro standard (black) (A). 
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Table ‎5-3: The percentage of secondary structure conformation for PspA4Pro 
standard and PspA4Pro released from anionic and cationic NPs/NCMPs. 
 
5.4.5. In vitro antigenicity study of PspA4Pro 
The antigenicity of PspA4Pro released from anionic and cationic NPs/NCMPs were 
evaluated using ELISA with specific PspA monoclonal antibody and presented as 
relative antigenicity. The ELISA assay measures the ability of released PspA4Pro to 
bind and be recognized by an anti-PspA antibody. The results show that the relative 
antigenicity of PspA4Pro is maintained after release from the anionic NPs/NCMPs 
(0.95±0.14) and from cationic NPs/NCMPs (0.26±0.00). 
5.4.6. Cytotoxicity study 
The cytotoxicity of unloaded anionic and cationic NPs on DCs cell line was assessed 
after 4 h exposure using MTT assay (219). Figure ‎5-6 shows decreasing cell viability 
with increasing NPs concentration. The anionic NPs displayed a cell viability of 
86.38±5.5 % at 5 mg/ml concentration after 4 h exposure. On the other hand, cationic 
NPs displayed a DCs viability of 69.82±5.28 % at 5 mg/ml concentration after 4 h 
exposure. Both NPs showed cell viability more than the A549 cell viability after 24 h 
reported in section ‎3.4.9 and ‎4.4.10. This could be due to short period of exposure. 
 
 
 
 
 
 Helix Strands Turns Unordered 
PspA standared 50.0 ± 0 22.0 ± 0.014 7.5 ± 0.007 21.0 ± 0.014 
PspA released from 
anionic NPs/NCMPs  
51.0 ± 0.04 21.0 ± 0.0566 7.50 ± 0.007 21.0 ± 0 
PspA released from 
cationic NPs/NCMPs 45.0 ± 0.0212 28.0 ± 0.0212 7.00 ± 0 20.0 ± 0 
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5.4.7. NPs cellular uptake by DCs 
The uptake of FITC-BSA loaded anionic and cationic NPs by DCs was confirmed by 
CLSM. The cell wall of the DCs was stained with WGA TR, the nucleus was stained 
with DAPI and the NPs loaded with FITC-BSA were observed under red, blue and 
green channel, respectively. Regardless of the surface charge of NPs, the green 
fluorescence was seen inside DCs confirming the presence of NPs. Figure ‎5-7 shows 
NPs intracellular localisation inside DCs after 1 h of co-incubation in cell culture media. 
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Figure ‎5-6: DCs viability measured by MTT assay after 4 h exposure to anionic 
and cationic NPs. Data represent mean ± SD, n=3. 
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B 
A 
C 
D 
B 
Figure ‎5-7: Confocal microscopic image of anionic NPs uptake by DCs. (A) DCs 
incubated without NPs at 20x, (B) DCs incubated with anionic NPs at 63x, and (C) 
DCs incubated with anionic NPs at 20x, and (D) DCs incubated with cationic NPs 
at 20x (red channel for WGA TR), (blue channel for DAPI), and (green channel for 
FITC-BSA). 
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5.5. Discussion 
The results obtained with BSA as a model antigen in chapters 3 and 4 were promising 
so further work was performed on PspA4Pro as a therapeutic antigen. However, it 
should be taken into account that each protein has a different molecular weight, and 
chemical structure. In this study, the optimum parameters inferred from BSA for 
PspA4Pro encapsulation into anionic and cationic NPs followed by spray drying with L-
leucine to produce NCMPs as pneumococcal protein vaccine against S. pneumonia to be 
administered by dry powder inhalation were used.  
The particle size of anionic NPs increased when CHL was incorporated (Table ‎5-1). The 
increase in size observed can be related to the increased viscosity of EAP due to the 
presence of CHL, which lowered the shear stress on polymer OP during sonication and 
produced larger emulsion droplets and consequently larger NPs. Also, it could be 
attributed to the presence of CHL on the surface of the cationic NPs. However, the 
CHL: PGA-co-PDL ratio in the final cationic NPs was lower than the theoretical ratio, 
due to the fact that a certain amount of CHL was remained in the EAP and removed by 
washing (212) (more detail discussed in section ‎4.5.1).  
Also, it could be observed that the particle size of BSA loaded anionic and cationic NPs 
(Table ‎4-2) were larger than the PspA4Pro loaded anionic and cationic NPs (Table ‎5-1).  
This could be attributed to the fact that the PspA4Pro has an elongated shape structure 
(Figure ‎5-1.B) and a lower Mwt (55 kDa) while the BSA has a heart shape structure 
(Figure ‎3-1) and larger Mwt (66 kDa) thus enhance increase in particle size of NPs. 
The efficiency of NP surface coating can be measured by estimating the zeta potential 
of the aqueous suspension containing NPs. The surface charge values may be positive 
or negative depending upon the nature of the polymer or the material used for coating. 
The zeta potential of the anionic NPs was negative, as expected, because of the 
hydroxyl end groups on PGA-co-PDL (Table ‎5-1). The cationic NPs were 
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electropositive confirming the presence of CHL on the PGA-co-PDL NPs surface 
Table ‎5-1. This could be explained by electrostatic interactions between the negatively 
charged groups of PGA-co-PDL and the positively charged CHL that induce adsorption 
of CHL onto the NPs surface. Only a fraction of the amino groups were required to 
neutralize the negative charges of PGA-co-PDL, whereas the remaining free amino 
groups were responsible for the resulting positive zeta potential (109; 211). 
The encapsulation efficiency of PspA4Pro in the anionic NPs 75.3±6.2% was 
significantly higher than for cationic NPs 50.2±7.1%. This could be explained by 
electrostatic interactions between the negative charge of PspA4Pro and the positive 
charge of CHL (214). The CHL attracts some of the PspA4Pro to the surface of the NPs 
during the preparation and hardening process, which significantly decreases the 
encapsulation efficiency (214). This was confirmed by the first initial burst release 
phase (section ‎0) at time 0 h which was considered as a result of loss of surface 
PspA4Pro. 
The PspA4Pro loading in anionic NPs (65.73±5.6 µg/mg) decreased substantially 
(9.84±1.4 µg/mg) when CHL was added to the EAP to produce cationic NPs. This was 
expected from predictions based on equation 1-2 in which DL is inversely proportional 
to the polymer amount (PGA-co-PDL alone for NPs and PGA-co-PDL and CHL for 
CHL-NPs) (147).  
Also, it could be observed that EE% and DL of BSA loaded anionic and cationic NPs 
(Table ‎4-4) were lower than the PspA4Pro loaded anionic and cationic NPs (Table ‎5-1).  
This could be attributed to the fact that BSA has a heart shape structure (Figure ‎3-1) and 
larger Mwt (66 kDa) while PspA4Pro has an elongated shape structure (Figure ‎5-1.B) 
and a lower Mwt (55 kDa) thus providing more space to encapsulate more protein 
inside the NPs. 
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It has been reported a dose of 1-5 µg of PspA was sufficient to stimulate an immune 
response in mice when injected intramuscularly or subcutaneously (30; 157; 220). 
However, when PspA was delivered nasally (a mucosal site) with an adjuvant (nontoxic 
A subunit mutant of cholera toxin S61F), a dose of only 100 ng was needed to stimulate 
an immune response correspondent to the response produced by oral delivery of 7.5 µg 
(221). Assuming that PGA-co-PDL particles developed in this study were delivered via 
inhalation (through mucosal site), the dose needed would be about 100 ng of PspA for 
mice which is equivalent to a dose of 4 µg of anionic NPs/NCMPs and 25 µg of cationic 
NPs/NCMPs. Also, one should consider that the dose of PspA4Pro would be changed 
when applied to human vaccination (although it would be based on the animal studies). 
The anionic and cationic NPs/NCMPs were produced via spray drying using L-leucine 
as a carrier. The photomicrograph of anionic and cationic NPs/NCMPs shows irregular 
and corrugated surface texture (for more detail and discussion see section ‎3.5.2). 
The higher burst release observed with the cationic NPs/NCMPs formulations at time 
zero (12.75±0.1%) compared to anionic NPs/NCMPs may be due to some of the PspA 
not being encapsulated in the particles, but instead was on the surface, due to 
interactions between the positive CHL and negative PspA, affecting the real 
encapsulation efficiencies (110). 
The in vitro release data of anionic NPs/NCMPs formulations showed a lower 
cumulative release achieving 21 % release after 48 h. The cationic NPs/NCMPs 
formulation showed higher cumulative releases, with nearly 83 % of PspA4Pro released 
at the end of 48 h. These differences in release pattern of the formulations may be due to 
a combination of factors, such as PspA4Pro loading, and presence of CHL on the 
surface of NPs (88). For both formulations the noticed change in release profile at 20-
24h after the initial burst release could be due to the distribution of PspA4Pro inside 
NPs or a change in degradation rate f NPs due to changed surface porosity (141). 
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CHL coating NPs dissolves in water and therefore does not slow down drug diffusion 
from NPs (156; 110). 
The in vitro release kinetics were studied to determine the PspA4Pro release 
mechanism. PspA4Pro was released from anionic NPs/NCMPs formulations according 
to Higuchi diffusion model. Therefore, the sustained release of PspA4Pro from anionic 
NPs/NCMPs appears to be a diffusion-limited process (66). PspA4Pro was released 
from cationic NPs/NCMPs formulations according to dual pattern first order model and 
Higuchi diffusion model. First order kinetics equation describes release of PspA4Pro 
which is not effectively encapsulated in NPs and is ready to dissolve from NPs surface. 
This is a rapid process occurring immediately after placing the formulation into the 
release medium (215). The Higuchi model describes the second and third phase of 
PspA4Pro release which appears to be a diffusion-limited process. 
The primary structure of PspA4Pro was investigated using SDS-PAGE analysis. The 
identical bands observed for PspA4Pro standard and released suggests the primary 
structure has been maintained and was not degraded or affected by the procedure. 
The secondary structure of PspA4Pro in the formulation was analysed using CD 
spectroscopy (172). The PspA4Pro released from anionic NPs/NCMPs confirmed the 
presence‎ of‎ α-helix structure. However, the PspA4Pro released from cationic 
NPs/NCMPs confirmed the decreased (~ 5 %) of‎α-helix structure compared to standard 
PspA4Pro. This has been related to electrostatic interaction between the positive charge 
of CHL and the negative charge of PspA4Pro (172). 
The ELISA was used to examine the ability of PspA antibody to bind to PspA4Pro 
released from anionic and cationic NPs/NCMPs (30). This assay determines the ability 
of PspA4Pro released from anionic and cationic NPs/NCMPs to be identified by a 
specific anti-PspA antibody. The results indicated the relative antigenicity of the 
PspA4Pro released from anionic NPs/NCMPs was preserved. These results demonstrate 
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that PspA4Pro was not susceptible to the conformational changes as those observed 
with other proteins. However, it was observed that PspA4Pro released from cationic 
NPs/NCMPs showed 25 % of relative antigenicity. This could be attributed to changes 
in secondary structure of PspA4Pro after release and could be due to the release of CHL 
from the surface of the particles and interact with PspA4Pro released in the medium.  
The formulation is designed to target DCs so cytotoxicity studies were performed on a 
DCs cell line. The anionic and cationic NPs were well tolerated by DCs with 
approximately 90 % viability at 0.312 mg/ml which decreased to 86.38±5.5 % with 
anionic NPs and 69.82±5.28 % with cationic NPs at 5 mg/ml concentration. This 
provides an indication about the feasibility of using anionic and cationic NPs as safe 
carriers to target DCs.  
The uptake of anionic and cationic NPs by JAWS II DC cell type after 1h co-incubation 
was confirmed by CLSM. Wischke et al. reported similar results with FITC-BSA 
loaded PLGA microparticles where the FITC-BSA loaded microparticles internalized 
successfully by DCs (135). In this study the fluorescence signal visualized have not 
quantified due to non specific staining visible in some parts of the well and to prevent 
false positive data.  
5.6. Conclusion 
This study introduced a successful method for preparing anionic and cationic 
NPs/NCMPs for encapsulating and delivering PspA4Pro as a dry powder. The results 
showed reproducible size and entrapment efficiency with a good antigen loading and 
morphological characteristics. The PspA4Pro antigen entrapped in NPs preserved its 
primary and secondary structure to a large extent. The relative antigenicity (i.e. activity) 
has been retained for anionic NPs/NCMPs while less antigenicity was observed for 
cationic NPs/NCMPs. Furthermore, cell viability studies on DCs showed that the 
particles were well tolerated. DCs uptake studies provide evidence of NPs uptake by 
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DCs within 1 h of incubation. This study suggests that PGA-co-PDL NPs/NCMPs could 
be further investigated for evaluating the activity and immunogenicity of the released 
PapA4Pro.  
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6. General Discussion 
 
 
 
 
 
 
 
 
 
 
 157 
 
6.1. Overview 
S. pneumoniae is one of the most significant human pathogens, causing high morbidity 
and mortality rates globally (3). It is implicated in both non-invasive diseases (e.g. otitis 
media, sinusitis, and bronchitis) which are generally non-life threating conditions, but 
lead to discomfort and loss of school or work days and invasive diseases (e.g. 
pneumonia, bacterial meningitis, and septicaemia) which are life threating conditions 
(4). There are two types of pneumococcal vaccine available: PPV and PCV. However, 
they are expensive and do not cover all serotypes (3; 4; 23; 24). Universal research is 
presently concentrated on establishing other pneumococcal-vaccine approaches that 
compromise these defects. PspA has gained a special focus because it is a surface 
protein located on the cell wall in all strains of pneumococci (29). S. pneumoniae are 
generally transmitted by air droplets or direct contact with contaminated respiratory 
secretions (7) so it is ideal to deliver the vaccine through the pulmonary route. There are 
limited studies published in literature regarding the development of a delivery system 
for PspA as a vaccine. The aim of this project was to formulate and characterise 
nanocomposite microparticles encapsulating PspA4Pro as a vaccine for the prevention 
of pneumococcal disease by dry powder pulmonary delivery. 
6.2. Optimisation of size and drug loading of NPs 
Precise adjustment of the various formulation and processing parameters is important to 
obtain NPs of a desired size and antigen‎loading.‎In‎this‎study,‎a‎particle‎size‎of‎≤‎500‎
nm was desired to facilitate uptake of NPs by DCs (43; 98; 156). BSA was used as a 
model antigen and Taguchi experimental design was applied to optimize the double 
emulsion solvent evaporation method to achieve desired size and loading.  
It was found that the NPs size was influenced by different parameters in the following 
order: polymer mass > OP volume > sonication amplitude > surfactant concentration > 
EAP sonication time IAP sonication time > IAP volume > BSA concentration. While 
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the influence on BSA loading had the following order: BSA concentration > IAP 
volume > polymer mass > surfactant concentration > OP volume > EAP sonication time 
> sonication amplitude > IAP sonication time. 
It was found that that the polymer mass followed by the OP volume and sonication 
amplitude had the greatest influence on the particle size of NPs. 
In general, an increase in the mass of substances used will increase the particle size. 
This effect of the polymer mass on the particle size attributed to the increased viscosity 
of the OP leading to a less efficient stirring of the medium and to increased NPs 
coalescence (144). Also, a low OP volume produces a concentrated and viscous 
polymer solution therefor it is more difficult to break up the polymer solution into 
smaller droplets during the second emulsification (222). This size increase was also 
observed with PLGA protein-loaded NPs, when using a double emulsion solvent 
evaporation method. When the polymer mass increased from 200 mg to 400mg the 
particle size increased from 207±6 nm to 1090±210 nm (143). The presence of high 
concentrations of the surfactant (PVA) in the IAP leads to increase in the viscosity of 
the primary emulsion (w/o) and lead to the formation of larger particles. Yang et al. 
investigate the effects of the presence of PVA into the IAP on the different 
characteristics of BSA loaded PCL microspheres. They noticed that at higher 
concentrations of PVA in the IAP the viscosity of the primary emulsion increased and 
lead to difficulty in breaking up the emulsion into smaller droplets (222). A similar 
result was reported in previous study in which the size of IgG loaded PCL microspheres 
increased with the presence of PVA in the IAP (223). 
Furthermore, the rate of size reduction decreased considerably when sonication was 
carried out beyond the amplitude of 45 % or when the EAP and IAP sonication time 
increased. This effect could be attributed to more cavitation created by increasing the 
amplitude, which reduced the efficiency of energy transmission and decreased the 
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ultrasonic effect (145). Similar results reported by Ito et al. who found that the particle 
size of PLGA microspheres was not affected by stirring time period (224). In contrast to 
Yang et al. who found that the speed of stirring is the predominant factor affecting 
particle size of PCL: PLGA microspheres encapsulating BSA (222). 
A successful drug delivery system should have a high loading capacity in order to 
decrease the amount of drug and excipients used for manufacturing the delivery system. 
(143). The influence of different parameters on the DL of NPs had the following order: 
BSA concentration>IAP volume > polymer mass > PVA concentration > OP volume > 
EAP sonication time and IAP sonication time > sonication amplitude. While the effect 
on the EE % had the following order: polymer mass > PVA concentration BSA 
concentration > IAP volume > OP volume > EAP sonication time and IAP sonication 
time > sonication amplitude. 
BSA concentration had the greatest influence on the DL. The DL increased profoundly 
as the BSA concentration increased from 0.2 to 1 %. This was expected from 
predictions based on equation used for DL calculation in which DL is positively 
proportional to the amount of BSA. Similar results were reported in literatures. Bilati et 
al. prepared FITC-BSA loaded PLGA NPs at different concentrations. When FITC-
BSA concentration increased the DL increased subsequently (143). Also, Youan et al. 
fabricated PCL microparticles using the w/o/w emulsion solvent evaporation method 
and BSA as a model drug. When the BSA: polymer ratio increased from 5:100 to 
37.5:100, an increase in BSA loading (11.8 times higher) was reported (225). 
Also, BSA concentration was the third factor that affects EE %. The EE % of BSA 
increased when BSA concentration increased from 0.2 to 0.5% but interestingly it 
decreased considerably as the BSA concentration increased further to 1%. In fact, an 
increase in BSA concentration to high levels (1 %) is not always beneficial; this trend 
has been explained by the amount of polymer used being insufficient to completely 
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encapsulate the BSA (143). Furthermore, higher concentration of BSA provide a higher 
BSA concentration in IAP droplets and thus increase the concentration gradient between 
the IAP droplets and the EAP and so increases the amount of BSA transported into the 
EAP (153). Yang et al. reported similar results. They prepared PCL: PLGA 65: 35 
microspheres encapsulating BSA. At higher BSA theoretical loading (0.57 to 4.8 %), 
the EE % decreased significantly (79.1 to 55 %) (222). 
IAP volume played an important role on DL and EE %, such that, the larger the volume 
of IAP used, the higher the BSA loading. This effect has been previously reported (147; 
152) and is thought to be due to a decrease in the concentration gradient between IAP 
and EAP. In contrast, Youan et al. found that an increase of IAP volume (0.25 to 1.25 
ml) lead to decrease in BSA EE % and loading (70 times lower) (225). 
The third factor affecting DL was polymer mass. DL decreases substantially with 
increasing polymer mass, as it was expected from predictions based in the respective 
equation 2-1 in which DL is inversely proportional to the polymer amount (147). 
Similar observation was reported by Baras et al. They found that the DL of BSA 
decreased with an increase in PCL concentrations. At a 0.5 % (w/w) concentration of 
PCL a 24 % BSA loading were obtained while at 3 % (w/w) concentration of PCL the 
BSA loading decreased to 3 % (w/w) (226). 
On the other hand, the polymer mass had the greatest influence on EE % of BSA. This 
could be correlated with the increased mass of the polymer resulting in a further 
stabilization of the primary emulsion and limiting the diffusion of BSA through and out 
of the OP due to higher viscosity of the OP (92). Similar observations were reported by 
Devineni et al. They found that the BSA EE % for microparticles prepared by 4 and 8% 
(w/v) PCL concentrations increased from 12 to 25% (227). In contrast, Baras et al. 
reported that the EE % of BSA decreased with an increase in PCL concentrations. At 
0.5 % (w/w) concentration of PCL a 73 % BSA encapsulation efficiency were obtained 
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while at 3 % (w/w) concentration of PCL the BSA encapsulation efficiency decreased to 
42 % (226). 
The fourth factor affecting DL was PVA concentration. Among the PVA concentrations 
used, 1 % PVA was found to result in a considerably higher BSA loading. One possible 
explanation is that 1% PVA concentration provided sufficient covering of the 
organic/aqueous interface so as to reduce possible leaching of the BSA. Consequently, 
any further increase in PVA concentration (5, 10 %) resulted in more BSA molecules 
partitioning rapidly into the aqueous phase during the emulsification procedure due to 
the emulsifying effect of PVA, resulting in decreased DL (146). Although the PVA 
concentrations ranked the second factor affecting EE % but there effects on EE % were 
similar to DL. Mao et al. reported similar results when preparing PLGA microspheres 
by double emulsion solvent evaporation method using PVA as a surfactant. When PVA 
concentration increased (0.1 to 0.5%) the results shows no further increase in DL and 
EE % (148). In contrast Yang et al. reported that increasing PVA concentration (from 
0.025 to 0.05 to 0.1 %) of the IAP results in an increase in EE % and loading of BSA 
encapsulated PCL microsphere (222).  
In addition, the results showed that reducing the OP volume increased DL and EE%. 
This could be due to the higher viscosity of the organic phase leading to a further 
stabilization of the primary emulsion and minimize the diffusion of BSA through the 
OP. This was consistent with Baras et al. who observed that the use of a lower OP 
volume leads to a significant increase in the BSA EE % (from 7 to 13 %) (226). 
EAP sonication time and IAP sonication time exert similar effects on DL and EE%. 
Increasing the sonication time of IAP and EAP resulted in higher encapsulation 
efficiency % and DL. These results were consistent with the results obtained by Bilati et 
al. They reported that increasing sonication time of IAP up to 30 seconds increased 
loading efficiency of BSA loaded PLGA microspheres (143). 
 162 
 
The factor that has the least effect was sonication amplitude. Increasing sonication 
amplitude (30 to 45 or 65%) had almost no effect on the BSA encapsulation efficiency 
% or DL. This effect have been reported in literature and is thought to be caused by a 
BSA precipitation within the sonication probe due to high pressure and increased fluid 
cavitations during sonication (136; 149). Similar results were obtained by Bilati et al. 
They reported that increasing sonication intensity from 35 to 65 W increased loading 
efficiency of BSA loaded PLGA microspheres (143). 
From the suggested optimized run produced NPs (HDL NPs) with DL 43.67±2.3 
µg/mg, particle size of 445±46.8 nm and zeta potential of –17.44±1.2 mV was selected 
for further investigations. 
6.3. Optimisation of size, drug loading and charge of cationic NPs 
Cationic NPs are effectively taken up by DCs. The ionic interaction between the 
positive charge on the particles surface and the negative charge on cell surface generates 
a successful bond and promotes particle uptake (87). Furthermore, cationic NPs have 
greater ability to interact with the proteoglycans on the surface of macrophages and DCs 
(173). Incorporation of cationic polymers such as chitosan or chitosan derivatives have 
been shown to enhance uptake of antigens by DCs and subsequently induce a strong 
immune responses (174). CHL adsorption to PGA-co-PDL NPs was used as a 
successful strategy to produce cationic NPs. In this study two strategies were used to 
adsorb CHL to NPs. The first strategy involved adsorption of CHL onto the surface of 
the already formed NPs by physical adsorption. The second strategy involved addition 
of CHL to EAP during the process of NPs preparation by double emulsion solvent 
evaporation method. 
In the first strategy, different concentrations of CHL were used with and without 1% 
PVA. When 1% PVA was used, upon addition of CHL, the zeta potential changed from 
negative to neutral regardless of CHL concentration. This was due to the ability of the 
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PVA layer to screen CHL charges leading to an almost neutral zeta potential value 
(228). These results were consistent with previous work carried out by Mura et al. They 
prepared PLGA NPs by emulsion solvent evaporation method and in the presence of 
PVA in EAP the fabricated NPs had neutral zeta potential (211).  
When PVA was not included the zeta potential changed from negative to neutral at 
lower CHL concentrations ( 4 and 8 mg/ml) but at higher CHL concentrations (20 and 
30 mg/ml) the zeta potential changed to positive. Chronopoulou et al reported similar 
pattern with chitosan coated PLGA NPs, in the case of lower concentration, the relative 
PLGA and chitosan concentrations correspond to a concentration close to the one of the 
isoelectric condition, justifying the finding that the zeta potential of the resulting coated 
PLGA NPs was very close to zero and then at higher concentration inverts its charge, 
indicating that the adsorbed chitosan reversed the NPs charge (110). At the highest 
concentration of CHL tested (34 mg/ml) the NPs surface charge was neutral, probably 
because of the high viscosity of the CHL solution and steric hindrance created by CHL 
molecules in the solution which would decrease the efficiency of adsorption (111; 229).  
The particle size increased significantly when the concentration of CHL increased to 8 
mg/ml. The increase in particle size has been attributed to either the increased viscosity 
of the CHL solution, which lowered the shear stress on NPs during stirring, and/or the 
increasing amounts of CHL on the surface of the NPs (212). Similar results reported by 
Yuan et al (212). It was reported that the NPs size increased (182 to 543 nm) with the 
increase of initial chitosan concentration (0 to 0.17%). However, at CHL concentration 
of 20 and 34 mg/ml there was no significant change in particle size. This indicated a 
complete coating of CHL on the surface leading to CHL molecules repelling each other, 
preventing particle aggregation and hence an increase in particle size (111).  
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At the same concentration of CHL there was no effect of different PVA concentration 
on the particle size. But when no PVA was used the particle size increased significantly 
this is because the PVA is known to prevent particle aggregation (80). 
The second strategy produced successfully CHL-NPs with positive charge in the whole 
range of CHL concentrations examined (2, 4, 6, 8, 10, 16, 20 mg/ml) while the first 
strategy failed to.  
The zeta-potential of cationic NPs increased with CHL feed concentrations until a zeta-
potential plateau was reached at approximately +24 mV (CHL concentration of 
approximately 16–20 mg/ml). This could be indicative of saturation in adsorption of 
CHL on the NPs (191; 111; 212). The particle size of cationic NPs was different with 
two groups of NPs present regardless of CHL concentrations. The particle size of 
cationic NPs increased significantly at low concentration of CHL ranging from 2 to 4m 
g/ml. This could be attributed to the increased viscosity of CHL, lowering the shear 
stress of the OP during sonication producing larger emulsion droplets and subsequently 
larger NPs (212). Higher concentrations of CHL (6, 10, 16 mg/ml) the particle size did 
not change significantly. This has been attributed to a complete coating of the NPs by 
CHL molecules so additional CHL would repel each and prevent particles aggregation.  
Similar results were reported by Guo et al. Cationic PLGA NPs were produced by 
adsorption of different chitosan concentrations (0–2.4 g/L) on PLGA, via double 
emulsion solvent evaporation method. They found that the NPs size increased from 
261.5 nm to 972.7 nm with increase in chitosan concentration from 0 to 2.4 g/L. These 
increase in size accompanied by increase in zeta potential from - 20.3 to +55 mV which 
confirm the adsorption of chitosan on PLGA NPs (111). 
Also, the pattern of change in particle size when CHL was added to the EAP was 
similar to that when CHL was added after NPs formation. It was observed that all 
cationic NPs regardless of preparation method displayed a neutral or positive charge 
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that could be due to electrostatic interactions between the negatively charged groups (-
OH) of PGA-co-PDL and the positively charged CHL inducing adsorption of CHL onto 
the NPs surface. Also, the change in zeta potential need a small ratio of the amino 
groups to neutralize the negative charges of PGA-co-PDL while the reset of free amino 
groups could be reason behind the change in zeta potential (211; 230). 
As the concentration of CHL increased the amount of adsorbed CHL per mg of NPs 
increased over the entire range of CHL concentrations examined (0–20 mg/ml) and 
there was no plateau of adsorption was reached. In contrast, the zeta potential did not 
change with increased amount of CHL adsorbed on the NPs at high concentrations of 
CHL (greater than approximately 16–20 mg/ml). This could be attributed to the multiple 
layers model of CHL adsorption on NPs. In this model only a small ratio of CHL 
influenced the zeta-potential (the first few layers) and the layers after do not change the 
zeta-potential due to the apparent surface charge (amine groups) per unit area is 
constant (111). 
The second strategy was selected to examine CHL adsorption onto NPs and to explain 
the mechanism of adsorption because it gave positive zeta potential over the entire 
range of CHL concentrations examined. The four adsorption isotherms (Langmuir, 
BET, Freundlich, and Halsey) models evaluated to describe the adsorption mechanism 
of CHL onto NPs. It was found that the adsorption of CHL on NPs complied with 
multilayer adsorption pattern irrespective of which model was examined. The leading 
factor particularly in the development of the first adsorption layer was electrostatic force 
between CHL (with positive charge) and PGA-co-PDL surface (with negative charge).  
When the CHL concentration increased it is likely that the following layers of CHL 
adsorbed on the first layer of CHL without interaction with the NPs surface. When more 
CHL layers adsorbed the CHL molecules would repel each due to similar charge other 
because of the same charge however CHL molecules interacted via hydrogen bonds, 
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hydrophobic interactions, and van‎ der‎Waal’s‎ forces. Mainly, the NPs great surface 
energy and surface area had a significant function in CHL multilayer adsorption (111). 
The cationic NPs prepared at a CHL concentration of 10 mg/ml was selected for further 
investigations in this study because these particles had a similar size (480.23±32.2 nm) 
to the anionic NPs. 
6.4. Preparation and characterisation of PspA loaded anionic and 
cationic NPs 
When the optimised conditions applied for the preparation of PspA encapsulated NPs 
the particle size of anionic NPs was 310.4±25.3 nm and for cationic NPs was 
409.7±49.5 nm. The presence of CHL increased the particle size significantly and 
changed zeta potential of anionic NPs (-29.17±0.09 mV) to positive (+21.33±1.2 mV).  
The EE % of Psp4ProA in the anionic NPs was 75.3±6.2% and it was significantly 
higher than EE% of cationic NPs 50.2±7.1%. Also, the PspA4Pro loading in cationic 
NPs (9.84±1.4 µg/mg) decreased significantly in comparison with anionic NPs 
(65.73±5.6 µg/mg). Similar results reported by Anish et al. (157). They prepared PLA 
microparticles encapsulating PspA using double emulsion solvent evaporation method. 
The EE % of PspA obtained ranged from 43 to 78 % and PspA loading of 2.5 to 3.67 
µ/mg (157). 
The dose of PspA in range of 1-5 µg has been shown to be sufficient to evoke immunity 
in mice when delivered intramuscularly or subcutaneously (30; 157; 220). On the other 
hand, when PspA was delivered through nasal route (i.e. mucosal site) with an adjuvant, 
only a dose of 100 ng was needed to stimulate immunity compared to the immunity 
produced by oral delivery of 7.5 µg (221). Assuming that PGA-co-PDL NPs/NCMPs 
developed in this study were to be delivered by inhalation (through mucosal site), the 
PspA dose would be about 100 ng for mice, which is equivalent dose of 4 µg of anionic 
NPs/NCMPs and 25 µg of cationic NPs/NCMPs. In addition, one should consider that 
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the dose of PspA4Pro would be changed when apply to human vaccination (although it 
would be based on the animals studies). 
The anionic and cationic NPs appear to be well tolerated by DCs. This provides an 
indication about the feasibility of using anionic and cationic NPs as safe carriers to 
target DCs.  
The uptake of anionic and cationic NPs by JAWS II DCs cell line after incubation for 1 
h was confirmed by CLSM. There was good agreement between particle size (around 
200 and 445 nm) and the ability for an uptake by DCs (89; 135). 
Similar results reported by Foged et al. (89). They examined the DCs uptake of a wide 
size range and surface charge characteristics of model fluorescent polystyrene particles. 
They found that the optimal size of particles for efficient uptake by DCs was 500 nm 
and below. Also, they found that the larger particles uptake enhanced by modifying the 
surface charge (89). 
So we may conclude that anionic and cationic NPs are efficiently ingested by DCs and 
could be applied for the delivery of antigens to DCs.  
6.5. Optimisation of spray drying of NPs into NCMPs  
The PGA-co-PDL NPs were dispersed into L-leucine solution and spray dried to 
produce NCMPs carriers suitable for pulmonary delivery via DPIs. The Taguchi 
experimental design was applied to evaluate the influence of the spray drying 
parameters on the yield % of NCMPs powder and the order was as follows: the feed rate 
> aspirator capacity > air flow rate > inlet drying temperature > the feed concentration. 
The highest yield (Run H, 50.96±2.26 %) was obtained when the suggested 
combinations were as following: the feed rate= 10 %, aspirator capacity= 100 %, air 
flow rate=400 L/h, inlet drying temperature= 100 ºC, the feed concentration= 12.5 
mg/ml.  
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The most important factor was feed rate at 15 %, the atomizing air may not be able to 
penetrate the stream of liquid. Consequently, insufficient atomization and drying may 
cause deposition of a large amount of NCMPs on the walls of the drying chamber and 
the cyclone separator (161). Similar observation was reported by Motlekar et. al. (161). 
They found that the high feed rate (25 %) of the spray suspension lead to almost no 
yield of dry powder (161). 
 The second important factor was aspiration as a high aspirator flow rate created greater 
centrifugal force leading to an increase in the collection efficiency (162). Airflow can 
have a negative effect on powder yield % at high spray flow small droplets are 
produced, which are collected less efficiently by the centrifugal force (162). Shi and 
Hickey optimised spray drying condition to prepare PLGA microparticles suitable for 
inhalation. They found that the airflow and aspirator capacity had significant effect on 
the yield of dry powder. Where the airflow had negative effect, showing that powder 
yield decreased with the increase of the airflow while the aspirator capacity had positive 
effect, showing that powder yield increased with the increase of the aspirator capacity 
(162).  
The inlet temperature of drying air had considerable effects on the yield of dry powder. 
It was noticed that as inlet temperature increased from 50 to 100 ºC this resulted in an 
increased powder yield. It has been reported that high inlet temperature can reduce the 
drying time and inhibit particle aggregation (163). Furthermore, a higher inlet 
temperature promotes a decrease of residual moisture by enhancing water evaporation 
resulting in less particles stick in the drying chamber (164).  
Also, it was observed that the change in the concentration of total solid in the spray 
dried suspension showed no improvement in the yield of dry powder. This observation 
was in contrast to the results reported by Jensen et al. were they found that as the 
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concentration of solid in the suspension increased the yield of dry powder increased 
(92). 
Optimum conditions for the production of the highest yield% of dry powder resulted in 
50.96±2.26 % of NCMPs (92). 
Photomicrographs of NCMPs showed irregular and porous microparticles. This 
occurred due to excessive build-up of vapour pressure during water evaporation in the 
spray drying process and occurs with hydrophobic amino acids, such as L-leucine, for 
improved aerosolisation performance (100; 165; 169). These observations were in 
contrast to results reported by Tawfeek et al (66). They produced PGA-coPDL/L-
leucine microparticles with smooth surface.  
Anionic NPs/NCMPs produced a higher FPD, and FPF % 45.00±4.70 µg and 78.57±0.1 
%, respectively, than cationic NPs/NCMPs 32.51±6.67 µg and 46.79±11.21 %, 
respectively. This could be attributed to incomplete powder de-aggregation as van der 
Waals forces between particles were not completely overcome upon inhalation despite 
the low density of the particles. In addition, powder aggregation of cationic 
NPs/NCMPs‎was‎confirmed‎with‎a‎Carr’s‎ index‎of‎≥32, indicating the flow was very 
poor (66). Similar results were reported previously where PGA-co-PDL/L-leucine 
NCMPs aerosolisation studies showed FPF% of 76.95±5.61% (68). 
As the anionic and cationic NPs/NCMPs deposition in term of MMAD will reach 
bronchial-alveolar region in the lung, cytotoxicity studies were carried out on A 549 cell 
line. The anionic and cationic NPs/NCMPs appear to be well tolerated by the cell line at 
2.5 mg/ml concentration indicating a good toxicity profile. This provides an indication 
about the feasibility of using anionic and cationic NPs/NCMPs as safe carriers for 
pulmonary drug delivery (68).  
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6.6. Investigation of In vitro release of protein  
In vitro release studies of NPs/NCMPs formulations showed biphasic release profile 
with a first initial burst release followed by a second continuous sustained release phase 
over 48h. In the cationic NPs/NCMPs formulations the observed high-burst release at 
time zero (22.41±6.7%) could be explained by the majority of the BSA being adsorbed 
onto the surface (110). Also, the cationic NPs/NCMPs formulations showed a higher 
cumulative BSA release at the end of 48 h compared to anionic NPs/NCMPs. These 
differences in release patterns may be due to a combination of factors, such as BSA 
loading, and presence of BSA on the surface of the NPs (152). Similar results reported 
by Wang et al. (230). They found that chitosan modified PLGA NPs showed higher 
burst release of the drug than the PLGA NPs.  
For both formulations the notable change in release profile at 20-24h after the initial 
burst release could be due to the distribution of BSA inside NPs or a change in 
degradation rate due to changed surface porosity (152). Furthermore, it is worth noting 
that CHL adsorbed on NPs dissolves in water and therefore does not hinder drug 
diffusion from the NPs (156; 110). These results were consistent with results reported 
by Gupta et al. where they found that poly-ω-caprolactone and chitosan coated poly-ω-
caprolactone NPs had similar in vitro percentage cumulative release of hemagglutinin 
protein irrespective of presence of chitosan coat on NPs surface (54).  
A study of the in vitro release kinetics was carried out to determine the mechanism of 
BSA release. BSA was released from anionic NPs/NCMPs formulations according to 
the Higuchi diffusion model. However, BSA was released from cationic NPs/NCMPs 
formulations according to a dual pattern first order model and Higuchi diffusion model. 
A first order kinetics equation described the release of BSA which was not effectively 
encapsulated in cationic NPs and is readily to dissolve from cationic NPs surface. This 
was a rapid process occurring immediately after introducing the formulation into the 
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release medium (215). The Higuchi model describes the second part of the BSA release 
which appears to be a diffusion-limited process. 
The in vitro release data of anionic and cationic NPs/NCMPs formulations showed 
similar results with PspA4Pro encapsulated. 
6.7. Investigation of structure and relative antigenicity of released 
protein  
In this study the released BSA and PspA4Pro from anionic and cationic NPs/NCMPs 
maintained their structure and preserved its activity. The BSA and PspA4Pro released 
maintained their primary structure and was not degraded or affected by the procedure. 
The secondary structure of BSA and PspA4Pro released from anionic NPs/NCMPs 
confirmed the presence‎ of‎ α-helix. However, the BSA and PspA4Pro released from 
cationic‎ NPs/NCMPs‎ confirmed‎ the‎ presence‎ of‎ decreased‎ α-helix (8.5 and 5 %, 
respectively) compared to standard BSA and PspA4Pro. This could be due to 
electrostatic interaction between positive charge of CHL and negative charge of BSA 
and PspA4Pro (172).‎ This‎ relative‎ low‎ decrease‎ in‎ α-helix content has also been 
reported in literature (140; 231; 232). 
The relative antigenicity of the PspA4Pro released from anionic NPs/NCMPs was 
preserved. These results demonstrate that PspA4Pro was not susceptible to formulation 
parameters induced conformational changes as those observed with other proteins. 
However, it was observed that PspA4Pro released from cationic NPs/NCMPs showed 
25% of relative antigenicity. This could be attributed to changes in secondary structure 
of PspA4Pro after release.  
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7.1. Future work 
These results would be helpful in improving optimised processes for producing 
polymeric particles to enhance the immunogenicity and stability of protein antigens. 
The selected formulations encapsulating PspA4Pro have been provided to Instituto 
Butantan, Brazil to examine the activity, immunogenicity, and pneumococcal challenge 
in vivo (233).  
Moreover, the immunogenicity of the formulation can be examined by measuring the up 
regulation of MHC II, CD 40, CD 80, CD83, and CD86 surface markers expressed on 
DCs surfaces by flow cytometry. 
The biological activity of PspA4Pro released from anionic and cationic NPs/NCMPs 
can be evaluated by Escherichia coli killing assay (30). This assay depends on the role 
of apolactoferrin as bactericidal. The function of PspA in pneumococcal infection is to 
interact with apolactoferrin and avoid its bactericidal action. Shortly, the E. coli culture 
will be grown to early log growth phase then it will be inoculated at predetermined 
number in a microtiter plate. Apolactoferrin will be dissolved in medium at a selected 
concentration, followed by the addition of control PspA or PspA released from 
NP/NCMPs. Then E. coli will be added. After overnight incubation colony forming 
units will be detected by counting colonies grown on plates. The log colony forming 
units killed will be figured out by subtracting the experimental readings from control 
bacteria cultures grown under the same conditions.  
The bio distribution of PspA after inhalation can be examined by radioisotope counting 
assay (35). Briefly, PspA will be labeled with indium chloride via N-terminal‎and‎ε-Lys 
amino groups, using diethylenetriaminepentaacetic acid then it will be delivered alone 
or as a complex with the formulation. The radioisotope counts in the body tissue 
(mouth, olfactory area, nasopharynx, bronchi, and lungs) at 0.5, 1, 4, 8, 20, and 40 h 
after inhalation will be evaluated with a γ-counter.  
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Further studies will evaluate the long term stability of the dry powder formulation at 
various temperature and humidity conditions. Stability of the formulation at ambient 
conditions is beneficial in order to prevent cold-chain requirements, avoid moisture 
adsorption which can lead to powder aggregation and poor flow and aerosolisation 
behaviour; moreover it will affect the stability and integrity of PspA4Pro. The stability 
of the dry powder will be examined using DSC and X-ray powder diffraction to 
determine changes in the crystallinity of the particles. PspA4Pro stability, integrity and 
activity will be evaluated by SDS-PAGE, CD and lactoferrin assay, respectively (30). 
Moreover, the biochemical response of NPs/NCMPs dry powder administered via 
inhalation into rat lung (in vivo) can be assessed. The potential inflammatory reactions 
will be evaluated by testing the following factors: lung fluid protein activity, lactate 
dehydrogenase activity, and existance of inflammatory polymorphonuclear cells (234).  
Briefly, the bronchoalveolar lavage fluid samples will be added to Coomassie- plus 
protein assay reagent and will be measured by spectrophotometer at 595 nm. The 
amount of total protein will be calculated by using a standard curve prepared with BSA 
(234).  
To examine lactate dehydrogenase activity in bronchoalveolar lavage fluid, samples will 
be centrifuged; then, the supernatant will be added to NADH in Tris/NaCl solution, 
followed by the addition of pyruvate solution. Lactate dehydrogenase activity was 
evaluated by kinetic measurements (234). 
To evaluate the existance of inflammatory polymorphonuclear cells the bronchoalveolar 
lavage fluid samples will be centrifuged and the pellet will be dissolved in saline then it 
will be stained with Diff-Quik and examined by light microscopy to identify 
macrophage and polymorphonuclear cells (234). 
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Appendix- 1 
SDS-PAGE analysis of protein integrity 
Sodium dodecyl sulfate poly (acrylamide) gels (10 cm W × 8 cm L × 0.5 mm thick) 
were freshly cast for all experiments. The resolving layer solution prepared using 6 mL 
protogel solution (to produce a final acrylamide concentration of 7.5%), 5 mL resolving 
buffer, and 8.78 mL water. Polymerization‎was‎ initiated‎ by‎ adding‎ 100‎ μl‎ of‎ freshly‎
prepared 10% ammonium persulfate (APS)‎ and‎ 10‎ μl‎ N,‎ N,‎ N`,‎ N`,-tetramethyl 
ethylenediamine (TEMED). Then the solution was poured between the gel casting 
plates and allowed to set for 15 minutes. The stacking layer gel was prepared using 1.3 
mL protogel solution (to produce 4% acrylamide final concentration), 2.5 mL stacking 
buffer, and 6 mL water. Polymerization‎ was‎ initiated‎ by‎ adding‎ 50‎ μl‎ of‎ freshly‎
prepared‎10%‎APS‎and‎10‎μl‎TEMED.‎Then‎the‎solution‎was‎poured‎between‎the‎gel‎
casting plates to the top of plates and the comb inserted between the plates. The gel was 
allowed to polymerise for 15 minutes then the comb gently removed. The gel was then 
placed into the electrophoresis tank, filled with fresh (10X) Tris-glycine-SDS Buffer. 
Protein samples and standard were treated with protein loading buffer in a ratio (1:1) for 
3 min at 95°C. The protein molecular weight marker, standard, and samples were 
loaded into the wells (25 µl per well). The gel was transferred to colloidal Coomassie 
Brilliant Blue stain (to stain the protein band) and placed on a shaker for 24 h. Then the 
gel was rinsed with water and placed on the shaker for a further 24 h (to destain the gel).  
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Abstract: Growing demands on a suitable formulation method that ensures the stability of the active compound coupled 
with the limitations of current methods (milling, lyophilization, spray drying, and freeze spray drying) has brought wide 
attention to supercritical fluid (SCF) technology. Advantages of using the SCF technology comprise its high abilities, 
adaptability in providing alternative processing methods, high compressibility and diffusivity of the supercritical fluid, ca-
pability as an alternative for conventional organic solvents, and the option to attain different processing parameters which 
would be otherwise difficult to conduct with traditional methods. This review proposes to present an up-to-date outlook on 
dry powder pulmonary formulations of macromolecules using SCF technology.  
Keywords:  Dry powder, inhalation, macromolecules, microparticles, peptide, protein, super critical fluid. 
1. INTRODUCTION 
 Over the past two decades a rapid growth of innovative 
technologies for producing novel therapeutic agents has 
arisen. This growth has mostly been initiated by the discov-
ery of new therapeutic agents, such as macromolecules, to-
gether with an increased understanding and knowledge of 
pathophysiology [1]. Consequently, novel macromolecules 
(also known as biotechnology-derived pharmaceuticals, bio-
therapeutics, or biological drugs and include recombinant 
therapeutic proteins, monoclonal antibody based products 
and nucleic acid-based medicinal products) can now be pro-
duced with preferential selectivity for definite targets [1, 2]. 
To date many macromolecule based drugs are in clinical 
trials or at approval phase (Table 1) [3]. Over the past decade 
pharmaceutical research and development has been focused 
on developing macromolecules for treatment of many dis-
eases, and are preferred due to their greater selectivity; lower 
disruption of normal biological processes; effective substitu-
tional therapy in mutated or deleted normal protein and less 
clinical development time in addition to a shorter FDA ap-
proval period [4,5]. 
 However, most of these macromolecules must be admin-
istered repeatedly using an invasive manner to reach a thera-
peutic concentration, even though these procedures would be 
painful to the patients [6-8]. As an alternative to repeated 
injection, pulmonary inhalation could enhance macromole-
cule administration because it is a non-invasive technique for 
local and systemic drug delivery. The lungs own many fa-
vorable features, including large surface area for absorption, 
highly vasculatures, thin epithelium in the alveolar tissue and 
short path of gas–blood exchange movement [8].  
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However, formulating macromolecules into suitable pulmo-
nary delivery systems remains a challenge.  
 A variety of micro/nanoparticulate systems such as 
polymer based micro/nanoparticles, liposomes and solid lipid 
micro/nanoparticles have been used for the encapsulation of 
macromolecules serving specific therapeutic purposes such 
as controlled release or targeted drug delivery. Major con-
cerns on the formulation method of macromolecules must be 
addressed when dealing with these molecules [7]. The stabil-
ity and biological activity of macromolecules are extensively 
dependent on their entire structures, and can be easily altered 
by physical means (e.g. denaturation, adsorption, or nonco-
valent aggregation) or chemical means (e.g. oxidation, 
deamidation, or peptide cleavage). The impact of modifica-
tions can be very complicated (losses in therapeutic activity, 
changes in absorption, biodistribution, elimination, toxicity 
and immunogenecity). In addition, these intact structures are 
important characteristics which have impact on the physico-
chemical properties of the final therapeutic products, espe-
cially in the case of pulmonary drug delivery that require 
careful manipulation of the particle size, shape, density, and 
surface properties (Table 2). Many different routes are em-
ployed to achieve solid-state formulations, including milling, 
freeze drying (lyophilization), spray drying (SD), and spray–
freeze drying (SFD) (Table 3). 
 Growing demands on a suitable formulation method that 
ensures the stability of the active compound coupled with the 
limitations of current methods (milling, lyophilization, spray 
drying, and freeze spray drying) brought wide attention to 
supercritical fluid (SCF) technology [2]. SCF are gases and 
liquids above their critical pressure (Pc) and critical tempera-
ture (Tc), and under these conditions, the molecules exhibit 
the flow, polarity, and solvency properties common of liq-
uids but have the diffusion and reactivity characteristics of 
gases. SCF technique can be performed using carbon dioxide 
(CO2), water, propane, acetone, nitrous oxide (N2O),
220-30;/11 $58.00+.00 © 2011 Bentham Science Publishers  
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Table 1. Examples of Therapeutic Macromolecules being Investigated for Systemic Delivery via the Pulmonary Route 
Type Active Agent Disease Ref. 
Erythropoeitin Anaemia [15] 
Insulin Diabetes [15] 
Parathyroid hormone Osteoporosis [14, 15] 
Cetrorelix LH-RH antagonist [15] 
Follicle stimulating hormone Fertility treatment [15] 
Hormone 
LH-RH analogues Endometriosis, prostate cancer [15] 
Sargramostim Sarcoma [15] 
Growth factor 
Growth hormone releasing factor Pituitary dwarfism [14] 
Blood derivative Immunoglobulin Trigger/modulate immune response [15] 
Interferon-beta Interferon Multiple sclerosis [14, 15] 
Calcitonin-salmon Osteoporosis [14, 15] 
Heparin Inhibit thrombosis [14, 15] Natural extract 
Cyclosporine immunosuppression [15] 
Recombinant protein Human recombinant F.IX Hemophilia B [15] 
HBsAg Hepatitis B [16] 
P30B2, (NANP)6P2P30 Malaria [16] 
SPf66 Malaria [16] 
Hemagglutinin Influenza [16] 
Mtb8.4 peptide Tuberculosis [16] 
HLA-A*0201 plasmid Tuberculosis [16] 
Diphtheria toxoid Diphtheria [16] 
Tetanus toxoid Tetanus [16] 
Vaccine 
Formalin- inactived rotovirus Rotavirus [16] 
 
Table 2. Product Parameters and Pharmaceutical Considerations in Drug Product Design 
Parameter Importance/Effect Ref. 
Particle size and distribution 
Precise targeting 
Content uniformity 
Rates of dissolution, 
Rates of release, 
Dose delivery 
[18-20] 
Particle shape (morphology) 
Flow property 
Dispersibility 
[21] 
Particle density 
Flow property 
Dispersibility 
[22] 
Particle surface charge 
Optimal surface properties of particles must be obtained to prevent particles agglomeration 
Flow property 
Dispersibility 
Precise targeting 
[16, 21, 23] 
Crystal form Crystal form influences all steps of the development from discovery to marketing [10] 
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Table 3. Common Methods for Formulations of Macromolecules 
Method Description Disadvantages Excipients Ref. 
Jet Milling 
Bulk particles are introduced into the milling chamber. Air or 
nitrogen, fed through nozzles at high pressure, accelerates the 
solid particles to sonic velocities. The particles collide and 
fracture. While flying around the mill, larger particles are sub-
jected to higher centrifugal forces and are forced to the outer 
perimeter of the chamber. Small particles exit the mill through 
the central discharge stream 
Broad particle size 
Physical/chemical degradation 
e.g. trehalose [21] 
Freeze drying 
(Lyophilization) 
The formulation is frozen and the bulk water is removed by 
sublimation. The resulting cake is composed of the protein, any 
nonvolatile excipients, and a small amount of residual water 
tightly associated with the protein 
Time consuming 
Broad particle size distribution 
e.g. trehalose, 
inulin,  dextran 
[6, 11] 
Spray drying 
Uses atomization to form microdispersed droplets. The water in 
these droplets quickly evaporates when passed through a 
stream of hot gas, resulting in the formation of a fine powder of 
microparticles containing protein and excipients 
Degradation 
Low process efficacy 
Time consuming 
e.g. leucine, 
lactose, treha-
lose, dipamitoyl-
phosphatidylcho-
line (DPPC), 
albumin 
[8, 11, 22, 
24, 25] 
Spray-freeze 
drying 
The microdispersed liquid particles are generated through the 
jet nozzle in the absence of heat, then collected and frozen in 
liquid nitrogen before sublimation occurs. The frozen particles 
are then lyophilized 
Degradation 
Low process efficacy 
Time consuming 
e.g. inulin, treha-
lose, manitol 
[6, 8, 21, 
24] 
Supercritical 
Fluid 
SCF are gases and liquids above their critical pressure and 
critical temperature. SCF technique can be performed using 
carbon dioxide (CO2), water, propane, acetone, nitrous oxide 
(N2O), trifluoromethane, chlorodifluoromethane, diethyl ether, 
water, or CO2 with ethanol 
Solubility of molecules in solvent 
Degradation 
Particle size control 
Residue of organic solvent 
Scale up of this process is re-
stricted by particle aggregation 
and nozzle blockage due to rapid 
expansion cooling. 
e.g. sucrose, 
trehalose,  
manitol 
[2, 8, 11, 
13] 
 
trifluoromethane, chlorodifluoromethane, diethyl ether, wa-
ter, or CO2 with ethanol [13]. In addition SCF possess sev-
eral fundamental advantages as solvents and/or anti-solvents 
for processing heat-labile solutes at low temperature. For 
example, supercritical CO2 is a good solvent for water-
insoluble as well as water-soluble compounds under suitable 
low critical conditions (Tc = 31.2 °C, Pc = 7.4 MPa) [8]. In 
addition, compressed CO2 is accessible in ample proportions 
with a higher degree of purity [9]. Moreover, CO2 is non-
toxic, nonflammable, and inexpensive [8]. Therefore, super-
critical CO2 has potential as an alternative for conventional 
organic solvents used in solvent-based processes for forming 
solid dosage forms. Furthermore, the general consideration 
of SCF as a “green” substitute has become very significant 
as the harmful effects of residual organic solvents, from both 
a processing and environmental point of view, have been 
known, and in addition, the regulatory specifications for the 
utilization and residual amounts of organic solvents in the 
final pharmaceutical product become more stringent [10]. 
 There are two major principles based on SCF. The first 
process utilizes supercritical fluids as a solvent. The Rapid 
Expansion of a Supercritical Solution (RESS) process is the 
method that represents this first principle. Initially the solute 
must dissolve in a SCF followed by sudden decompression, 
after which the solution is rapidly expanded at low pressure 
by passing through an orifice. The restrictions facing appli-
cation of RESS for macromolecules formulations include: it 
is restricted to molecules that are soluble in SCF CO2, rela-
tively high temperature required for the rapid expansion 
(typical temperature of 40 ºC) which can destroy proteins, 
lacking control of particle size, and scale up of this process is 
restricted by particle aggregation and nozzle blockage due to 
rapid expansion cooling [8].  
 The second process involves the solute being insoluble in 
SCF and hence utilizes SCF as an antisolvent. Many macro-
molecules which are suitable as therapeutic agents are 
slightly soluble in SCF and have high solubility in water. 
These processes use SCF as an antisolvent where a solute is 
dissolved in an organic solvent then precipitated by SCF. 
Precipitation develops when the SCF is absorbed by the or-
ganic solvent followed by expansion of the liquid phase and 
decreases in the solvent power leading to particle formation. 
The Gas Anti-Solvent (GAS), Aerosol Solvent Extraction 
System (ASES), Supercritical Fluid Antisolvent (SAS), Pre-
cipitation with Compressed Antisolvent (PCA), Solution 
Enhanced Dispersion by Supercritical Fluids (SEDS), and 
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supercritical fluid extraction of emulsion (SFEE) are the 
processes that exemplify this second group Fig. (1). The 
main disadvantage of the second process that applies SCF as 
antisolvent is the difficulty to remove the residual organic 
solvent completely [8]. 
 Thorough discussions of differences in the above tech-
niques have been recently published elsewhere [8-13]. This 
review proposes to present an up-to-date outlook on the pro-
gression of dry powder formulations for inhalation of mac-
romolecules using SCF techniques, covering its challenges, 
possibilities and recent developments.  
2. SUPERCRITICAL FLUID APPLICATIONS IN 
PREPARATION OF MACROMOLECULES FOR DRY 
POWDER INHALATION 
 Unlike conventional methods of particle formation such 
as milling, lyophilization, spray-drying, and freeze-spray 
drying, where large particles are reduced to the intended size, 
SCF technology includes developing the particles in a con-
trolled approach to achieve the intended size. Therefore the 
negative effect of the energy transmitted to the system such 
as denaturation of protein to produce the desired size can be 
avoided. Ideally, the particles once formed must not be sub-
jected to further treatment and this property makes SCF 
technology suitable to produce macromolecules in their na-
tive pure state and/or encapsulating these agents [13].  
 Advantages of using the SCF technology comprise its 
high abilities, adaptability in providing alternative processing 
methods, the high compressibility and diffusivity of SCF, 
capability as an alternative for conventional organic solvents, 
and the ability to reach different processing parameters (such 
as pressure and the rate of solvent evaporation) which would 
otherwise be difficult to conduct with conventional methods 
[10]. 
2.1. Encapsulation of Insulin 
 SCF have unique properties as mentioned above that 
makes them applicable for various processing methods such 
as particle formation and extractions. Recently, a significant 
interest in SCF technology has been revealed in an attempt to 
find other preferable approaches of insulin processing. 
 Todo et al. [26] examined the absorption of insulin dry 
powders processed with mannitol (carrier) and citric acid (an 
absorption enhancer) by the SCF process known as solution 
enhanced dispersion by supercritical fluids (SEDS) with that 
prepared by spray drying (SD) technique. In this investiga-
tion insulin powder was precipitated by dispersing the insu-
lin aqueous solutions through V-type nozzles into supercriti-
cal CO2/ethanol/water ternary system. Water feed rate, liquid 
CO2 feed rate, ethanol feed rate, pressure, and temperature 
were 0.035 mL/min, 5.7 g/min, 0.665 mL/min, 15 MPa, and 
35 ºC, respectively. These operating conditions enabled the 
water to be miscible with the non-polar CO2. A manual in-
jector was used to introduce aqueous 0.25 % insulin solution 
with 0.2% citric acid and 5.0 % mannitol into the water 
stream. For dry powders (0.25 % insulin solutions containing 
5 % mannitol and 0.20 % citric acid) prepared by SD tech-
nique the following standard operating parameters were 
used: an inlet temperature of 90 ºC, a drying air flow rate of 
0.75 m
3
/min, a solution feed rate of 5 mL/min, and an atom-
izing air pressure of 100 kPa. The authors found that insulin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Schematic diagrams of various particle-formation processes using supercritical fluid technology. RESS: Rapid Expansion of a Su-
percritical Solution, GAS: Gas Anti-Solvent, ASES: Aerosol Solvent Extraction System, SAS: Supercritical Fluid Antisolvent, PCA: Precipi-
tation with Compressed Antisolvent, SEDS: Solution Enhanced Dispersion by Supercritical Fluids, and SFEE: supercritical fluid extraction 
of emulsion. 
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powder prepared by the SCF method showed enhanced aero-
solisation efficiency at 28 L/min using an Andersen Cascade 
Impactor in comparison with insulin powder prepared by the 
SD method. For example, SCF insulin powders had the 
greatest quantity of powder retrieved from stages 2–7 and a 
mass median aerodynamic diameter of 3.2 m with 
respirable fraction of 47.6 %. The hypoglycemic effect of 
insulin powder processed by SCF after intratracheal applica-
tion was higher than that produced by SD. In addition, they 
found that SCF technique provided the largest yield of insu-
lin powder (>80 %) although it was on a laboratory scale 
production. These results demonstrated that the SCF process 
would be beneficial to prepare inhalable insulin powder.  
 Amidi et al. [27] demonstrated that PCA-type SCF tech-
nology is an appropriate method to manufacture inhalable 
insulin-loaded microparticles with specific particle properties 
and retained structure of insulin. The authors used N-
trimethyl chitosan (TMC), as a mucoadhesive absorption 
enhancer, and dextran as carriers for insulin, and prepared 
two formulations of 10 % (w/w) of insulin/TMC or insulin/ 
dextran. The particles were formed by spraying an acidic 
water/dimethyl sulfoxide (DMSO) solution of insulin and 
polymer within supercritical CO2. The flow rates of polymer-
insulin solution and CO2 were 4.5 mL/min and 333 g/min, 
respectively. The pressure and temperature were maintained 
at 110 bar and 40 °C. The mass median aerodynamic diame-
ter was 4 m and the percentages of the emitted dose were 
62 and 67 % for insulin/TMC and insulin/dextran respec-
tively. The water content of the particles was 4 % (w/w), and 
neither crumpled nor agglomerated after formation and stor-
age. The intact structure of insulin in the freshly formulated 
dried insulin powders were monitored by circular dichroism 
spectroscopy, which indicated the secondary and tertiary 
structures of insulin was retained in all preparations. Fur-
thermore, at the end of one-year storage at 4 °C, the particle 
properties were preserved and the insulin structure almost 
retained in the TMC powders.  
 Kim et al. [28] compared micronized insulin using man-
nitol as a stabilizer alone or with the addition of trehalose as 
a second stabilizer using a process known as aerosol solvent 
extraction system (ASES) SCF technology. They injected 
co-currently the solution of insulin/mannitol (15/85 wt.%) 
with or without 10 and 15 wt.% trehalose with the CO2 into 
the precipitation vessel using the solvent, N,N-
dimethylformamide (DMF) at 35 °C, 180 bar, 8 mg/mL solu-
tion concentration, and 5 ml/min solution flow rate. Results 
indicated that when trehalose was used as a second stabilizer, 
the particles were almost uniform, more spherical, less adhe-
sive, and less aggregated in air flow, in comparison to insu-
lin mannitol particles alone. The mass median aerodynamic 
diameter of the insulin/mannitol particles was ~5 m and of 
the insulin/mannitol/trehalose particles was ~2.32 μm, 
which are appropriate for inhalable dosage from. In vitro 
aerosolisation deposition test conducted with a micro-orifice 
uniform deposit impactor (MOUDI-II™Impactor) at 30 
L/min revealed 69 % by weight of the insulin/mannitol and 
41 % by weight of the insulin/manitol/trehalose particles was 
deposited on stages 3, 4, 5 and 6. This study showed the 
ASES process was able to retain the secondary structures of 
insulin in both insulin/mannitol and insulin/manitol/trehalose 
particles. 
2.2. Gene Powders 
 Polymer based non-viral gene delivery systems have 
been shown to offer protection from nuclease degradation, 
increased plasmid DNA (pDNA) uptake and sustained dura-
tion of pDNA action [29]. These gene delivery systems can 
be prepared from biologically compatible and degradable 
polymers e.g. poly (d,l-lactic-co-glycolic) acid (PLGA). The 
effectiveness of gene therapeutic systems depends on the 
ability of such system to deliver nucleic acid into the target 
cells. Gene dry powders are anticipated to have further ad-
vantage of prolonged shelf life of the preparation [29]. 
 Okamoto et al. [29] compared stability of a chitosan–
pDNA complex powder processed by a SEDS-type SCF 
technique and gene solution alone for inhalation. They pre-
cipitated the gene powder by dispersing an aqueous chito-
san–pDNA complex solution with mannitol into the stream 
of a SCF CO2/ethanol admixture. In the mixing column, the 
CO2 was admixed with ethanol at a flow rate of 5.7 g/min 
and 0.665 mL/min respectively. Using these operating condi-
tions resulted in complete miscibility of ethanol, water, and 
CO2. The admixture was dispersed into the particle forma-
tion vessel at 35 ºC and 15 MPa using one end of the V-
shaped nozzle, while the other end of the V-shaped nozzle 
was used to disperse water at a flow rate of 0.035 mL/min. 
The aqueous chitosan–pDNA complex solution (0.4 mL) 
was manually injected into the water stream and the dry 
powder was collected from the depressurized vessel. This 
procedure resulted in powder yields of ~80 % and aerody-
namic particle sizes of ~3 m, which was appropriate for 
pulmonary delivery. Scanning electron microscopy examina-
tion revealed the powders to have rectangular shape. Gene 
integrity and transfection potency were determined by elec-
trophoresis and in vivo pulmonary transfection test in mice. 
The SCF technique minimized the supercoiled DNA during 
the formulation processing; although, the reduction in the 
remaining supercoiled and open circular DNA in the pow-
ders during storage was more prolonged than in solutions. As 
a result, the powders generated using SEDS had increased 
transfection potency in comparison to the gene solutions for 
the same quantity of DNA.  
 Mayo et al. [30] developed a SCF extraction of emul-
sions (SFEE) technique based on CO2 for formulating 
nanoparticles having high plasmid (pFlt23K, an anti-
angiogenic pDNA capable of inhibiting vascular endothelial 
growth factor (VEGF) secretion) loading and loading effi-
ciency. First they prepared a lipophilic phase by dissolving 
PLGA into ethyl acetate and the inner aqueous phase com-
posed of pFlt23K Tris-EDTA buffer. The aqueous phase was 
sonicated for 1 min (15W) with the lipophilic phase to obtain 
a 1° emulsion (w/o). The outer aqueous phase consisted of 
0.5 % (w/v) polyvinyl alcohol (PVA) saturated with ethyl 
acetate. The 1° emulsion was further sonicated with the outer 
aqueous phase for 3 min to obtain the 2° emulsion (w/o/w). 
The emulsion extraction and particle production was per-
formed using coaxial SFEE apparatus consisting of a cylin-
drical pressure vessel, placed in a temperature controlled 
water bath at 45 °C. Supercritical CO2 was injected via a 
syringe pump to the base of this vessel. The emulsion was 
introduced counter currently by means of a 100 m capillary 
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tube within a 1/16” stainless steel high pressure tubing at the 
top of the vessel, permiting CO2 to flow continually from the 
vessel. During the process the pressure and flow rate of the 
emulsion were kept at 8 MPa and 0.4 ml/ min, respectively. 
Results revealed spherical particles with smooth surface and 
280 nm in diameter. In addition, a high loading of pFlt23K 
(19.7 %, w/w) and high encapsulation efficiency (>98 %) 
was achieved, while a low residual solvents (<50 ppm), at-
tributed to rapid particle formation due to successful solvent 
removal afforded by the SFEE technique. In vitro transfec-
tion of pFlt23K-PLGA nanoparticles were able to signifi-
cantly reduce secreted VEGF from human lung alveolar 
epithelial cells (A549) with normoxic and hypoxic status, 
with no cytotoxicty detected. 
2.3. Vaccination 
 Recently immunization by inhalation has been investi-
gated as a substituent for parenteral vaccination. Vaccines 
delivered via the lung route can initiate both systemic and 
local immune responses due to the presence of extensive 
dendritic cells and macrophages lining the respiratory epithe-
lium. 
 Amidi et al. [31] examined the potential of N-Trimethyl 
chitosan (TMC) and dextran microparticles for pulmonary 
delivery of diphtheria toxoid (DT). DT-loaded microparticles 
were formulated by spraying an aqueous solution of 
DT/dextran (w/w) or DT/TMC into supercritical CO2 and 
ethanol using SEDS type SCF technology. When the operat-
ing temperature (38 ºC) and pressure (100 bar) was achieved, 
CO2 and ethanol were completely miscible forming a single 
supercritical phase. The ethanol/CO2 mixture was immedi-
ately introduced via a concentric coaxial two-fluid nozzle 
and sprayed into the vessel for 5 min. This was subsequently 
followed by pumping the aqueous polymer-DT solution into 
the T-mixer at a flow rate of 0.5 ml/min using two syringe 
pumps. This was mixed with SCF-CO2 (367 g/min) and 
ethanol (25 ml/min) and fed into the precipitation vessel 
through the concentric coaxial two-fluid nozzle. Smooth 
spherical particles were produced with median volume di-
ameter of ~3 m and the fine particle mass fractions less 
than 5 m, as revealed by cascade impactor analysis at 30 
L/min, were 35 % for the dextran and 56 % for the TMC 
formulations. 
 This study demonstrated that the generated powders had 
a significant mass fraction of particles less than 5 m, suit-
able for inhalation. In addition, this investigation revealed 
that TMC microparticles were a potent pulmonary delivery 
system for DT antigen. Pulmonary immunization with DT-
TMC microparticles containing 2 or 10 Lf of DT produced a 
strong immune response as manifested by the production of 
IgM, IgG, IgG subclasses (IgG1 and IgG2) antibodies simi-
lar to or significantly greater than those gained after subcuta-
neous application of alum-adsorbed DT (2 Lf). In addition, 
the IgG2/IgG1 ratio after pulmonary immunization with DT-
TMC microparticles was significantly greater in comparison 
with subcutaneous administered alum-adsorbed DT. While 
pulmonary administrations of DT-dextran particles produced 
a very poor immune response.  
 
3. CONCLUSION 
 There has been great progress in supercritical CO2 tech-
niques to increase performance of macromolecules without 
losing the biological activity of these sensitive molecules. 
However, there are still possibilities for optimizing process-
ing parameters, such as temperature, pressure, flow rates, 
and concentration of ingredients. In addition, processing of 
therapeutic macromolecules with supercritical CO2 permit a 
wide range of macromolecules to be processed, and in the 
future it is expected that SCF techniques will provide a more 
favorable alternative to producing formulations encapsulat-
ing macromolecules.  
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Introduction 
As an alternative to repeated injection, dry powder 
pulmonary inhalation offers a non-invasive technique for 
local and systemic delivery of protein-based formulation 
(1). The lungs possess many favourable features (2). In 
our laboratory we have been investigating and 
developing alternative biodegradable polyester polymers 
[poly (glycerol adipate-co-ω-pentadecalactone, PGA-co-
PDL)]. Using this polymer we have successfully 
encapsulated a model protein (α-chymotrypsin enzyme). 
In addition, release studies revealed most of the protein 
released over several hours (3). Furthermore, we have 
successfully demonstrated that PGA-co-PDL 
microparticles could be used as an alternative carrier for 
pulmonary delivery with enhanced aerosol performance 
and reduced toxicity to normal lung cells compared to 
PLGA microparticles (4).  
In this study we aim to produce PGA-co-PDL 
nanocomposite microparticles (NMs) loaded with bovine 
serum albumin (BSA), a model protein, which may be 
administered to the lung via dry powder inhalation. The 
impact of these characteristics on important aspects of 
pulmonary delivery such as aerosolization, and release 
will be determined. 
Methods 
Nanoparticles Preparation 
BSA (Avenchem, UK) loaded PGA-co-PDL nanoparticles 
(NPs) were prepared by probe sonication (sonics, VCX 
500) of water-in-oil-in-water (w/o/w) double 
emulsion/solvent evaporation method (Table 1). The 
double emulsion was stirred for 2 h at room temperature 
and the NPs were collected by centrifugation at 30,000 g 
(Beckman J2-2IM/E) for 45 min at 4 ºC. Control empty 
NPs were prepared. 
Spray drying NPs 
The NMs were prepared by spray drying NPs suspension 
in aqueous L-leucine solutions (1.5%w/w) using a mini-
spray dryer (Büchi, B-290) with two-fluid nozzle (0.7 mm 
diameter), feed rate of 15 ml/min, air flow of 414 L/h, 
aspirator  at  40m³/h, inlet and outlet temperature of 100 
and 47 ºC, respectively. 
Nanocomposite Microparticles characterisation 
Particle size & zeta potential  
The particle size & zeta potential were measured using a 
Zetaplus. Briefly, 100μl of the suspension was diluted to 5 
ml using double distilled water and the measurements 
recorded at 25ºC (n=3). 
Spray dried yeild & drug loading 
The yield of spray dried NMs was quantified as a 
percentage mass of expected total powder yield (n=3). 
The amount of BSA loaded in the NPs was determined 
by measuring the amount of BSA remaining in the 
supernatant with a QuantiPro BCA protein assay (Sigma) 
after centrifugation (n=3). 
Particle morphology 
Spray dried NMs were mounted on gold coated 
aluminium stubs (EmiTech K 550X Gold Sputter Coater, 
25mA for 3 min), and visualised by scanning electron 
microscopy.  
In-vitro relese study 
20mg of BSA encapsulated spray dried NMs were placed 
in an eppendorf and dispersed in 1.2ml of PBS (pH 7.4). 
The samples were incubated at 37C in the orbital shaker 
set at 250 rpm. At predetermined time intervals up to 24h, 
the samples were centrifuged (30,000 g for 20 min) and 
1ml of the supernatant removed and replaced with fresh 
buffer. The supernatant was analysed by QuantiPro BCA 
protein assay as mentioned above (n=3). 
 
 
 
Table 1 Different formulation parameters for 
preparation of NPs by (w/o/w) double emulsion 
solvent evaporation 
Formula 
No. 
Polymer 
conc. 
(mg/ml) 
BSA 
 Conc. 
(%) 
 
IAP volume 
(µl) 
PVA 
Conc
. IAP  
(%) 
PVA 
Conc. 
EAP  
(%) 
EAP 
volume 
(ml) 
NM1 25 0.5 500 1 13 25 
NM2 25 0.5 500 5 13 25 
NM3 25 0.5 250 5 13 25 
*IAP: internal aqueous phase **EAP: external aqueous phase   
Aerosolisation studies  
Dry powder samples (10mg) were manually loaded into 
hydroxypropyl methylcellulose capsules (size 3), and 
aerosolised via a cyclohaler into a Next Generation 
Impactor (NGI), coated with 5% tween 80: acetone 
solution, at a flow rate of 60L/min for 4s to determine 
aerodynamic particle size. The samples were collected 
by washing with DCM/0.15 M NaCl mixture (2:1) to 
dissolve the polymer and the encapsulated BSA, which 
was determined by QuantiPro BCA protein assay as 
mentioned above (n=3). The FPF (%) was determined as 
the fraction of emitted dose deposited in the NGI with 
aerodynamic diameters less than 4.6 μm, and the MMAD 
was calculated from log-probability analysis. 
Results & Discussion 
Nanocomposite Microparticles characterisation 
The particle size achieved ranged from 196.6±1.9 – 
290.6±7.5 and the yield of NMs achieved after spray 
drying ranged from 24.4±4.7 – 35.9±5.1 (Table 2). All 
particles had a negative zeta potential, possibly due to 
PVA remaining on the particles after centrifugation and 
washing.  The drug loading ranged from 14.6±2.5 to 
20.54±3.1 µg/mg particle. There was a significant 
increase in drug loading between NM1 and NM2, due to 
an increase in PVA concentration in the IAP. However, 
decreasing IAP volume led to no significant difference in 
BSA loading between NM2 and NM3. 
SEM analysis indicated that NMs (NM2) had a 
corrugated surface with pores visible on the surface (Fig. 
1). This occurred due to excessive build-up of vapor 
pressure during solvent evaporation in the spray drying 
process and occurs with hydrophobic amino acids, such 
as L-leucine, for improved aerosolization performance 
(5). The size of the NM was approximately 2-3 µm 
according to SEM analysis.  
 
Figure 1 SEM images of NMs (NM2). Scale bar 
represents 5 µm (A) & 2 µm (B) respectively. 
 
Formula 
No. 
Particle 
size 
(nm) 
Zeta 
potential 
(mV) 
Yield 
(%) 
BSA 
loading 
(µg/mg) 
NM1 275.5±12.7 -24.5±1.3 25.4±5.3 14.6±2.5 
NM2 196.6±1.9 -19.3±3.3 24.4±4.7 20.5±3.1 
NM3 290.6±7.5 -12.4±2.1 35.9±5.1 19.5±0.6 
The data in Fig.2 represents the % cumulative 
release of BSA as a percentage of the drug 
loading.  All formulation showed biphasic release 
profile with a first initial burst release followed by a 
second continuous sustained release phase over 
24h. All formulations had a similar initial burst 
release of BSA ranging from 9.6±1.0 – 11.5±2.3%. 
Significant difference was noted in release profile (2 
– 24 h) between NM1 and NM3, with NM1 achieving 
19.8±1.5% release after 24 h compared to NM3 
(14.1±2.0%). 
Conclusion 
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 we have shown the potential for encapsulating 
proteins within PGA-co-PDL NMs as carriers for 
pulmonary delivery using double emulsion/spray 
drying as a preparation method. Future studies will 
involve improving the drug loading, stability studies 
and release by optimising the preparation method.  
Table 2 The drug loading, particle size, zeta 
potential, spray dried yield & drug loading of different 
NMs formulations.  
Figure 2 % cumulative in-vitro release profiles for 
different BSA-PGA-co-PDL NMs as a percentage of 
drug loading in phosphate buffer saline, pH 7.4. 
NM2 was chosen for aerosolisation studies due to a 
high drug loading and reasonable drug release 
profile compared to NM1 and NM3. The results in 
Tab.3 indicate good aerosolisation properties and 
the MMAD corresponds to particle size data 
achieved with SEM. 
Table 3 Aerosolisation performance of NM2 
Formula No. FPF (%) MMAD (µm) 
NM2 70.1 ±13.2 1.6 ± 0.4 
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Introduction 
  Over the past decade pharmaceutical research has been focused on developing macromolecules for 
treatment of many diseases [1]. Most of these macromolecules are administered using an invasive 
manner to reach a therapeutic concentration, even though these procedures would be painful to the 
patients. As an alternative, pulmonary inhalation could enhance macromolecules administration because it 
is a non-invasive technique for local and systemic drug delivery. The lungs own many favourable features, 
including large surface area for absorption, high vasculatures, thin epithelium in the alveolar tissue and 
short path of gas–blood exchange movement [2]. However, formulating these macromolecules into 
suitable pulmonary delivery systems remains a challenge. .  
  The most common method for the encapsulation of proteins in polymer-based nanoparticles (NPs) is the 
water/oil/water (w/o/w) double-emulsion solvent evaporation method [3]. NPs can also be formulated into 
dry powders for inhalation by spray-drying.  
  Here at Liverpool John Moores University we have been investigating poly glycerol adipate-co-ω-
pentadecalactone (PGA-co-PDL) as alternative to PLGA as a carrier for pulmonary delivery of 
macromolecules [4]. The results revealed that these polyesters could exhibit an alternative pulmonary 
delivery as they provide a protective matrix and faster release in a short period of time in comparison with 
other similar polymers, such as PLGA. 
Objective 
  
 The aim of this study was to formulate PGA-co-PDL NPs encapsulating bovine serum albumin (BSA), a 
model protein, incorporated into a microparticle L-leucine matrix via spray drying to produce 
nanocomposite microparticle (NCMPs) carriers suitable for pulmonary delivery via dry powder inhalation. 
Formulation & Drug Delivery 
Research 
Protein Loaded PGA-co-PDL Nanocomposite Microparticles for Inhalation 
 
Methods 
Nanocomposite microparticles preparation 
  The protein solution 1% 0.5 ml was emulsified in dichloromethane,DCM containing 50 mg PGA-co-PDL, by a 
probe sonicator at 45% amplitude over an ice. Then emulsified into a 1% PVA solution 25ml at 45% ampliyude and 
stirred for 2h at room temperature to evaporate DCM. NPs collected by centrifugation at 25,750xg and 4⁰C.  
  NCMPs were prepared by spray drying NPs suspended in L-leucine solution (1:1.5w/w) using a mini-spray dryer 
(Büchi, B-290) at pump: 10%, air flow: 50 mm, aspirator: 50 % and inlet temperature:100 ºC. 
  
Nanocomposite microparticles characterization 
• NCMPs zeta potential and size were carried out using a Zetaplus, Brookhaven Instruments, U.K.  
• BSA loaded in NPs was determined by measuring BSA remaining in the supernatant and wash after 
centrifugation using a QuantiPro BCA  protein assay kit (Sigma-aldrich).  
• NCMPs were visualised by scanning electron microscopy (SEM) (FEI – Inspect S Low VAV Scanning). 
• The yield of NCMPs was quantified as a percentage mass of expected total powder yield. 
  
In-vitro release study 
  Ten mg of NCMPs were dispersed in 1.2ml of phosphate buffer saline, PBS (pH7.4) at 37°C and rotated on a 
mixer (HulaMixer, Life Technologies).  
  
Aerosolisation study (Next Generation Impactor, NGI) 
  Ten mg of NCMPs were loaded into HMC capsules and aerosolised via a cyclohaler into a NGI, coated with tween 
80: acetone solution,flow rate of 60L/min for 4s. Samples were collected by washing with DCM/0.15M NaCl 
mixture. FPF%: the fraction of emitted dose deposited in NGI with aerodynamic diameters < 4.6μm and the MMAD 
was calculated from log-probability analysis. 
 
 
 
Results and Discussion 
 
 
 
Nanocomposite microparticles characterization 
The selected w/o/w double emulsion solvent evaporation process produced particles in the nanometer 
size range with a narrow particle size distribution (Table 1). The %EE of BSA loaded NPs was 39.49±2.63 
% with BSA loading of 35.9±2.39 µg/mg and a zeta potential of -17.17±0.61 mV. NPs were further spray-
dried to produce NCMPs with a reasonable yield for BSA loaded (38.22±1.17 %) and empty NCMPs 
(61.32±5.67 %). 
 
Table 1 The particle size, polydispersity index (PDI), zeta potential, encapsulation efficiency (%EE), drug 
loading (DL), and yield (%) of  NCMPs (n=3). 
 
 
 
 
 
 
 
SEM analysis (Figure 1) indicated that NCMPs were irregular and corrugated with a porous surface. The 
geometrical particle size of the produced nanocomposite microparticles as observed by SEM was 
approximately 2-4 µm. 
 
Figure 1 SEM images of spray dried BSA-PGA-co-PDL NCMPs. (The scale bar represents 1µm). 
 
 
 
 
Conclusions 
  The water-oil-water double emulsion solvent evaporation technique was able to manufacture PGA-co-PDL NPs with suitable BSA EE % (39.49%) and sustained release over 48h. Incorporating L-leucine during spray 
drying to produce NCMPs yielded FPF (70%) and MMAD (1.5 µm)  allowing for high efficient delivery of protein to the lungs.  
 
Formulation 
Particle size 
 (nm) 
PDI 
Zeta potential 
(mV) 
 
EE 
 (%) 
 
DL  
(µg/mg) 
 
Yield  
(%) 
BSA-PGA-co-PDL  203.03±5.4 0.145 -17.17±0.61 39.49±2.63 35.9±2.39 38.22±1.17 
Empty PGA-co-PDL  284.1±9.9 0.280 -15.86±0.85 - - 61.32±5.67 
 
 
In-vitro release study 
BSA showed biphasic release profile (Figure 2) with an initial burst release followed by a second 
continuous sustained release phase over 48h. The initial burst release of BSA from NCMPs was 
1.26±1.5% which after 4 h increased rapidly to 9.08±3.4%, which then slowed to 20.84±4.2% after 48 h.  
Figure 2 In-vitro release profiles of BSA –PGA-co-PDL NCMPs in PBS, pH 7.4 (n=3). 
 
 
 
 
 
 
 
 
 
Aerosolisation study (Next Generation Impactor, NGI) 
Aerodynamic particle characteristics revealed that the studied formulation yielded NCMPs capable of 
delivering efficient BSA with %FPF of 70.97±4.7% and a MMAD of 1.5±0.35 µm, indicating deposition in 
the bronchial-alveolar region. As NCMPs penetrate to the bronchial-alveolar region it is anticipated the L-
leucine component will dissolve, releasing PGA-co-PDL NPs which will eventually degrade into its 
individual components (glycerol, divinyl adipate, and caprolactone) releasing BSA for uptake. 
 
Table 2 The % fine particle fraction & MMAD(µm) of BSA-PGA-co-PDL nanocomposite NCMPs (n=3). 
 
 
Formulation %FPF  MMAD (µm) 
BSA-PGA-co-PDL 70.97±4.7 1.5±0.35  
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Introduction 
  Pulmonary vaccine delivery has gained major attention to produce both mucosal and systemic immunity 
(1). The encapsulation of antigens in nanoparticles (NPs) has been investigated extensively as an 
approach to enhance immunogenicity (2). 
  A number of polymers have been studied for pulmonary vaccine delivery. In recent years, poly glycerol 
adipate-co-ω-pentadecalactone (PGA-co-PDL) was studied as a drug carrier (3), (4).   
  Chitosan hydrochloride (CHCl) has been described as a water-soluble and a positively charged 
polyelectrolyte, which may overcome the low water solubility of chitosan at neutral pH. However, like other 
cationic polymers, the strong positive charge of CHCl contributes to the toxicity of the polymer. The 
amount of CHCl can be decreased by making CHCl-coated PGA-co-PDL NPs, because only a lower 
amount of CHCl was expected to coat on the surface of a particle compared to CHCl NPs (5).  
  
Objective 
  The aim of this study was to prepare CHCl coated PGA-co-PDL NPs encapsulating bovine serum 
albumin (BSA), a model antigen to produce cationic NPs which further spray dried to form nanocomposite 
microparticles (NCMPs) suitable for antigen delivery via inhalation. 
  
 
 
Formulation & Drug Delivery 
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Cationic PGA-co-PDL nanocomposite microparticles for antigen delivery via inhalation 
 
Methods 
Nanocomposite microparticles preparation 
  The protein solution 1%, 0.5ml was emulsified in 2ml of dichloromethane,DCM containing 50mg of PGA-co-PDL, by sonication using a probe 
sonicator at 45% amplitude (VC X 500 Vibra-CellTM, Sonics & Materials, Inc., USA) for 5s over an ice bath. Then it was emulsified into a a mixture of 
1% CHCl and 1% PVA solution 25ml using a probe sonicator at 45% amplitude for 15s. Then it was stirred magnetically for 2h to evaporate DCM. The 
NPs were collected by centrifugation (SIGMA 3-30 K, SIGMA Laborzentrifugen GmbH, Germany) at 40,000xg for 1h at 4⁰C, and washed with distilled 
water.        
  NCMPs were prepared by spray drying NPs suspended in aqueous L-leucine solutions (1:1.5 w/w) using a mini-spray dryer (Büchi, B-290) with a 
standard two-fluid nozzle, feed rate of 10ml/min, air flow of 535L/h, aspirator  at  50% and inlet temperature of 100ºC. 
  
Nanocomposite microparticles characterization 
• NCMPs zeta potential and size were carried out using a Malvern NanoZS (Malvern Instruments Ltd., Worcestershire, UK).   
• The amount of BSA loaded in the NPs was determined by measuring the amount of BSA remaining in the supernatant and wash after 
centrifugation using a QuantiPro bicinchoninic acid (BCA) protein assay kit (Sigma-aldrich).  
• Spray dried NCMPs were visualised by scanning electron microscopy (SEM) (FEI – Inspect S Low VAV Scanning Electron Microscope). 
  
In-vitro release study 
  Ten mg of NCMPs were dispersed in 1.2ml of phosphate buffer saline (pH7.4) at 37°C and rotated on a sample mixer (HulaMixer, Life Technologies).  
  
Aerosolisation study (Next Generation Impactor, NGI) 
  Fifteen mg of NCMPs were loaded into HMC capsules, and aerosolised via a cyclohaler into a NGI, coated with 1% tween 80: acetone solution, at a 
flow rate of 60L/min for 4s. The samples were collected by washing with DCM/0.15M NaCl mixture (2:1). The FPF (%) was determined as the fraction 
of emitted dose deposited in the NGI with aerodynamic diameters less than 4.6μm, and the MMAD was calculated from log-probability analysis. 
 
 
 
Results and Discussion 
 
 
 
Nanocomposite microparticles characterization 
The w/o/w double emulsion solvent evaporation process produced particles in the nanometer size range 
with a narrow particle size distribution (Table 1). The BSA loading for CHCl coated and uncoated PGA-co-
PDL nanoparticles were 7.2±1.3 and 33.1±3 µg/mg respectively. The change in BSA loading observed 
attributed to increased amount of solid. The surface charge of CHCl coated PGA-co-PDL nanoparticles 
changed to +14.2±0.7mV. 
 
Table 1 The particle size, polydispersity index (PDI), zeta potential, and drug loading (DL) for 
nanocomposite microparticles (n=3). 
 
 
 
 
 
 
 
SEM analysis (Figure 1) indicated that NCMPs were irregular and corrugated with a porous surface. The 
geometrical particle size of the produced nanocomposite microparticles as observed by SEM was 
approximately 2-4 µm. 
 
Figure 1 SEM images of spray dried  
CHCl-PGA-co-PDL nanocomposite 
 microparticles.  
(The scale bar represents 1µm). 
 
 
 
 
Conclusions 
The water-oil-water double emulsion solvent evaporation technique was able to manufacture CHCl-PGA-co-PDL NPs with suitable BSA loading (7µg/mg) and sustained release 
over 48h. The use of L-leucine during spray drying produced NCMPs with FPF (47%) and MMAD of 1.7±0.29 µm allowing for high efficient delivery of protein to the lungs. 
 
 
 
 
 
 
In-vitro release study 
BSA showed biphasic release profile (Figure 2) with a first initial burst release followed by a second 
continuous sustained release phase over 48h. The initial burst release of BSA from NCMPs was 19.6±6% 
which after 4 h increased rapidly to 49.7±2%, which then slowed to 57.96±3.03% after 20 h then 
increased to 74.52±10% after 24 h followed by slow release to 81.9±12% after 48 h. This could be 
attributed to the distribution of BSA inside NPs matrix or a change in matrix degradation rate due to 
changed surface porosity.  
  
Figure 2 In-vitro release profiles for CHCl-PGA-co-PDL nanocomposite microparticles in phosphate 
buffer saline, pH 7.4 (n=3). 
 
 
 
 
 
 
 
 
 
 
 
 
Aerosolisation study (Next Generation Impactor, NGI) 
Aerodynamic particle characteristics revealed that formulation yielded NCMPs capable of delivering BSA 
with %FPF of 47.3±12% and a MMAD of 1.7±0.29 µm, indicating deposition in the bronchial-alveolar 
region. As NCMPs penetrate to the bronchial-alveolar region it is anticipated that the L-leucine 
component will dissolve, releasing CHCl-PGA-co-PDL NPs for cells uptake. 
Formulation 
Particle size  (nm) Zeta Potential (mV) DL (µg/mg) Polydispersity  (PDI) 
PGA-co-PDL 
  
445±46.8 -17.4±1.2  33.1±3 0.145 
  
CHCl-PGA-co-PDL 
  
480.2±32.2 +14.2±0.7 7.2±1.3 0.280 
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Introduction 
As an alternative to repeated injection, dry powder 
pulmonary inhalation offers a non-invasive technique for 
local and systemic delivery of protein-based formulation 
(1). The lungs possess many favourable features (2). In 
our laboratory we have been investigating and 
developing alternative biodegradable polyester polymers 
[poly (glycerol adipate-co-ω-pentadecalactone, PGA-co-
PDL)]. Using this polymer we have successfully 
encapsulated a model protein (α-chymotrypsin enzyme). 
In addition, release studies revealed most of the protein 
released over several hours (3). Furthermore, we have 
successfully demonstrated that PGA-co-PDL 
microparticles could be used as an alternative carrier for 
pulmonary delivery with enhanced aerosol performance 
and reduced toxicity to normal lung cells compared to 
PLGA microparticles (4).  
In this study we aim to produce PGA-co-PDL 
nanocomposite microparticles (NMs) loaded with bovine 
serum albumin (BSA), a model protein, which may be 
administered to the lung via dry powder inhalation. The 
impact of these characteristics on important aspects of 
pulmonary delivery such as aerosolization, and release 
will be determined. 
Methods 
Nanoparticles Preparation 
BSA (Avenchem, UK) loaded PGA-co-PDL nanoparticles 
(NPs) were prepared by probe sonication (sonics, VCX 
500) of water-in-oil-in-water (w/o/w) double 
emulsion/solvent evaporation method (Table 1). The 
double emulsion was stirred for 2 h at room temperature 
and the NPs were collected by centrifugation at 30,000 g 
(Beckman J2-2IM/E) for 45 min at 4 ºC. Control empty 
NPs were prepared. 
Spray drying NPs 
The NMs were prepared by spray drying NPs suspension 
in aqueous L-leucine solutions (1.5%w/w) using a mini-
spray dryer (Büchi, B-290) with two-fluid nozzle (0.7 mm 
diameter), feed rate of 15 ml/min, air flow of 414 L/h, 
aspirator  at  40m³/h, inlet and outlet temperature of 100 
and 47 ºC, respectively. 
Nanocomposite Microparticles characterisation 
Particle size & zeta potential  
The particle size & zeta potential were measured using a 
Zetaplus. Briefly, 100μl of the suspension was diluted to 5 
ml using double distilled water and the measurements 
recorded at 25ºC (n=3). 
Spray dried yeild & drug loading 
The yield of spray dried NMs was quantified as a 
percentage mass of expected total powder yield (n=3). 
The amount of BSA loaded in the NPs was determined 
by measuring the amount of BSA remaining in the 
supernatant with a QuantiPro BCA protein assay (Sigma) 
after centrifugation (n=3). 
Particle morphology 
Spray dried NMs were mounted on gold coated 
aluminium stubs (EmiTech K 550X Gold Sputter Coater, 
25mA for 3 min), and visualised by scanning electron 
microscopy.  
In-vitro relese study 
20mg of BSA encapsulated spray dried NMs were placed 
in an eppendorf and dispersed in 1.2ml of PBS (pH 7.4). 
The samples were incubated at 37C in the orbital shaker 
set at 250 rpm. At predetermined time intervals up to 24h, 
the samples were centrifuged (30,000 g for 20 min) and 
1ml of the supernatant removed and replaced with fresh 
buffer. The supernatant was analysed by QuantiPro BCA 
protein assay as mentioned above (n=3). 
 
 
 
Table 1 Different formulation parameters for 
preparation of NPs by (w/o/w) double emulsion 
solvent evaporation 
Formula 
No. 
Polymer 
conc. 
(mg/ml) 
BSA 
 Conc. 
(%) 
 
IAP volume 
(µl) 
PVA 
Conc
. IAP  
(%) 
PVA 
Conc. 
EAP  
(%) 
EAP 
volume 
(ml) 
NM1 25 0.5 500 1 13 25 
NM2 25 0.5 500 5 13 25 
NM3 25 0.5 250 5 13 25 
*IAP: internal aqueous phase **EAP: external aqueous phase   
Aerosolisation studies  
Dry powder samples (10mg) were manually loaded into 
hydroxypropyl methylcellulose capsules (size 3), and 
aerosolised via a cyclohaler into a Next Generation 
Impactor (NGI), coated with 5% tween 80: acetone 
solution, at a flow rate of 60L/min for 4s to determine 
aerodynamic particle size. The samples were collected 
by washing with DCM/0.15 M NaCl mixture (2:1) to 
dissolve the polymer and the encapsulated BSA, which 
was determined by QuantiPro BCA protein assay as 
mentioned above (n=3). The FPF (%) was determined as 
the fraction of emitted dose deposited in the NGI with 
aerodynamic diameters less than 4.6 μm, and the MMAD 
was calculated from log-probability analysis. 
Results & Discussion 
Nanocomposite Microparticles characterisation 
The particle size achieved ranged from 196.6±1.9 – 
290.6±7.5 and the yield of NMs achieved after spray 
drying ranged from 24.4±4.7 – 35.9±5.1 (Table 2). All 
particles had a negative zeta potential, possibly due to 
PVA remaining on the particles after centrifugation and 
washing.  The drug loading ranged from 14.6±2.5 to 
20.54±3.1 µg/mg particle. There was a significant 
increase in drug loading between NM1 and NM2, due to 
an increase in PVA concentration in the IAP. However, 
decreasing IAP volume led to no significant difference in 
BSA loading between NM2 and NM3. 
SEM analysis indicated that NMs (NM2) had a 
corrugated surface with pores visible on the surface (Fig. 
1). This occurred due to excessive build-up of vapor 
pressure during solvent evaporation in the spray drying 
process and occurs with hydrophobic amino acids, such 
as L-leucine, for improved aerosolization performance 
(5). The size of the NM was approximately 2-3 µm 
according to SEM analysis.  
 
Figure 1 SEM images of NMs (NM2). Scale bar 
represents 5 µm (A) & 2 µm (B) respectively. 
 
Formula 
No. 
Particle 
size 
(nm) 
Zeta 
potential 
(mV) 
Yield 
(%) 
BSA 
loading 
(µg/mg) 
NM1 275.5±12.7 -24.5±1.3 25.4±5.3 14.6±2.5 
NM2 196.6±1.9 -19.3±3.3 24.4±4.7 20.5±3.1 
NM3 290.6±7.5 -12.4±2.1 35.9±5.1 19.5±0.6 
The data in Fig.2 represents the % cumulative 
release of BSA as a percentage of the drug 
loading.  All formulation showed biphasic release 
profile with a first initial burst release followed by a 
second continuous sustained release phase over 
24h. All formulations had a similar initial burst 
release of BSA ranging from 9.6±1.0 – 11.5±2.3%. 
Significant difference was noted in release profile (2 
– 24 h) between NM1 and NM3, with NM1 achieving 
19.8±1.5% release after 24 h compared to NM3 
(14.1±2.0%). 
Conclusion 
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 we have shown the potential for encapsulating 
proteins within PGA-co-PDL NMs as carriers for 
pulmonary delivery using double emulsion/spray 
drying as a preparation method. Future studies will 
involve improving the drug loading, stability studies 
and release by optimising the preparation method.  
Table 2 The drug loading, particle size, zeta 
potential, spray dried yield & drug loading of different 
NMs formulations.  
Figure 2 % cumulative in-vitro release profiles for 
different BSA-PGA-co-PDL NMs as a percentage of 
drug loading in phosphate buffer saline, pH 7.4. 
NM2 was chosen for aerosolisation studies due to a 
high drug loading and reasonable drug release 
profile compared to NM1 and NM3. The results in 
Tab.3 indicate good aerosolisation properties and 
the MMAD corresponds to particle size data 
achieved with SEM. 
Table 3 Aerosolisation performance of NM2 
Formula No. FPF (%) MMAD (µm) 
NM2 70.1 ±13.2 1.6 ± 0.4 
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Introduction 
  Over the past decade pharmaceutical research has been focused on developing macromolecules for 
treatment of many diseases [1]. Most of these macromolecules are administered using an invasive 
manner to reach a therapeutic concentration, even though these procedures would be painful to the 
patients. As an alternative, pulmonary inhalation could enhance macromolecules administration because it 
is a non-invasive technique for local and systemic drug delivery. The lungs own many favourable features, 
including large surface area for absorption, high vasculatures, thin epithelium in the alveolar tissue and 
short path of gas–blood exchange movement [2]. However, formulating these macromolecules into 
suitable pulmonary delivery systems remains a challenge. .  
  The most common method for the encapsulation of proteins in polymer-based nanoparticles (NPs) is the 
water/oil/water (w/o/w) double-emulsion solvent evaporation method [3]. NPs can also be formulated into 
dry powders for inhalation by spray-drying.  
  Here at Liverpool John Moores University we have been investigating poly glycerol adipate-co-ω-
pentadecalactone (PGA-co-PDL) as alternative to PLGA as a carrier for pulmonary delivery of 
macromolecules [4]. The results revealed that these polyesters could exhibit an alternative pulmonary 
delivery as they provide a protective matrix and faster release in a short period of time in comparison with 
other similar polymers, such as PLGA. 
Objective 
  
 The aim of this study was to formulate PGA-co-PDL NPs encapsulating bovine serum albumin (BSA), a 
model protein, incorporated into a microparticle L-leucine matrix via spray drying to produce 
nanocomposite microparticle (NCMPs) carriers suitable for pulmonary delivery via dry powder inhalation. 
Formulation & Drug Delivery 
Research 
Protein Loaded PGA-co-PDL Nanocomposite Microparticles for Inhalation 
 
Methods 
Nanocomposite microparticles preparation 
  The protein solution 1% 0.5 ml was emulsified in dichloromethane,DCM containing 50 mg PGA-co-PDL, by a 
probe sonicator at 45% amplitude over an ice. Then emulsified into a 1% PVA solution 25ml at 45% ampliyude and 
stirred for 2h at room temperature to evaporate DCM. NPs collected by centrifugation at 25,750xg and 4⁰C.  
  NCMPs were prepared by spray drying NPs suspended in L-leucine solution (1:1.5w/w) using a mini-spray dryer 
(Büchi, B-290) at pump: 10%, air flow: 50 mm, aspirator: 50 % and inlet temperature:100 ºC. 
  
Nanocomposite microparticles characterization 
• NCMPs zeta potential and size were carried out using a Zetaplus, Brookhaven Instruments, U.K.  
• BSA loaded in NPs was determined by measuring BSA remaining in the supernatant and wash after 
centrifugation using a QuantiPro BCA  protein assay kit (Sigma-aldrich).  
• NCMPs were visualised by scanning electron microscopy (SEM) (FEI – Inspect S Low VAV Scanning). 
• The yield of NCMPs was quantified as a percentage mass of expected total powder yield. 
  
In-vitro release study 
  Ten mg of NCMPs were dispersed in 1.2ml of phosphate buffer saline, PBS (pH7.4) at 37°C and rotated on a 
mixer (HulaMixer, Life Technologies).  
  
Aerosolisation study (Next Generation Impactor, NGI) 
  Ten mg of NCMPs were loaded into HMC capsules and aerosolised via a cyclohaler into a NGI, coated with tween 
80: acetone solution,flow rate of 60L/min for 4s. Samples were collected by washing with DCM/0.15M NaCl 
mixture. FPF%: the fraction of emitted dose deposited in NGI with aerodynamic diameters < 4.6μm and the MMAD 
was calculated from log-probability analysis. 
 
 
 
Results and Discussion 
 
 
 
Nanocomposite microparticles characterization 
The selected w/o/w double emulsion solvent evaporation process produced particles in the nanometer 
size range with a narrow particle size distribution (Table 1). The %EE of BSA loaded NPs was 39.49±2.63 
% with BSA loading of 35.9±2.39 µg/mg and a zeta potential of -17.17±0.61 mV. NPs were further spray-
dried to produce NCMPs with a reasonable yield for BSA loaded (38.22±1.17 %) and empty NCMPs 
(61.32±5.67 %). 
 
Table 1 The particle size, polydispersity index (PDI), zeta potential, encapsulation efficiency (%EE), drug 
loading (DL), and yield (%) of  NCMPs (n=3). 
 
 
 
 
 
 
 
SEM analysis (Figure 1) indicated that NCMPs were irregular and corrugated with a porous surface. The 
geometrical particle size of the produced nanocomposite microparticles as observed by SEM was 
approximately 2-4 µm. 
 
Figure 1 SEM images of spray dried BSA-PGA-co-PDL NCMPs. (The scale bar represents 1µm). 
 
 
 
 
Conclusions 
  The water-oil-water double emulsion solvent evaporation technique was able to manufacture PGA-co-PDL NPs with suitable BSA EE % (39.49%) and sustained release over 48h. Incorporating L-leucine during spray 
drying to produce NCMPs yielded FPF (70%) and MMAD (1.5 µm)  allowing for high efficient delivery of protein to the lungs.  
 
Formulation 
Particle size 
 (nm) 
PDI 
Zeta potential 
(mV) 
 
EE 
 (%) 
 
DL  
(µg/mg) 
 
Yield  
(%) 
BSA-PGA-co-PDL  203.03±5.4 0.145 -17.17±0.61 39.49±2.63 35.9±2.39 38.22±1.17 
Empty PGA-co-PDL  284.1±9.9 0.280 -15.86±0.85 - - 61.32±5.67 
 
 
In-vitro release study 
BSA showed biphasic release profile (Figure 2) with an initial burst release followed by a second 
continuous sustained release phase over 48h. The initial burst release of BSA from NCMPs was 
1.26±1.5% which after 4 h increased rapidly to 9.08±3.4%, which then slowed to 20.84±4.2% after 48 h.  
Figure 2 In-vitro release profiles of BSA –PGA-co-PDL NCMPs in PBS, pH 7.4 (n=3). 
 
 
 
 
 
 
 
 
 
Aerosolisation study (Next Generation Impactor, NGI) 
Aerodynamic particle characteristics revealed that the studied formulation yielded NCMPs capable of 
delivering efficient BSA with %FPF of 70.97±4.7% and a MMAD of 1.5±0.35 µm, indicating deposition in 
the bronchial-alveolar region. As NCMPs penetrate to the bronchial-alveolar region it is anticipated the L-
leucine component will dissolve, releasing PGA-co-PDL NPs which will eventually degrade into its 
individual components (glycerol, divinyl adipate, and caprolactone) releasing BSA for uptake. 
 
Table 2 The % fine particle fraction & MMAD(µm) of BSA-PGA-co-PDL nanocomposite NCMPs (n=3). 
 
 
Formulation %FPF  MMAD (µm) 
BSA-PGA-co-PDL 70.97±4.7 1.5±0.35  
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Introduction 
  Pulmonary vaccine delivery has gained major attention to produce both mucosal and systemic immunity 
(1). The encapsulation of antigens in nanoparticles (NPs) has been investigated extensively as an 
approach to enhance immunogenicity (2). 
  A number of polymers have been studied for pulmonary vaccine delivery. In recent years, poly glycerol 
adipate-co-ω-pentadecalactone (PGA-co-PDL) was studied as a drug carrier (3), (4).   
  Chitosan hydrochloride (CHCl) has been described as a water-soluble and a positively charged 
polyelectrolyte, which may overcome the low water solubility of chitosan at neutral pH. However, like other 
cationic polymers, the strong positive charge of CHCl contributes to the toxicity of the polymer. The 
amount of CHCl can be decreased by making CHCl-coated PGA-co-PDL NPs, because only a lower 
amount of CHCl was expected to coat on the surface of a particle compared to CHCl NPs (5).  
  
Objective 
  The aim of this study was to prepare CHCl coated PGA-co-PDL NPs encapsulating bovine serum 
albumin (BSA), a model antigen to produce cationic NPs which further spray dried to form nanocomposite 
microparticles (NCMPs) suitable for antigen delivery via inhalation. 
  
 
 
Formulation & Drug Delivery 
Research 
Cationic PGA-co-PDL nanocomposite microparticles for antigen delivery via inhalation 
 
Methods 
Nanocomposite microparticles preparation 
  The protein solution 1%, 0.5ml was emulsified in 2ml of dichloromethane,DCM containing 50mg of PGA-co-PDL, by sonication using a probe 
sonicator at 45% amplitude (VC X 500 Vibra-CellTM, Sonics & Materials, Inc., USA) for 5s over an ice bath. Then it was emulsified into a a mixture of 
1% CHCl and 1% PVA solution 25ml using a probe sonicator at 45% amplitude for 15s. Then it was stirred magnetically for 2h to evaporate DCM. The 
NPs were collected by centrifugation (SIGMA 3-30 K, SIGMA Laborzentrifugen GmbH, Germany) at 40,000xg for 1h at 4⁰C, and washed with distilled 
water.        
  NCMPs were prepared by spray drying NPs suspended in aqueous L-leucine solutions (1:1.5 w/w) using a mini-spray dryer (Büchi, B-290) with a 
standard two-fluid nozzle, feed rate of 10ml/min, air flow of 535L/h, aspirator  at  50% and inlet temperature of 100ºC. 
  
Nanocomposite microparticles characterization 
• NCMPs zeta potential and size were carried out using a Malvern NanoZS (Malvern Instruments Ltd., Worcestershire, UK).   
• The amount of BSA loaded in the NPs was determined by measuring the amount of BSA remaining in the supernatant and wash after 
centrifugation using a QuantiPro bicinchoninic acid (BCA) protein assay kit (Sigma-aldrich).  
• Spray dried NCMPs were visualised by scanning electron microscopy (SEM) (FEI – Inspect S Low VAV Scanning Electron Microscope). 
  
In-vitro release study 
  Ten mg of NCMPs were dispersed in 1.2ml of phosphate buffer saline (pH7.4) at 37°C and rotated on a sample mixer (HulaMixer, Life Technologies).  
  
Aerosolisation study (Next Generation Impactor, NGI) 
  Fifteen mg of NCMPs were loaded into HMC capsules, and aerosolised via a cyclohaler into a NGI, coated with 1% tween 80: acetone solution, at a 
flow rate of 60L/min for 4s. The samples were collected by washing with DCM/0.15M NaCl mixture (2:1). The FPF (%) was determined as the fraction 
of emitted dose deposited in the NGI with aerodynamic diameters less than 4.6μm, and the MMAD was calculated from log-probability analysis. 
 
 
 
Results and Discussion 
 
 
 
Nanocomposite microparticles characterization 
The w/o/w double emulsion solvent evaporation process produced particles in the nanometer size range 
with a narrow particle size distribution (Table 1). The BSA loading for CHCl coated and uncoated PGA-co-
PDL nanoparticles were 7.2±1.3 and 33.1±3 µg/mg respectively. The change in BSA loading observed 
attributed to increased amount of solid. The surface charge of CHCl coated PGA-co-PDL nanoparticles 
changed to +14.2±0.7mV. 
 
Table 1 The particle size, polydispersity index (PDI), zeta potential, and drug loading (DL) for 
nanocomposite microparticles (n=3). 
 
 
 
 
 
 
 
SEM analysis (Figure 1) indicated that NCMPs were irregular and corrugated with a porous surface. The 
geometrical particle size of the produced nanocomposite microparticles as observed by SEM was 
approximately 2-4 µm. 
 
Figure 1 SEM images of spray dried  
CHCl-PGA-co-PDL nanocomposite 
 microparticles.  
(The scale bar represents 1µm). 
 
 
 
 
Conclusions 
The water-oil-water double emulsion solvent evaporation technique was able to manufacture CHCl-PGA-co-PDL NPs with suitable BSA loading (7µg/mg) and sustained release 
over 48h. The use of L-leucine during spray drying produced NCMPs with FPF (47%) and MMAD of 1.7±0.29 µm allowing for high efficient delivery of protein to the lungs. 
 
 
 
 
 
 
In-vitro release study 
BSA showed biphasic release profile (Figure 2) with a first initial burst release followed by a second 
continuous sustained release phase over 48h. The initial burst release of BSA from NCMPs was 19.6±6% 
which after 4 h increased rapidly to 49.7±2%, which then slowed to 57.96±3.03% after 20 h then 
increased to 74.52±10% after 24 h followed by slow release to 81.9±12% after 48 h. This could be 
attributed to the distribution of BSA inside NPs matrix or a change in matrix degradation rate due to 
changed surface porosity.  
  
Figure 2 In-vitro release profiles for CHCl-PGA-co-PDL nanocomposite microparticles in phosphate 
buffer saline, pH 7.4 (n=3). 
 
 
 
 
 
 
 
 
 
 
 
 
Aerosolisation study (Next Generation Impactor, NGI) 
Aerodynamic particle characteristics revealed that formulation yielded NCMPs capable of delivering BSA 
with %FPF of 47.3±12% and a MMAD of 1.7±0.29 µm, indicating deposition in the bronchial-alveolar 
region. As NCMPs penetrate to the bronchial-alveolar region it is anticipated that the L-leucine 
component will dissolve, releasing CHCl-PGA-co-PDL NPs for cells uptake. 
Formulation 
Particle size  (nm) Zeta Potential (mV) DL (µg/mg) Polydispersity  (PDI) 
PGA-co-PDL 
  
445±46.8 -17.4±1.2  33.1±3 0.145 
  
CHCl-PGA-co-PDL 
  
480.2±32.2 +14.2±0.7 7.2±1.3 0.280 
